[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_46a2a138-123b-49fe-8011-1983733f6782":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:46a2a138-123b-49fe-8011-1983733f6782,\"}":112},{"code":4,"data":5,"meta":20},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":22,"manageAffiliations":47,"indexDatabases":62,"url":20,"thumbnailPath":20,"statistic":101,"gsStatistic":20,"type":111,"analyzePriority":20},"46a2a138-123b-49fe-8011-1983733f6782","2024-04-06T00:57:23.055+00:00","2025-11-21T10:07:12.316+00:00",[],"Infectious-Agents-and-Cancer",{"issn":12,"title":14,"url":16},{"VOID":13},"17509378",{"EN":15},"Infectious Agents and Cancer",{"VOID":17},"https:\u002F\u002Flink.springer.com\u002Fjournal\u002F13027","PUBLISHER","PENDING",null,0,[23,29,35,41],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":25,"label":26,"description":28,"parentId":20,"standard":20,"scholarHubFieldId":20},"740fbbd4-0204-4499-bc5d-be3ba61fc9be",[],{"EN":27},"Cancer Research",{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":31,"label":32,"description":34,"parentId":20,"standard":20,"scholarHubFieldId":20},"9ac6f77e-ea80-470e-ab08-c9065379174a",[],{"EN":33},"Epidemiology",{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":37,"label":38,"description":40,"parentId":20,"standard":20,"scholarHubFieldId":20},"d9687dc3-fd83-46ff-aef4-1925044c24eb",[],{"EN":39},"Oncology",{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":43,"label":44,"description":46,"parentId":20,"standard":20,"scholarHubFieldId":20},"837c26ad-ce88-445d-9621-a6d173c82561",[],{"EN":45},"Infectious Diseases",{},[48,55],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":50,"slug":20,"properties":51,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":54,"statistic":20},"c5894808-4e99-4047-bbce-594f58821845",[],{"title":52},{"EN":53},"BioMed Central Ltd.",[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":57,"slug":20,"properties":58,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":61,"statistic":20},"67883518-0c98-470e-b6b0-160ab49bb03d",[],{"title":59},{"EN":60},"BMC",[],[63,83],{"id":64,"indexDatabase":65,"url":75,"indexYears":76,"academicFieldIds":77,"indexDatabaseRanking":82},"d6652835-dba4-4f6f-a9a4-7a2672f3fef6",{"id":66,"createTime":20,"updateTime":20,"relativeEntities":67,"label":68,"description":70,"key":72,"publicationTags":73,"standard":20},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9",[],{"EN":69,"VI":69},"Scopus - Elsevier",{"EN":69,"VI":71},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[74],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F5700191215","2006-2025",[78,79,80,81],"ee505398-b96f-423d-82ed-9f73f07d49d4","462e3fe4-4fc0-4c02-80d6-8d2af4fc74ea","1a7c8bc3-0575-4f8d-b22c-aec346a0168a","d5e18365-217e-4716-96b9-4b5d58e7f231","SCOPUS__Q3",{"id":84,"indexDatabase":85,"url":97,"indexYears":20,"academicFieldIds":98,"indexDatabaseRanking":20},"bbd4df77-0dd5-4a16-8a35-8c4ddcec48ba",{"id":86,"createTime":20,"updateTime":20,"relativeEntities":87,"label":88,"description":90,"key":93,"publicationTags":94,"standard":20},"a4921856-b128-4d9f-8f1f-e80813d3bbd4",[],{"EN":89,"VI":89},"ISI\u002FSCIE - Science Citation Index Expanded",{"EN":91,"VI":92},"SCIE database","Cơ sở dữ liệu SCIE","scie",[95,96],"SCIE","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1750-9378",[99,100],"03744874-dcbd-436b-8d5c-f6fa955ce005","248e54de-c562-4c06-8a10-d7f8a37c06fe",{"impactFactor":21,"impactFactorByYear":102,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":104,"totalCitation":21,"totalCitationByYear":109,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":110,"hindexLast5Year":21,"hindex":21},{},28,{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},1,2,3,6,{},{},"JOURNAL",{"meta":113,"data":115},{"total":114},"721",[116,542,871,1414,1649,1815,1942,2302,2450,2627],{"id":117,"createTime":118,"updateTime":119,"relativeEntities":120,"slug":121,"properties":122,"entityType":131,"verifyStatus":132,"verifyTime":133,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":135,"fullTextUrl":20,"authors":136,"publicationType":287,"publisherRelationship":288,"citationCount":347,"citationInfo":348,"publishDate":352,"publishYear":349,"citationAnalyzeStatus":353,"lastCitationAnalyze":119,"indexDatabases":354,"openAccess":20,"references":355,"isForceReanalyzing":541},"f777c4a3-ec9c-49df-803c-e8777956ca89","2024-02-12T05:29:18.280+00:00","2026-08-25T00:05:00.205+00:00",[],"Qualitative-assessment-of-EOB-GD-DTPA-and-Gd-BT-DO3A-MR-contrast-studies-in-HCC-patients-and-colorectal-liver-metastases",{"abstract":123,"title":125,"gsPaper":127,"doi":129},{"EN":124},"To compare liver-specific EOB-GD-DTPA and liver-non-specific Gd-BT-DO3A MR, in hepatocellular carcinoma (HCC) and liver colorectal metastases. Seventy HCC patients with 158 nodules and 90 colorectal liver metastases (mCRC) with 370 lesions were included in the retrospective analysis. HCC patients underwent MR at 0 time (MR0), after 3 (MR3) and 6 months (MR6) using two different CM; 69 mCRC patients underwent MR with Gd-EOB-BTPA and 21 mCRC patients with Gd-BT-DO3A. We evaluated arterial phase hyperenhancement, lesion-to-liver contrast during portal phase, hepatobiliary phase parenchymal hyperenhancement. In HCC patients arterial phase hyperenhancement degree was statistically higher (p = 0.03) with Gd-BT-DO3A (mean 4) than GD-EOB-DTPA (mean 2.6), while we found no significant statistical differences among mean (2.6) values at MR0 and MR6 using GD-EOB-DTPA. For all 209 patients underwent Gd-EOB-DTPA, we found that lesion-to-liver contrast during portal phase mean value was 4 while for patients underwent MR with Gd-BT-DO3A was 3 (p = 0.04). For HCC hepatobiliary phase parenchymal hyperenhancement mean value was 2.4. For mCRC patients: among 63 patients underwent previous chemotherapy hepatobiliary phase parenchymal hyperenhancement mean value was 3.1 while for 6 patients no underwent previous chemotherapy was 4 (p = 0.05). Gd-EOB-DTPA should be chosen in pre surgical setting in patients with colorectal liver metastases.",{"EN":126},"Qualitative assessment of EOB-GD-DTPA and Gd-BT-DO3A MR contrast studies in HCC patients and colorectal liver metastases",{"VOID":128},"[\"17421681623923635138\"]",{"VOID":130},"10.1186\u002Fs13027-019-0264-3","PUBLICATION","VERIFIED","2024-05-01T13:13:02.633+00:00","Auto Verify","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13027-019-0264-3",[137,155,170,185,200,214,230,243,259,273],{"id":138,"sortIndex":21,"researcher":20,"roles":139,"affiliations":141,"properties":150,"displayName":152,"givenName":20,"familyName":20},"8ea7141f-ceaf-4ab9-ba26-29100042faaf",[140],"AUTHOR",[142],{"id":143,"sortIndex":21,"affiliation":144,"properties":20},"31c56b93-ad2c-46ec-9ec4-9d9abb62d531",{"id":143,"createTime":20,"updateTime":20,"relativeEntities":145,"slug":20,"properties":146,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":149,"statistic":20},[],{"title":147},{"VI":148},"Division of Radiology, ISTITUTO NAZIONALE TUMORI – IRCCS - FONDAZIONE G. PASCALE, NAPOLI, ITALIA, Naples, Italy",[],{"title":151,"gsAuthor":153},{"VI":152},"Vincenza Granata",{"VOID":154},"[\"3cIBgHYAAAAJ\"]",{"id":156,"sortIndex":105,"researcher":20,"roles":157,"affiliations":158,"properties":165,"displayName":167,"givenName":20,"familyName":20},"c62bc85a-1bae-4e71-b833-2dbc6baa9284",[140],[159],{"id":143,"sortIndex":21,"affiliation":160,"properties":20},{"id":143,"createTime":20,"updateTime":20,"relativeEntities":161,"slug":20,"properties":162,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":164,"statistic":20},[],{"title":163},{"VI":148},[],{"title":166,"gsAuthor":168},{"VI":167},"Roberta Fusco",{"VOID":169},"[\"YG2SnncAAAAJ\"]",{"id":171,"sortIndex":106,"researcher":20,"roles":172,"affiliations":173,"properties":182,"displayName":184,"givenName":20,"familyName":20},"ba3886a4-678d-4ee3-bd91-5b5b044b1696",[140],[174],{"id":175,"sortIndex":21,"affiliation":176,"properties":20},"e4f48817-3d50-470a-857b-b2739bdb582b",{"id":175,"createTime":20,"updateTime":20,"relativeEntities":177,"slug":20,"properties":178,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":181,"statistic":20},[],{"title":179},{"VI":180},"Division of Radiology, Università degli Studi di Napoli Federico II, Naples, Italy",[],{"title":183},{"VI":184},"Francesca Maio",{"id":186,"sortIndex":107,"researcher":20,"roles":187,"affiliations":188,"properties":197,"displayName":199,"givenName":20,"familyName":20},"1afc5ae6-e0d4-4796-b3a2-d51f6185501c",[140],[189],{"id":190,"sortIndex":21,"affiliation":191,"properties":20},"fbe94b89-9dc6-4932-84b6-c4e809bd9fee",{"id":190,"createTime":20,"updateTime":20,"relativeEntities":192,"slug":20,"properties":193,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":196,"statistic":20},[],{"title":194},{"VI":195},"Division of Abdominal Oncology, ISTITUTO NAZIONALE TUMORI – IRCCS - FONDAZIONE G. PASCALE, NAPOLI, ITALIA, Naples, Italy",[],{"title":198},{"VI":199},"Antonio Avallone",{"id":201,"sortIndex":202,"researcher":20,"roles":203,"affiliations":204,"properties":211,"displayName":213,"givenName":20,"familyName":20},"0f80e249-a0fd-4b91-ae5c-2f122bee871e",4,[140],[205],{"id":190,"sortIndex":21,"affiliation":206,"properties":20},{"id":190,"createTime":20,"updateTime":20,"relativeEntities":207,"slug":20,"properties":208,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":210,"statistic":20},[],{"title":209},{"VI":195},[],{"title":212},{"VI":213},"Guglielmo Nasti",{"id":215,"sortIndex":216,"researcher":20,"roles":217,"affiliations":218,"properties":227,"displayName":229,"givenName":20,"familyName":20},"4526c7ab-d3f1-466b-9297-22f1d11f80e1",5,[140],[219],{"id":220,"sortIndex":21,"affiliation":221,"properties":20},"6523d12f-1222-43c0-b52c-e215519e4786",{"id":220,"createTime":20,"updateTime":20,"relativeEntities":222,"slug":20,"properties":223,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":226,"statistic":20},[],{"title":224},{"VI":225},"Division of Abdominal Surgical Oncology, Hepatobiliary, ISTITUTO NAZIONALE TUMORI – IRCCS - FONDAZIONE G. PASCALE, NAPOLI, ITALIA, Naples, Italy",[],{"title":228},{"VI":229},"Raffaele Palaia",{"id":231,"sortIndex":108,"researcher":20,"roles":232,"affiliations":233,"properties":240,"displayName":242,"givenName":20,"familyName":20},"42e35131-3532-443d-a201-09762bc8f1a1",[140],[234],{"id":220,"sortIndex":21,"affiliation":235,"properties":20},{"id":220,"createTime":20,"updateTime":20,"relativeEntities":236,"slug":20,"properties":237,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":239,"statistic":20},[],{"title":238},{"VI":225},[],{"title":241},{"VI":242},"Vittorio Albino",{"id":244,"sortIndex":245,"researcher":20,"roles":246,"affiliations":247,"properties":256,"displayName":258,"givenName":20,"familyName":20},"0b11322a-a9ff-4fe9-b6ef-eea321a7c2cb",7,[140],[248],{"id":249,"sortIndex":21,"affiliation":250,"properties":20},"33617e33-9230-4e93-abf8-0c226ac70b09",{"id":249,"createTime":20,"updateTime":20,"relativeEntities":251,"slug":20,"properties":252,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":255,"statistic":20},[],{"title":253},{"VI":254},"Division of Radiology, Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy",[],{"title":257},{"VI":258},"Roberto Grassi",{"id":260,"sortIndex":261,"researcher":20,"roles":262,"affiliations":263,"properties":270,"displayName":272,"givenName":20,"familyName":20},"bb231716-f37a-4ce8-81df-b09829bfab45",8,[140],[264],{"id":220,"sortIndex":21,"affiliation":265,"properties":20},{"id":220,"createTime":20,"updateTime":20,"relativeEntities":266,"slug":20,"properties":267,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":269,"statistic":20},[],{"title":268},{"VI":225},[],{"title":271},{"VI":272},"Francesco Izzo",{"id":274,"sortIndex":275,"researcher":20,"roles":276,"affiliations":277,"properties":284,"displayName":286,"givenName":20,"familyName":20},"0248f02a-efb8-4ed0-8856-8ca1f733fb50",9,[140],[278],{"id":143,"sortIndex":21,"affiliation":279,"properties":20},{"id":143,"createTime":20,"updateTime":20,"relativeEntities":280,"slug":20,"properties":281,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":283,"statistic":20},[],{"title":282},{"VI":148},[],{"title":285},{"VI":286},"Antonella Petrillo","ARTICLE",{"url":135,"publisher":289,"properties":342},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":290,"slug":10,"properties":291,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":294,"manageAffiliations":311,"indexDatabases":322,"url":20,"thumbnailPath":20,"statistic":337,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":292,"title":293},{"VOID":13},{"EN":15},[295,299,303,307],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":296,"label":297,"description":298,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":300,"label":301,"description":302,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":304,"label":305,"description":306,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":308,"label":309,"description":310,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[312,317],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":313,"slug":20,"properties":314,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":316,"statistic":20},[],{"title":315},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":318,"slug":20,"properties":319,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":321,"statistic":20},[],{"title":320},{"EN":60},[],[323,330],{"id":64,"indexDatabase":324,"url":75,"indexYears":76,"academicFieldIds":329,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":325,"label":326,"description":327,"key":72,"publicationTags":328,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":331,"url":97,"indexYears":20,"academicFieldIds":336,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":332,"label":333,"description":334,"key":93,"publicationTags":335,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":338,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":339,"totalCitation":21,"totalCitationByYear":340,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":341,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":343,"volume":345},{"VOID":344},"1-9",{"VOID":346},"14",38,{"total":347,"publishYear":349,"statisticByYear":350},2019,{"2020":106,"2021":108,"2022":351,"2023":275,"2024":106,"2025":106},16,"2019-11-27","ERROR_IN_ANALYZE_CITATION",[82,95],[356,359,365,371,374,380,383,386,389,392,398,401,404,407,410,413,419,422,425,428,434,437,443,446,452,455,458,461,466,472,475,478,481,487,493,499,505,508,511,514,517,520,523,526,529,532,535],{"id":20,"text":357,"url":20,"identifiers":358},"Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol. 2012;57(2):421–9.",{},{"id":360,"text":361,"url":362,"identifiers":363},"4c68646b-0035-4279-8000-0006b275d4fa","Granata V, Fusco R, Avallone A, Filice F, Tatangelo F, Piccirillo M, Grassi R, Izzo F, Petrillo A. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: lights and shadows. Oncotarget. 2017;8(31):51224–37.","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs10440-022-00541-7",{"doi":364},"10.1007\u002Fs10440-022-00541-7",{"id":366,"text":367,"url":368,"identifiers":369},"befd0993-803a-459c-bcfa-c35928fcced7","Granata V, Fusco R, Avallone A, Catalano O, Filice F, Leongito M, Palaia R, Izzo F, Petrillo A. Major and ancillary magnetic resonance features of LI-RADS to assess HCC: an overview and update. Infect Agent Cancer. 2017;12:23.","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13027-017-0132-y",{"doi":370},"10.1186\u002Fs13027-017-0132-y",{"id":360,"text":372,"url":362,"identifiers":373},"Granata V, Cascella M, Fusco R, dell’Aprovitola N, Catalano O, Filice S, Schiavone V, Izzo F, Cuomo A, Petrillo A. Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 Examinations. Biomed Res Int. 2016;2016:3918292.",{"doi":364},{"id":375,"text":376,"url":377,"identifiers":378},"024e745f-922f-40bd-89af-e9b89b1a3d52","Granata V, Catalano O, Fusco R, Tatangelo F, Rega D, Nasti G, Avallone A, Piccirillo M, Izzo F, Petrillo A. The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA \"uptake\" on the hepatobiliary phase of MR imaging. Abdom Imaging. 2015;40(7):2364–71.","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs00261-015-0488-7",{"doi":379},"10.1007\u002Fs00261-015-0488-7",{"id":360,"text":381,"url":362,"identifiers":382},"Goodwin MD, Dobson JE, Sirlin CB, Lim BG, Stella DL. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics. 2011;31:1547–68.",{"doi":364},{"id":360,"text":384,"url":362,"identifiers":385},"Davenport MS, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, Maturen KE, Chenevert TL, Hussain HK. Comparison of acute transient dyspnea after intravenous adminis- tration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology. 2013;266:452–61.",{"doi":364},{"id":360,"text":387,"url":362,"identifiers":388},"Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affecting hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology. 2014;271:426–34.",{"doi":364},{"id":360,"text":390,"url":362,"identifiers":391},"Davenport MS, Bashir MR, Pietryga JA, Weber JT, Khalatbari S, Hussain HK. Dose-toxicity relationship of gadoxetate disodium and transient severe respiratory motion artifact. AJR Am J Roentgenol. 2014;203:796–802.",{"doi":364},{"id":393,"text":394,"url":395,"identifiers":396},"9f6a77a1-7023-49a4-8357-15543de76801","Akai H, Yasaka K, Nojima M, Kunimatsu A, Inoue Y, Abe O, Ohtomo K, Kiryu S. Gadoxetate disodium-induced tachypnoea and the effect of dilution method: a proof-of-concept study in mice. Eur Radiol. 2017 Sep;11.","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs00330-017-5037-z",{"doi":397},"10.1007\u002Fs00330-017-5037-z",{"id":360,"text":399,"url":362,"identifiers":400},"Davenport MS, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, Maturen KE, Chenevert TL, Hussain HK. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology. 2013;266(2):452–61.",{"doi":364},{"id":360,"text":402,"url":362,"identifiers":403},"Bashir MR, Castelli P, Davenport MS, Larson D, Marin D, Hussain HK, Jaffe TA. Respiratory motion artifact affecting hepatic arterial phase MR imaging with gadoxetate disodium is more common in patients with a prior episode of arterial phase motion associated with gadoxetate disodium. Radiology. 2015;274:141–8.",{"doi":364},{"id":360,"text":405,"url":362,"identifiers":406},"Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affect- ing hepatic arterial phase imaging with gadoxetate disodium: examination recovery with a multiple arterial phase acquisition. Radiology. 2014;271:426–34.",{"doi":364},{"id":360,"text":408,"url":362,"identifiers":409},"Davenport MS, Caoili EM, Kaza RK, Hussain HK. Matched within-patient cohort study of transient arterial phase respiratory motion-related artifact in MR imaging of the liver: gadoxetate disodium versus gadobenate dimeglumine. Radiology. 2014;272:123–31.",{"doi":364},{"id":20,"text":411,"url":20,"identifiers":412},"Yoo JL, Lee CH, Park YS, Kim JW, Lee J, Kim KA, Seol HY, Park CM. The short breath-hold technique, controlled aliasing in parallel imaging results in higher acceleration, can be the first step to overcoming a degraded hepatic arterial phase in liver magnetic resonance imaging: a prospective randomized control study. Investig Radiol. 2016;51(7):440–6.",{},{"id":414,"text":415,"url":416,"identifiers":417},"09532fcb-0826-4fdb-a600-817ff5cae4ed","Schalkx HJ, van Stralen M, Coenegrachts K, van den Bosch MA, van Kessel CS, van Hillegersberg R, van Erpecum KJ, Verkooijen HM, Pluim JP, Veldhuis WB, van Leeuwen MS. Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB DTPA in normal liver parenchyma. Eur Radiol. 2014;24(9):2146–56.","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs00330-014-3275-x",{"doi":418},"10.1007\u002Fs00330-014-3275-x",{"id":360,"text":420,"url":362,"identifiers":421},"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60.",{"doi":364},{"id":360,"text":423,"url":362,"identifiers":424},"Saito K, Kotake F, Ito N, et al. Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4:1–9.",{"doi":364},{"id":360,"text":426,"url":362,"identifiers":427},"Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996;200:59–67.",{"doi":364},{"id":429,"text":430,"url":431,"identifiers":432},"6e299051-5199-4364-8c42-f331694d8cac","Feuerlein S, Gupta RT, Boll DT, Merkle EM. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine. Eur J Radiol. 2012;81(9):2037–41.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0720048X11005535",{"doi":433},"10.1016\u002Fj.ejrad.2011.06.014",{"id":360,"text":435,"url":362,"identifiers":436},"Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol. 2010;195(1):29–41.",{"doi":364},{"id":438,"text":439,"url":440,"identifiers":441},"d7b8b378-950f-466a-8f27-e89f845985c1","Campos JT, Sirlin CB, Choi JY. Focal hepatic lesions in Gd- EOB-DTPA enhanced MRI: the atlas. Insights Imaging. 2012;3(5):451–74.","https:\u002F\u002Finsightsimaging.springeropen.com\u002Farticles\u002F10.1007\u002Fs13244-012-0179-7",{"doi":442},"10.1007\u002Fs13244-012-0179-7",{"id":414,"text":444,"url":416,"identifiers":445},"Schalkx HJ, van Stralen M, Coenegrachts K, van den Bosch MA, van Kessel CS, van Hillegersberg R, van Erpecum KJ, Verkooijen HM, Pluim JP, Veldhuis WB, van Leeuwen MS. Liver perfusion in dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI): comparison of enhancement in Gd-BT-DO3A and Gd-EOB-DTPA in normal liver parenchyma. Eur Radiol. 2014 Sep;24(9):2146–56.",{"doi":418},{"id":447,"text":448,"url":449,"identifiers":450},"bf63c138-afa5-4fc8-bf9d-3fd9c032f5ec","Reimer P, Rummeny EJ, Daldrup HE, Hesse T, Balzer T, Tombach B, Peters PE. Enhancement characteristics of liver metastases, hepato- cellular carcinomas, and hemangiomas with Gd-EOB-DTPA: prelim- inary results with dynamic MR imaging. Eur Radiol. 1997;7(2):275–80.","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs003300050150",{"doi":451},"10.1007\u002Fs003300050150",{"id":360,"text":453,"url":362,"identifiers":454},"Dahlqvist Leinhard O, Dahlstrom N, Kihlberg J, Sandström P, Brismar TB, Smedby O, Lundberg P. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur Radiol. 2012;22(3):642–53.",{"doi":364},{"id":360,"text":456,"url":362,"identifiers":457},"Frydrychowicz A, Nagle SK, D'Souza SL, Vigen KK, Reeder SB. Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid. J Magn Reson Imaging. 2011;34(3):585–94.",{"doi":364},{"id":360,"text":459,"url":362,"identifiers":460},"Filippone A, Blakeborough A, Breuer J, Grazioli L, Gschwend S, Hammerstingl R, Heinz-Peer G, Kittner T, Laghi A, Leen E, Lencioni R, Lucidarme O, Remplik P, Robinson PJ, Ruehm SG, Schaefer F, Stoupis C, Tombach B, Valette PJ, Zech CJ, Huppertz A. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging. 2010;31(2):356–64.",{"doi":364},{"id":20,"text":462,"url":463,"identifiers":464},"Granata V, Fusco R, Avallone A, Catalano O, Piccirillo M, Palaia R, Nasti G, Petrillo A, Izzo F. A radiologist's point of view in the presurgical and intraoperative setting of colorectal liver metastases. Future Oncol. 2018. https:\u002F\u002Fdoi.org\u002F10.2217\u002Ffon-2018-0080.","http:\u002F\u002Fdx.doi.org\u002F10.2217\u002Ffon-2018-0080",{"doi":465},"10.2217\u002Ffon-2018-0080",{"id":467,"text":468,"url":469,"identifiers":470},"516f745e-59f4-4fc0-bd7c-af788c180969","Tsuda N, Okada M, Murakami T. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol. 2010;73:137–42.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0720048X08005482",{"doi":471},"10.1016\u002Fj.ejrad.2008.09.036",{"id":20,"text":473,"url":20,"identifiers":474},"Planchamp C, Pastor CM, Balant L, Becker CD, Terrier F, Gex-Fabry M. Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA. Investig Radiol. 2005;40:705–14.",{},{"id":360,"text":476,"url":362,"identifiers":477},"Tajima T, Takao H, Akai H, Imamura H, Watanabe Y, Shibahara J, Kokudo N, Akahane M, Ohtomo K. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr. 2010;34:362–6.",{"doi":364},{"id":360,"text":479,"url":362,"identifiers":480},"Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, Araki T. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EO B-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009;30:1042–6.",{"doi":364},{"id":482,"text":483,"url":484,"identifiers":485},"6f39a45c-d0ae-4abd-81e3-0172650e9576","Tamada T, Ito K, Higaki A, Yoshida K, Kanki A, Sato T, Higashi H, Sone T. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol. 2011;80:311–6.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0720048X11000490",{"doi":486},"10.1016\u002Fj.ejrad.2011.01.020",{"id":488,"text":489,"url":490,"identifiers":491},"0c2397a2-b9b2-44ff-9fe4-38d15974bf6b","Motosugi U, Ichikawa T, Oguri M, Sano K, Sou H, Muhi A, Matsuda M, Fujii H, Enomoto N, Araki T. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging. 2011;29:1047–52.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0730725X11001846",{"doi":492},"10.1016\u002Fj.mri.2011.05.007",{"id":494,"text":495,"url":496,"identifiers":497},"42223192-29de-4811-9456-d449758294c2","Utsunomiya T, Shimada M, Hanaoka J, Kanamoto M, Ikemoto T, Morine Y, Imura S, Harada M. Possible utility of MRI using Gd-EOB-DTPA for estimating liver functional reserve. J Gastroenterol. 2012;47:470–6.","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs00535-011-0513-8",{"doi":498},"10.1007\u002Fs00535-011-0513-8",{"id":500,"text":501,"url":502,"identifiers":503},"668392ed-03d4-456c-9ead-b94f151e1e67","Nishie A, Ushijima Y, Tajima T, Asayama Y, Ishigami K, Kakihara D, Nakayama T, Takayama Y, Okamoto D, Abe K, Obara M, Yoshimitsu K, Honda H. Quantitative analysis of liver function using superparamagnetic iron oxide- and Gd-EOB-DTPA-enhanced MRI: comparison with technetium-99m galactosyl serum albumin scintigraphy. Eur J Radiol. 2012;81:1100–4.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0720048X11002397",{"doi":504},"10.1016\u002Fj.ejrad.2011.02.053",{"id":360,"text":506,"url":362,"identifiers":507},"Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, Bae KT. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology. 2011;259:142–50.",{"doi":364},{"id":360,"text":509,"url":362,"identifiers":510},"Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, Imai Y, Kudo M, Murakami T. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Investig Radiol. 2011;46:277–83.",{"doi":364},{"id":360,"text":512,"url":362,"identifiers":513},"Galia M, Agnello F, Sparacia G, Matranga D, Albano D, Midiri M, Lagalla R. Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients. Radiol Med. 2018 Jul;123(7):489–97.",{"doi":364},{"id":360,"text":515,"url":362,"identifiers":516},"Granata V, Fusco R, Filice S, Incollingo P, Belli A, Izzo F, Petrillo A. Comment on \"State of the art in magnetic resonance imaging of hepatocellular carcinoma\": the role of DWI. Radiol Oncol. 2019 Jul 13.",{"doi":364},{"id":20,"text":518,"url":20,"identifiers":519},"Calistri L, Castellani A, Matteuzzi B et al. Focal Liver Lesions Classifications and Characterization. What Value do DWI and ADC have? J Comput Assist Tomogr 40:701–8.",{},{"id":20,"text":521,"url":20,"identifiers":522},"Izzo F, Granata V, Grassi R, Fusco R, Palaia R, Delrio P, Carrafiello G, Azoulay D, Petrillo A, Curley SA. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. Oncologist. 2019 Jun 19. pii:theoncologist.2018–0337.",{},{"id":360,"text":524,"url":362,"identifiers":525},"Granata V, Fusco R, Setola SV, Picone C, Vallone P, Belli A, Incollingo P, Albino V, Tatangelo F, Izzo F, Petrillo A. Microvascular invasion and grading in hepatocellular carcinoma: correlation with major and ancillary features according to LIRADS. Abdom Radiol (NY). 2019;44(8):2788–800.",{"doi":364},{"id":360,"text":527,"url":362,"identifiers":528},"Granata V, Fusco R, Filice S, Catalano O, Piccirillo M, Palaia R, Izzo F, Petrillo A. The current role and future prospectives of functional parameters by diffusion weighted imaging in the assessment of histologic grade of HCC. Infect Agent Cancer. 2018;13:23.",{"doi":364},{"id":360,"text":530,"url":362,"identifiers":531},"Granata V, Md FR, Catalano O, Filice S, Avallone A, Piccirillo M, Leongito M, Palaia R, Grassi R, Izzo F, Petrillo A. Uncommon neoplasms of the biliary tract: radiological findings. Br J Radiol. 2017;90(1078):20160561.",{"doi":364},{"id":360,"text":533,"url":362,"identifiers":534},"Granata V, Fusco R, Catalano O, Avallone A, Palaia R, Botti G, Tatangelo F, Granata F, Cascella M, Izzo F, Petrillo A. Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases. PLoS One. 2017;12(6):e0179951.",{"doi":364},{"id":536,"text":537,"url":538,"identifiers":539},"174a3cd3-b35c-45fb-b977-3ac5b59f4e40","Granata V, Fusco R, Catalano O, Avallone A, Leongito M, Izzo F, Petrillo A. Peribiliary liver metastases MR findings. Med Oncol. 2017;34(7):124.","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs12032-017-0981-7",{"doi":540},"10.1007\u002Fs12032-017-0981-7",false,{"id":543,"createTime":544,"updateTime":545,"relativeEntities":546,"slug":547,"properties":548,"entityType":131,"verifyStatus":132,"verifyTime":557,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":558,"fullTextUrl":20,"authors":559,"publicationType":287,"publisherRelationship":694,"citationCount":275,"citationInfo":753,"publishDate":756,"publishYear":754,"citationAnalyzeStatus":19,"lastCitationAnalyze":757,"indexDatabases":758,"openAccess":20,"references":759,"isForceReanalyzing":541},"1fc7f986-406e-4337-803f-7e8dd6ade039","2024-01-01T17:50:15.909+00:00","2026-07-21T09:45:57.470+00:00",[],"Clustering-patterns-of-human-papillomavirus-infections-among-HIV-positive-women-in-Kenya",{"abstract":549,"title":551,"gsPaper":553,"doi":555},{"EN":550},"HIV-positive women are at increased risk of human papillomavirus (HPV) infection, and, especially, multiple infections compared to HIV-negative women. Whether certain HPV types have a tendency to cluster in multiple infections beyond or below what would be expected by shared risk factors (e.g., sexual behavior and the degree of immunosuppression) is unclear. We, therefore, investigated clustering patterns of 44 HPV types in HIV-positive women from Kenya. HPV status was assessed on cervical scrapings from 498 women using GP5+\u002F6+ PCR and reverse line blot. Logistic regression was used to model type-specific HPV positivity, adjusted for age, specific HPV type prevalence, CD4, combination antiretroviral therapy, and, in the Full Model, individual-level random effects that represent unobservable risk factors common to all HPV types. We found a modest excess of women with co-infections with 2 HPV types (1.12; 95% credible intervals: 1.03-1.21) in the Full Model but no significant associations of individual types. No significant deviations of observed\u002Fexpected counts were observed for any 2-way combination of HPV types at either the chosen level of significance, p = 0.00005, or at p = 0.01. Findings were substantially similar when women with CIN2\u002F3 were excluded and when they were stratified by use of anti-retroviral therapy or CD4 count. HPV co-infections occurred at random in the cervix of HIV-positive women as previously found in HIV-negative women. The removal of HPV types through vaccination should not result, therefore, in an increase or decrease in the prevalence of HPV types not targeted by vaccination in immunosuppressed women.",{"EN":552},"Clustering patterns of human papillomavirus infections among HIV-positive women in Kenya",{"VOID":554},"[\"10371348255997192409\"]",{"VOID":556},"10.1186\u002F1750-9378-8-50","2024-05-01T10:51:29.770+00:00","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002F1750-9378-8-50",[560,577,590,605,620,633,648,661],{"id":561,"sortIndex":21,"researcher":20,"roles":562,"affiliations":563,"properties":572,"displayName":574,"givenName":20,"familyName":20},"c3fa605f-39c9-4a4f-9594-3761f4b5dbbc",[140],[564],{"id":565,"sortIndex":21,"affiliation":566,"properties":20},"1492791e-60ce-4942-9c6b-953bf52de837",{"id":565,"createTime":20,"updateTime":20,"relativeEntities":567,"slug":20,"properties":568,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":571,"statistic":20},[],{"title":569},{"VI":570},"International Agency for Research on Cancer, Lyon CEDEX 08, France",[],{"title":573,"gsAuthor":575},{"VI":574},"Salvatore Vaccarella",{"VOID":576},"[\"reP3x7IAAAAJ\"]",{"id":578,"sortIndex":105,"researcher":20,"roles":579,"affiliations":580,"properties":587,"displayName":589,"givenName":20,"familyName":20},"e5ec963e-dde7-4b87-9e6b-6609352999cb",[140],[581],{"id":565,"sortIndex":21,"affiliation":582,"properties":20},{"id":565,"createTime":20,"updateTime":20,"relativeEntities":583,"slug":20,"properties":584,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":586,"statistic":20},[],{"title":585},{"VI":570},[],{"title":588},{"VI":589},"Hugo De Vuyst",{"id":591,"sortIndex":106,"researcher":20,"roles":592,"affiliations":593,"properties":602,"displayName":604,"givenName":20,"familyName":20},"08969312-3a70-4dc3-9737-d68a324ad001",[140],[594],{"id":595,"sortIndex":21,"affiliation":596,"properties":20},"463c3034-f90d-41b1-9ca6-02b9c3393a5e",{"id":595,"createTime":20,"updateTime":20,"relativeEntities":597,"slug":20,"properties":598,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":601,"statistic":20},[],{"title":599},{"VI":600},"Department of Obstetrics and Gynecology, Kenyatta National Hospital, Nairobi, Kenya",[],{"title":603},{"VI":604},"Nelly R Mugo",{"id":606,"sortIndex":107,"researcher":20,"roles":607,"affiliations":608,"properties":617,"displayName":619,"givenName":20,"familyName":20},"85f33bfa-72e9-4076-88b7-74e3288dbf93",[140],[609],{"id":610,"sortIndex":21,"affiliation":611,"properties":20},"614b42fb-fd6b-4280-8228-d4d00af381f4",{"id":610,"createTime":20,"updateTime":20,"relativeEntities":612,"slug":20,"properties":613,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":616,"statistic":20},[],{"title":614},{"VI":615},"Coptic Hospital, Nairobi, Kenya",[],{"title":618},{"VI":619},"Samah R Sakr",{"id":621,"sortIndex":202,"researcher":20,"roles":622,"affiliations":623,"properties":630,"displayName":632,"givenName":20,"familyName":20},"78417c69-1ce6-453f-a9d9-3325349c8e72",[140],[624],{"id":565,"sortIndex":21,"affiliation":625,"properties":20},{"id":565,"createTime":20,"updateTime":20,"relativeEntities":626,"slug":20,"properties":627,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":629,"statistic":20},[],{"title":628},{"VI":570},[],{"title":631},{"VI":632},"Martyn Plummer",{"id":634,"sortIndex":216,"researcher":20,"roles":635,"affiliations":636,"properties":645,"displayName":647,"givenName":20,"familyName":20},"f0be0761-7927-4529-b86a-11367726c68d",[140],[637],{"id":638,"sortIndex":21,"affiliation":639,"properties":20},"63093f4e-26d3-425e-9493-65de56f0c6f9",{"id":638,"createTime":20,"updateTime":20,"relativeEntities":640,"slug":20,"properties":641,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":644,"statistic":20},[],{"title":642},{"VI":643},"Department of Pathology, VU University Medical Center (VUMC), Amsterdam, The Netherlands",[],{"title":646},{"VI":647},"Daniëlle A M Heideman",{"id":649,"sortIndex":108,"researcher":20,"roles":650,"affiliations":651,"properties":658,"displayName":660,"givenName":20,"familyName":20},"759ceb9a-22bf-49f1-a2ab-d26a6b076bd9",[140],[652],{"id":565,"sortIndex":21,"affiliation":653,"properties":20},{"id":565,"createTime":20,"updateTime":20,"relativeEntities":654,"slug":20,"properties":655,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":657,"statistic":20},[],{"title":656},{"VI":570},[],{"title":659},{"VI":660},"Silvia Franceschi",{"id":662,"sortIndex":245,"researcher":20,"roles":663,"affiliations":664,"properties":691,"displayName":693,"givenName":20,"familyName":20},"0fa7d993-0d04-4810-8082-c7e1f9ce881f",[140],[665,673,682],{"id":666,"sortIndex":21,"affiliation":667,"properties":20},"ca8d4a60-2cb2-4c47-92f8-2a5f59a28569",{"id":666,"createTime":20,"updateTime":20,"relativeEntities":668,"slug":20,"properties":669,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":672,"statistic":20},[],{"title":670},{"VI":671},"Department of Global Health, University of Washington, Seattle, USA",[],{"id":674,"sortIndex":105,"affiliation":675,"properties":681},"19865214-117b-4d5a-95fe-caf9d0b7e635",{"id":674,"createTime":20,"updateTime":20,"relativeEntities":676,"slug":20,"properties":677,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":680,"statistic":20},[],{"title":678},{"VI":679},"Department of Medicine, University of Washington, Seattle, USA",[],{},{"id":683,"sortIndex":106,"affiliation":684,"properties":690},"96381d73-9d1f-4a91-a008-bf565fee545f",{"id":683,"createTime":20,"updateTime":20,"relativeEntities":685,"slug":20,"properties":686,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":689,"statistic":20},[],{"title":687},{"VI":688},"Department of Epidemiology, University of Washington, Seattle, USA",[],{},{"title":692},{"VI":693},"Michael Chung",{"url":558,"publisher":695,"properties":748},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":696,"slug":10,"properties":697,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":700,"manageAffiliations":717,"indexDatabases":728,"url":20,"thumbnailPath":20,"statistic":743,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":698,"title":699},{"VOID":13},{"EN":15},[701,705,709,713],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":702,"label":703,"description":704,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":706,"label":707,"description":708,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":710,"label":711,"description":712,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":714,"label":715,"description":716,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[718,723],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":719,"slug":20,"properties":720,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":722,"statistic":20},[],{"title":721},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":724,"slug":20,"properties":725,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":727,"statistic":20},[],{"title":726},{"EN":60},[],[729,736],{"id":64,"indexDatabase":730,"url":75,"indexYears":76,"academicFieldIds":735,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":731,"label":732,"description":733,"key":72,"publicationTags":734,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":737,"url":97,"indexYears":20,"academicFieldIds":742,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":738,"label":739,"description":740,"key":93,"publicationTags":741,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":744,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":745,"totalCitation":21,"totalCitationByYear":746,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":747,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":749,"volume":751},{"VOID":750},"1-4",{"VOID":752},"8",{"total":275,"publishYear":754,"statisticByYear":755},2013,{"2013":105,"2015":106,"2016":105,"2019":105,"2020":105,"2021":106,"2022":105},"2013-12-19","2026-07-21T09:45:57.469+00:00",[82,95],[760,764,772,780,785,794,802,805,814,822,831,840,843,852,860,863],{"id":20,"text":761,"url":20,"identifiers":762},"Clifford GM, Goncalves MA: Franceschi S, for the HPV and HIV Study Group: human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006, 20: 2337-2344. 10.1097\u002F01.aids.0000253361.63578.14.",{"doi":763},"10.1097\u002F01.aids.0000253361.63578.14",{"id":20,"text":765,"url":766,"identifiers":767},"De Vuyst H, Lillo F, Broutet N, Smith JS: HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev. 2008, 17: 545-554. 10.1097\u002FCEJ.0b013e3282f75ea1.","https:\u002F\u002Fdoi.org\u002F10.1097\u002Fcej.0b013e3282f75ea1",{"mag":768,"openalex":769,"pm":770,"doi":771},"2074610446","W2074610446","18941376","10.1097\u002Fcej.0b013e3282f75ea1",{"id":20,"text":773,"url":774,"identifiers":775},"Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M: Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev. 2010, 19: 503-510. 10.1158\u002F1055-9965.EPI-09-0983.","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1055-9965.epi-09-0983",{"mag":776,"openalex":777,"pm":778,"doi":779},"2130254527","W2130254527","20142247","10.1158\u002F1055-9965.epi-09-0983",{"id":20,"text":781,"url":782,"identifiers":783},"Chaturvedi A, Katki H, Hildesheim A, Rodriguez AC, Quint W, Schiffman M, Van Doorn LJ, Porras C, Wacholder S, Gonzalez P, Sherman M, Herrero R: Human papillomavirus infection with multiple types: pattern of co-infection and risk of cervical disease. J Infect Dis. 2011, 203: 910-920. 10.1093\u002Finfdis\u002Fjiq139.","http:\u002F\u002Fdx.doi.org\u002F10.1016\u002Fj.yobg.2011.05.094",{"doi":784},"10.1016\u002Fj.yobg.2011.05.094",{"id":20,"text":786,"url":787,"identifiers":788},"Vaccarella S, Franceschi S, Herrero R, Schiffman M, Rodriguez AC, Hildesheim A, Burk RD, Plummer M: Clustering of multiple human papillomavirus infections in women from a population-based study in Guanacaste, Costa Rica. J Infect Dis. 2011, 204: 385-390. 10.1093\u002Finfdis\u002Fjir286.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Finfdis\u002Fjir286",{"mag":789,"pmc":790,"openalex":791,"pm":792,"doi":793},"2112276697","3132145","W2112276697","21742837","10.1093\u002Finfdis\u002Fjir286",{"id":20,"text":795,"url":796,"identifiers":797},"Carozzi F, Ronco G, Gillio-Tos A, De Marco L, Del Mistro A, Girlando S, Franceschi S, Plummer M, Vaccarella S: Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study. Eur J Cancer. 2012, 48: 1633-1637. 10.1016\u002Fj.ejca.2011.10.010.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ejca.2011.10.010",{"mag":798,"openalex":799,"pm":800,"doi":801},"2100713579","W2100713579","22088483","10.1016\u002Fj.ejca.2011.10.010",{"id":360,"text":803,"url":362,"identifiers":804},"Vaccarella S, Soderlund-Strand A, Franceschi S, Plummer M, Dillner J: Patterns of human papillomavirus types in multiple infections: an analysis in women and men of the high throughput human papillomavirus monitoring study. Plos One. 2013, 8: e71617-10.1371\u002Fjournal.pone.0071617.",{"doi":364},{"id":20,"text":806,"url":807,"identifiers":808},"Vaccarella S, Plummer M, Franceschi S, Gravitt P, Papenfuss M, Smith D, Villa L, Ponce EL, Giuliano AR: Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J Infect Dis. 2011, 204: 1500-1504. 10.1093\u002Finfdis\u002Fjir595.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Finfdis\u002Fjir595",{"mag":809,"pmc":810,"openalex":811,"pm":812,"doi":813},"2129154220","3222106","W2129154220","21908729","10.1093\u002Finfdis\u002Fjir595",{"id":20,"text":815,"url":816,"identifiers":817},"Chaturvedi AK, Myers L, Hammons AF, Clark RA, Dunlap K, Kissinger PJ, Hagensee ME: Prevalence and clustering patterns of human papillomavirus genotypes in multiple infections. Cancer Epidemiol Biomarkers Prev. 2005, 14: 2439-2445. 10.1158\u002F1055-9965.EPI-05-0465.","https:\u002F\u002Fdoi.org\u002F10.1158\u002F1055-9965.epi-05-0465",{"mag":818,"openalex":819,"pm":820,"doi":821},"2111520654","W2111520654","16214929","10.1158\u002F1055-9965.epi-05-0465",{"id":20,"text":823,"url":824,"identifiers":825},"De Vuyst H, Mugo NR, Chung MH, McKenzie KP, Nyongesa-Malava E, Tenet V, Njoroge JW, Sakr SR, Meijer CM, Snijders PJ, Rana FS, Franceschi S: Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. Br J Cancer. 2012, 107: 1624-1630. 10.1038\u002Fbjc.2012.441.","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fbjc.2012.441",{"mag":826,"pmc":827,"openalex":828,"pm":829,"doi":830},"2133164108","3493776","W2133164108","23033006","10.1038\u002Fbjc.2012.441",{"id":20,"text":832,"url":833,"identifiers":834},"Chung MH, McKenzie KP, Richardson BA, John-Stewart GC, Coombs RW, De Vuyst H, Njoroge JW, Nyongesa-Malava E, Sakr SR, Mugo NR: Cervical HIV-1 RNA shedding after cryotherapy among HIV-positive women with cervical intraepithelial neoplasia stage 2 or 3. AIDS. 2011, 25: 1915-1919. 10.1097\u002FQAD.0b013e32834a3654.","https:\u002F\u002Fdoi.org\u002F10.1097\u002Fqad.0b013e32834a3654",{"mag":835,"pmc":836,"openalex":837,"pm":838,"doi":839},"2076471277","3248579","W2076471277","21716072","10.1097\u002Fqad.0b013e32834a3654",{"id":360,"text":841,"url":362,"identifiers":842},"Chung MH, McKenzie KP, De Vuyst H, Richardson BA, Rana FS, Pamnani R, Njoroge JW, Nyongesa-Malava E, Sakr SR, John-Stewart GC, Mugo NR: Comparing pap smear, via, and hpv cervical cancer screening methods among hiv-positive women by immune status, and antiretroviral therapy. AIDS. 2013, [Epub ahead of print]",{"doi":364},{"id":20,"text":844,"url":845,"identifiers":846},"van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ: GP5+\u002F6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002, 40: 779-787. 10.1128\u002FJCM.40.3.779-787.2002.","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fjcm.40.3.779-787.2002",{"mag":847,"pmc":848,"openalex":849,"pm":850,"doi":851},"2141641834","120256","W2141641834","11880393","10.1128\u002Fjcm.40.3.779-787.2002",{"id":20,"text":853,"url":854,"identifiers":855},"Plummer M, Vaccarella S, Franceschi S: Multiple human papillomavirus infections: the exception or the rule?. J Infect Dis. 2011, 203: 891-893. 10.1093\u002Finfdis\u002Fjiq146.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Finfdis\u002Fjiq146",{"mag":856,"openalex":857,"pm":858,"doi":859},"2112071277","W2112071277","21402540","10.1093\u002Finfdis\u002Fjiq146",{"id":20,"text":861,"url":20,"identifiers":862},"Vaccarella S, Plummer M, Franceschi S: Reply to Cervantes. J Infect Dis. 2011, 204: 1816-1817.",{},{"id":20,"text":864,"url":865,"identifiers":866},"Strickler HD, Palefsky JM, Shah KV, Anastos K, Klein RS, Minkoff H, Duerr A, Massad LS, Celentano DD, Hall C, Fazzari M, Cu-Uvin S, Bacon M, Schuman P, Levine AM, Durante AJ, Gange S, Melnick S, Burk RD: Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst. 2003, 95: 1062-1071. 10.1093\u002Fjnci\u002F95.14.1062.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fjnci\u002F95.14.1062",{"mag":867,"openalex":868,"pm":869,"doi":870},"1973422557","W1973422557","12865452","10.1093\u002Fjnci\u002F95.14.1062",{"id":872,"createTime":873,"updateTime":874,"relativeEntities":875,"slug":876,"properties":877,"entityType":131,"verifyStatus":132,"verifyTime":886,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":887,"fullTextUrl":20,"authors":888,"publicationType":287,"publisherRelationship":1097,"citationCount":21,"citationInfo":1156,"publishDate":1159,"publishYear":1157,"citationAnalyzeStatus":19,"lastCitationAnalyze":1160,"indexDatabases":1161,"openAccess":20,"references":1162,"isForceReanalyzing":541},"540ac616-b5e9-4195-802e-ebe1096240a5","2024-01-14T07:09:37.437+00:00","2026-07-16T14:02:49.562+00:00",[],"Association-between-PEG3-DNA-methylation-and-high-grade-cervical-intraepithelial-neoplasia",{"abstract":878,"title":880,"gsPaper":882,"doi":884},{"EN":879},"Epigenetic mechanisms are hypothesized to contribute substantially to the progression of cervical intraepithelial neoplasia (CIN) to cervical cancer, although empirical data are limited. Women (n = 419) were enrolled at colposcopic evaluation at Duke Medical Center in Durham, North Carolina. Human papillomavirus (HPV) was genotyped by HPV linear array and CIN grade was ascertained by biopsy pathologic review. DNA methylation was measured at differentially methylated regions (DMRs) regulating genomic imprinting of the IGF2\u002FH19, IGF2AS, MESTIT1\u002FMEST, MEG3, PLAGL1\u002FHYMAI, KvDMR and PEG10, PEG3 imprinted domains, using Sequenom-EpiTYPER assays. Logistic regression models were used to evaluate the associations between HPV infection, DMR methylation and CIN risk overall and by race. Of the 419 participants, 20 had CIN3+, 52 had CIN2, and 347 had ≤ CIN1 (CIN1 and negative histology). The median participant age was 28.6 (IQR:11.6) and 40% were African American. Overall, we found no statistically significant association between altered methylation in selected DMRs and CIN2+ compared to ≤CIN1. Similarly, there was no significant association between DMR methylation and CIN3+ compared to ≤CIN2. Restricting the outcome to CIN2+ cases that were HR-HPV positive and p16 staining positive, we found a significant association with PEG3 DMR methylation (OR: 1.56 95% CI: 1.03–2.36). While the small number of high-grade CIN cases limit inferences, our findings suggest an association between altered DNA methylation at regulatory regions of PEG3 and high grade CIN in high-risk HPV positive cases.",{"EN":881},"Association between PEG3 DNA methylation and high-grade cervical intraepithelial neoplasia",{"VOID":883},"[\"3395455488678441111\"]",{"VOID":885},"10.1186\u002Fs13027-021-00382-3","2024-05-03T02:36:29.153+00:00","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13027-021-00382-3",[889,906,921,938,955,970,983,998,1013,1028,1041,1055,1069,1083],{"id":890,"sortIndex":21,"researcher":20,"roles":891,"affiliations":892,"properties":901,"displayName":903,"givenName":20,"familyName":20},"88f563f2-fec2-4988-a11e-61041469702b",[140],[893],{"id":894,"sortIndex":21,"affiliation":895,"properties":20},"07a0c306-5e3f-4bf3-a87e-28ac0a615911",{"id":894,"createTime":20,"updateTime":20,"relativeEntities":896,"slug":20,"properties":897,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":900,"statistic":20},[],{"title":898},{"EN":899},"Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, USA",[],{"title":902,"gsAuthor":904},{"VI":903},"Claire Bosire",{"VOID":905},"[\"j3gQb40AAAAJ\"]",{"id":907,"sortIndex":105,"researcher":20,"roles":908,"affiliations":909,"properties":918,"displayName":920,"givenName":20,"familyName":20},"c7ea41e0-6bba-429e-8f79-29356759979a",[140],[910],{"id":911,"sortIndex":21,"affiliation":912,"properties":20},"88aa6f9c-f636-4d1c-a0be-bc36dacb8e6e",{"id":911,"createTime":20,"updateTime":20,"relativeEntities":913,"slug":20,"properties":914,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":917,"statistic":20},[],{"title":915},{"VI":916},"Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, USA",[],{"title":919},{"VI":920},"Adriana C. Vidal",{"id":922,"sortIndex":106,"researcher":20,"roles":923,"affiliations":924,"properties":933,"displayName":935,"givenName":20,"familyName":20},"134e7ea3-34d5-472b-994b-163c103f0df2",[140],[925],{"id":926,"sortIndex":21,"affiliation":927,"properties":20},"9e8b22d7-07c4-4c3b-aa33-ecb86617422a",{"id":926,"createTime":20,"updateTime":20,"relativeEntities":928,"slug":20,"properties":929,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":932,"statistic":20},[],{"title":930},{"VI":931},"Department of Epidemiology, Gillings School of Global Public Health and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA",[],{"title":934,"gsAuthor":936},{"VI":935},"Jennifer S. Smith",{"VOID":937},"[\"tC48DeMAAAAJ\"]",{"id":939,"sortIndex":107,"researcher":20,"roles":940,"affiliations":941,"properties":950,"displayName":952,"givenName":20,"familyName":20},"6bf3b334-db94-4f60-883d-9f2e11222e04",[140],[942],{"id":943,"sortIndex":21,"affiliation":944,"properties":20},"5482ab58-42d9-4fe5-82aa-ccc808d13fe1",{"id":943,"createTime":20,"updateTime":20,"relativeEntities":945,"slug":20,"properties":946,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":949,"statistic":20},[],{"title":947},{"VI":948},"Department of Biological Sciences, Center for Human Health and the Environment, North Carolina State University, Raleigh, USA",[],{"title":951,"gsAuthor":953},{"VI":952},"Dereje Jima",{"VOID":954},"[\"sOPfFGAAAAAJ\"]",{"id":956,"sortIndex":202,"researcher":20,"roles":957,"affiliations":958,"properties":967,"displayName":969,"givenName":20,"familyName":20},"7b221a9e-dc16-4fe8-be02-b4841a08e155",[140],[959],{"id":960,"sortIndex":21,"affiliation":961,"properties":20},"7957f1d4-2660-40bd-983a-fe3351a9d879",{"id":960,"createTime":20,"updateTime":20,"relativeEntities":962,"slug":20,"properties":963,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":966,"statistic":20},[],{"title":964},{"VI":965},"Department of Obstetrics and Gynecology, Division of Reproductive Sciences, Duke University School of Medicine, Durham, USA",[],{"title":968},{"VI":969},"Zhiqing Huang",{"id":971,"sortIndex":216,"researcher":20,"roles":972,"affiliations":973,"properties":980,"displayName":982,"givenName":20,"familyName":20},"637f0748-2e81-4796-b918-a9a006633af6",[140],[974],{"id":943,"sortIndex":21,"affiliation":975,"properties":20},{"id":943,"createTime":20,"updateTime":20,"relativeEntities":976,"slug":20,"properties":977,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":979,"statistic":20},[],{"title":978},{"VI":948},[],{"title":981},{"VI":982},"David Skaar",{"id":984,"sortIndex":108,"researcher":20,"roles":985,"affiliations":986,"properties":995,"displayName":997,"givenName":20,"familyName":20},"10a404fb-6f16-46b9-979b-6a709f598a10",[140],[987],{"id":988,"sortIndex":21,"affiliation":989,"properties":20},"f73c651e-ee16-4e97-80e4-b1c713d77a1b",{"id":988,"createTime":20,"updateTime":20,"relativeEntities":990,"slug":20,"properties":991,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":994,"statistic":20},[],{"title":992},{"VI":993},"Department of Obstetrics and Gynecology, Virginia Tech Carilion School of Medicine, Roanoke, USA",[],{"title":996},{"VI":997},"Fidel Valea",{"id":999,"sortIndex":245,"researcher":20,"roles":1000,"affiliations":1001,"properties":1010,"displayName":1012,"givenName":20,"familyName":20},"236e7143-b23e-4ce0-a815-ac7daece0937",[140],[1002],{"id":1003,"sortIndex":21,"affiliation":1004,"properties":20},"acf13f95-0367-4c92-8268-32913b72d5a1",{"id":1003,"createTime":20,"updateTime":20,"relativeEntities":1005,"slug":20,"properties":1006,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1009,"statistic":20},[],{"title":1007},{"EN":1008},"Department of Pathology, Duke University School of Medicine, Durham, USA",[],{"title":1011},{"VI":1012},"Rex Bentley",{"id":1014,"sortIndex":261,"researcher":20,"roles":1015,"affiliations":1016,"properties":1025,"displayName":1027,"givenName":20,"familyName":20},"9f26c825-dbf3-4939-9129-d6b480993098",[140],[1017],{"id":1018,"sortIndex":21,"affiliation":1019,"properties":20},"612e11d8-6e92-4305-9920-e8d7c6b17c25",{"id":1018,"createTime":20,"updateTime":20,"relativeEntities":1020,"slug":20,"properties":1021,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1024,"statistic":20},[],{"title":1022},{"VI":1023},"Department of Family Medicine and Community Health, Duke University School of Medicine, Durham, USA",[],{"title":1026},{"VI":1027},"Margaret Gradison",{"id":1029,"sortIndex":275,"researcher":20,"roles":1030,"affiliations":1031,"properties":1038,"displayName":1040,"givenName":20,"familyName":20},"1ee78432-79bb-4e71-99e7-369bc15a79b6",[140],[1032],{"id":1018,"sortIndex":21,"affiliation":1033,"properties":20},{"id":1018,"createTime":20,"updateTime":20,"relativeEntities":1034,"slug":20,"properties":1035,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1037,"statistic":20},[],{"title":1036},{"VI":1023},[],{"title":1039},{"VI":1040},"Kimberly S. H. Yarnall",{"id":1042,"sortIndex":1043,"researcher":20,"roles":1044,"affiliations":1045,"properties":1052,"displayName":1054,"givenName":20,"familyName":20},"c83a277c-c471-4877-84ec-6cd59c864923",10,[140],[1046],{"id":960,"sortIndex":21,"affiliation":1047,"properties":20},{"id":960,"createTime":20,"updateTime":20,"relativeEntities":1048,"slug":20,"properties":1049,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1051,"statistic":20},[],{"title":1050},{"VI":965},[],{"title":1053},{"VI":1054},"Anne Ford",{"id":1056,"sortIndex":1057,"researcher":20,"roles":1058,"affiliations":1059,"properties":1066,"displayName":1068,"givenName":20,"familyName":20},"85cb36e5-9498-4e98-8abf-cd31af7769aa",11,[140],[1060],{"id":1018,"sortIndex":21,"affiliation":1061,"properties":20},{"id":1018,"createTime":20,"updateTime":20,"relativeEntities":1062,"slug":20,"properties":1063,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1065,"statistic":20},[],{"title":1064},{"VI":1023},[],{"title":1067},{"VI":1068},"Francine Overcash",{"id":1070,"sortIndex":1071,"researcher":20,"roles":1072,"affiliations":1073,"properties":1080,"displayName":1082,"givenName":20,"familyName":20},"029d8aff-7027-47c1-99f5-655185b588ed",12,[140],[1074],{"id":960,"sortIndex":21,"affiliation":1075,"properties":20},{"id":960,"createTime":20,"updateTime":20,"relativeEntities":1076,"slug":20,"properties":1077,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1079,"statistic":20},[],{"title":1078},{"VI":965},[],{"title":1081},{"VI":1082},"Susan K. Murphy",{"id":1084,"sortIndex":1085,"researcher":20,"roles":1086,"affiliations":1087,"properties":1094,"displayName":1096,"givenName":20,"familyName":20},"bc3141cc-ef48-4bfb-8b6e-f84c3519399e",13,[140],[1088],{"id":943,"sortIndex":21,"affiliation":1089,"properties":20},{"id":943,"createTime":20,"updateTime":20,"relativeEntities":1090,"slug":20,"properties":1091,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1093,"statistic":20},[],{"title":1092},{"VI":948},[],{"title":1095},{"VI":1096},"Cathrine Hoyo",{"url":887,"publisher":1098,"properties":1151},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1099,"slug":10,"properties":1100,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1103,"manageAffiliations":1120,"indexDatabases":1131,"url":20,"thumbnailPath":20,"statistic":1146,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":1101,"title":1102},{"VOID":13},{"EN":15},[1104,1108,1112,1116],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1105,"label":1106,"description":1107,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1109,"label":1110,"description":1111,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1113,"label":1114,"description":1115,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":1117,"label":1118,"description":1119,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[1121,1126],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1122,"slug":20,"properties":1123,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1125,"statistic":20},[],{"title":1124},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":1127,"slug":20,"properties":1128,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1130,"statistic":20},[],{"title":1129},{"EN":60},[],[1132,1139],{"id":64,"indexDatabase":1133,"url":75,"indexYears":76,"academicFieldIds":1138,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1134,"label":1135,"description":1136,"key":72,"publicationTags":1137,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":1140,"url":97,"indexYears":20,"academicFieldIds":1145,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":1141,"label":1142,"description":1143,"key":93,"publicationTags":1144,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":1147,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":1148,"totalCitation":21,"totalCitationByYear":1149,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1150,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":1152,"volume":1154},{"VOID":1153},"1-8",{"VOID":1155},"16",{"total":21,"publishYear":1157,"statisticByYear":1158},2021,{},"2021-06-13","2026-07-16T14:02:49.561+00:00",[82,95],[1163,1166,1169,1173,1180,1187,1190,1193,1202,1211,1220,1229,1237,1240,1249,1258,1264,1273,1281,1290,1299,1307,1316,1324,1333,1342,1348,1356,1359,1367,1376,1382,1391,1400,1409],{"id":20,"text":1164,"url":20,"identifiers":1165},"American College of Obstetricians and Gynecologists. Practice bulletin no. 168: cervical cancer screening and prevention. Obstet Gynecol. 2016;128(4):e111–e30.",{},{"id":20,"text":1167,"url":20,"identifiers":1168},"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.",{},{"id":20,"text":1170,"url":1171,"identifiers":1172},"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2018. Bethesda: National Cancer Institute. 2021. Available at:https:\u002F\u002Fseer.cancer.gov\u002Fcsr\u002F1975_2018. Accessed May 21 2021.","https:\u002F\u002Fseer.cancer.gov\u002Fcsr\u002F1975_2018",{},{"id":20,"text":1174,"url":1175,"identifiers":1176},"Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for cervical cancer: US preventive services task force recommendation statement. JAMA. 2018;320(7):674–86. https:\u002F\u002Fdoi.org\u002F10.1001\u002Fjama.2018.10897.","https:\u002F\u002Fdoi.org\u002F10.1097\u002F01.ogx.0000549540.69362.81",{"mag":1177,"openalex":1178,"doi":1179},"2904815224","W2904815224","10.1097\u002F01.ogx.0000549540.69362.81",{"id":20,"text":1181,"url":1182,"identifiers":1183},"Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320(1):43–52. https:\u002F\u002Fdoi.org\u002F10.1001\u002Fjama.2018.7464.","https:\u002F\u002Fdoi.org\u002F10.1097\u002Fogx.0000000000000608",{"mag":1184,"openalex":1185,"doi":1186},"2901731388","W2901731388","10.1097\u002Fogx.0000000000000608",{"id":360,"text":1188,"url":362,"identifiers":1189},"Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, et al. Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017;8:CD008587.",{"doi":364},{"id":20,"text":1191,"url":20,"identifiers":1192},"Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Soulsby MA. Screening for cervical cancer with high-risk human papillomavirus testing: a systematic evidence review for the U.S. Prev Serv Task Force. 2018.",{},{"id":20,"text":1194,"url":1195,"identifiers":1196},"Wikström I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary pap-smear in women not regularly attending screening: a randomised study. Br J Cancer. 2011;105(3):337–9. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fbjc.2011.236.","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fbjc.2011.236",{"mag":1197,"pmc":1198,"openalex":1199,"pm":1200,"doi":1201},"1995608212","3172898","W1995608212","21730977","10.1038\u002Fbjc.2011.236",{"id":20,"text":1203,"url":1204,"identifiers":1205},"Lorincz AT. Cancer diagnostic classifiers based on quantitative DNA methylation. Expert Rev Mol Diagn. 2014;14(3):293–305. https:\u002F\u002Fdoi.org\u002F10.1586\u002F14737159.2014.897610.","https:\u002F\u002Fdoi.org\u002F10.1586\u002F14737159.2014.897610",{"mag":1206,"pmc":1207,"openalex":1208,"pm":1209,"doi":1210},"2081898372","4225655","W2081898372","24649818","10.1586\u002F14737159.2014.897610",{"id":20,"text":1212,"url":1213,"identifiers":1214},"Kelly H, Benavente Y, Pavon MA, De Sanjose S, Mayaud P, Lorincz AT. Performance of DNA methylation assays for detection of high-grade cervical intraepithelial neoplasia (CIN2+): a systematic review and meta-analysis. Br J Cancer. 2019;121(11):954–65. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41416-019-0593-4.","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41416-019-0593-4",{"mag":1215,"pmc":1216,"openalex":1217,"pm":1218,"doi":1219},"2981289376","6889421","W2981289376","31616037","10.1038\u002Fs41416-019-0593-4",{"id":20,"text":1221,"url":1222,"identifiers":1223},"Feinberg AP, Koldobskiy MA, Göndör A. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat Rev Genet. 2016;17(5):284–99. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrg.2016.13.","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrg.2016.13",{"mag":1224,"pmc":1225,"openalex":1226,"pm":1227,"doi":1228},"2297701691","4888057","W2297701691","26972587","10.1038\u002Fnrg.2016.13",{"id":20,"text":1230,"url":1231,"identifiers":1232},"Mai M, Qian C, Yokomizo A, Tindall DJ, Bostwick D, Polychronakos C, et al. Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene. 1998;17(13):1739–41. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsj.onc.1202099.","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsj.onc.1202099",{"mag":1233,"openalex":1234,"pm":1235,"doi":1236},"1981548290","W1981548290","9796703","10.1038\u002Fsj.onc.1202099",{"id":360,"text":1238,"url":362,"identifiers":1239},"Kazanets A, Shorstova T, Hilmi K, Marques M, Witcher M. Epigenetic silencing of tumor suppressor genes: paradigms, puzzles, and potential. Biochim Biophys Acta. 2016;1865(2):275–88.",{"doi":364},{"id":20,"text":1241,"url":1242,"identifiers":1243},"Kremer WW, Steenbergen R, Heideman D, Kenter GG, Meijer C. The use of host cell DNA methylation analysis in the detection and management of women with advanced cervical intraepithelial neoplasia: a review. BJOG. 2021;128(3):504–14. https:\u002F\u002Fdoi.org\u002F10.1111\u002F1471-0528.16395.","https:\u002F\u002Fdoi.org\u002F10.1111\u002F1471-0528.16395",{"mag":1244,"pmc":1245,"openalex":1246,"pm":1247,"doi":1248},"3039347884","7818489","W3039347884","32619334","10.1111\u002F1471-0528.16395",{"id":20,"text":1250,"url":1251,"identifiers":1252},"Nye MD, Hoyo C, Huang Z, Vidal AC, Wang F, Overcash F, et al. Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer. PLoS One. 2013;8(2):e56325. https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0056325.","https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0056325",{"mag":1253,"pmc":1254,"openalex":1255,"pm":1256,"doi":1257},"2025828552","3571954","W2025828552","23418553","10.1371\u002Fjournal.pone.0056325",{"id":1259,"text":1260,"url":1261,"identifiers":1262},"b37e0b4e-325d-41fd-8d3f-e9f6c9be7b0d","Vidal AC, Henry NM, Murphy SK, Oneko O, Nye M, Bartlett JA, et al. PEG1\u002FMEST and IGF2 DNA methylation in CIN and in cervical cancer. Clin Transl Oncol. 2014;16(3):266–72. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs12094-013-1067-4.","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs12094-013-1067-4",{"doi":1263},"10.1007\u002Fs12094-013-1067-4",{"id":20,"text":1265,"url":1266,"identifiers":1267},"Gomih A, Smith JS, North KE, Hudgens MG, Brewster WR, Huang Z, et al. DNA methylation of imprinted gene control regions in the regression of low-grade cervical lesions. Int J Cancer. 2018;143(3):552–60. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.31350.","https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.31350",{"mag":1268,"pmc":1269,"openalex":1270,"pm":1271,"doi":1272},"2792459568","6019167","W2792459568","29490428","10.1002\u002Fijc.31350",{"id":20,"text":1274,"url":1275,"identifiers":1276},"Song JY, Lee JK, Lee NW, Jung HH, Kim SH, Lee KW. Microarray analysis of normal cervix, carcinoma in situ, and invasive cervical cancer: identification of candidate genes in pathogenesis of invasion in cervical cancer. Int J Gynecol Cancer. 2008;18(5):1051–9. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1525-1438.2007.01164.x.","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1525-1438.2007.01164.x",{"mag":1277,"openalex":1278,"pm":1279,"doi":1280},"1966519709","W1966519709","18217980","10.1111\u002Fj.1525-1438.2007.01164.x",{"id":20,"text":1282,"url":1283,"identifiers":1284},"Zhang J, Yao T, Lin Z, Gao Y. Aberrant methylation of MEG3 functions as a potential plasma-based biomarker for cervical cancer. Sci Rep. 2017;7(1):6271. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41598-017-06502-7.","https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41598-017-06502-7",{"mag":1285,"pmc":1286,"openalex":1287,"pm":1288,"doi":1289},"2739330347","5524906","W2739330347","28740189","10.1038\u002Fs41598-017-06502-7",{"id":20,"text":1291,"url":1292,"identifiers":1293},"Rodriguez BA, Weng YI, Liu TM, Zuo T, Hsu PY, Lin CH, et al. Estrogen-mediated epigenetic repression of the imprinted gene cyclin-dependent kinase inhibitor 1C in breast cancer cells. Carcinogenesis. 2011;32(6):812–21. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fcarcin\u002Fbgr017.","https:\u002F\u002Fdoi.org\u002F10.1093\u002Fcarcin\u002Fbgr017",{"mag":1294,"pmc":1295,"openalex":1296,"pm":1297,"doi":1298},"2115251481","3106431","W2115251481","21304052","10.1093\u002Fcarcin\u002Fbgr017",{"id":20,"text":1300,"url":1301,"identifiers":1302},"Nakano S, Murakami K, Meguro M, Soejima H, Higashimoto K, Urano T, et al. Expression profile of LIT1\u002FKCNQ1OT1 and epigenetic status at the KvDMR1 in colorectal cancers. Cancer Sci. 2006;97(11):1147–54. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1349-7006.2006.00305.x.","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1349-7006.2006.00305.x",{"mag":1303,"openalex":1304,"pm":1305,"doi":1306},"2063977955","W2063977955","16965397","10.1111\u002Fj.1349-7006.2006.00305.x",{"id":20,"text":1308,"url":1309,"identifiers":1310},"Vidal AC, Smith JS, Valea F, Bentley R, Gradison M, Yarnall KS, et al. HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. Cancer Causes Control. 2014;25(8):1055–62. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10552-014-0406-2.","https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10552-014-0406-2",{"mag":1311,"pmc":1312,"openalex":1313,"pm":1314,"doi":1315},"2118379328","4082644","W2118379328","24928693","10.1007\u002Fs10552-014-0406-2",{"id":20,"text":1317,"url":1318,"identifiers":1319},"Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829–46. https:\u002F\u002Fdoi.org\u002F10.1097\u002FAOG.0b013e3182883a34.","https:\u002F\u002Fdoi.org\u002F10.1097\u002Faog.0b013e3182883a34",{"mag":1320,"openalex":1321,"pm":1322,"doi":1323},"2114418380","W2114418380","23635684","10.1097\u002Faog.0b013e3182883a34",{"id":20,"text":1325,"url":1326,"identifiers":1327},"Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357–61. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJCM.38.1.357-361.2000.","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fjcm.38.1.357-361.2000",{"mag":1328,"pmc":1329,"openalex":1330,"pm":1331,"doi":1332},"2096478290","88724","W2096478290","10618116","10.1128\u002Fjcm.38.1.357-361.2000",{"id":20,"text":1334,"url":1335,"identifiers":1336},"Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998;36(10):3020–7. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJCM.36.10.3020-3027.1998.","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fjcm.36.10.3020-3027.1998",{"mag":1337,"pmc":1338,"openalex":1339,"pm":1340,"doi":1341},"2151164686","105104","W2151164686","9738060","10.1128\u002Fjcm.36.10.3020-3027.1998",{"id":1343,"text":1344,"url":1345,"identifiers":1346},"96ecf42f-3c63-49ab-b8de-6654cc372306","Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst. 1995;87(11):796–802. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fjnci\u002F87.11.796.","https:\u002F\u002Facademic.oup.com\u002Fjnci\u002Farticle-lookup\u002Fdoi\u002F10.1093\u002Fjnci\u002F87.11.796",{"doi":1347},"10.1093\u002Fjnci\u002F87.11.796",{"id":20,"text":1349,"url":1350,"identifiers":1351},"Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204. https:\u002F\u002Fdoi.org\u002F10.1016\u002FS1470-2045(05)70086-3.","https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs1470-2045(05)70086-3",{"mag":1352,"openalex":1353,"pm":1354,"doi":1355},"2006924252","W2006924252","15830458","10.1016\u002Fs1470-2045(05)70086-3",{"id":20,"text":1357,"url":20,"identifiers":1358},"Apgar BS, Zoschnick L, Wright TC Jr. The 2001 Bethesda system terminology. Am Fam Physician. 2003;68(10):1992–8.",{},{"id":20,"text":1360,"url":1361,"identifiers":1362},"Johnson MD, Wu X, Aithmitti N, Morrison RS. Peg3\u002FPw1 is a mediator between p53 and Bax in DNA damage-induced neuronal death. J Biol Chem. 2002;277(25):23000–7. https:\u002F\u002Fdoi.org\u002F10.1074\u002Fjbc.M201907200.","https:\u002F\u002Fdoi.org\u002F10.1074\u002Fjbc.m201907200",{"mag":1363,"openalex":1364,"pm":1365,"doi":1366},"2096199626","W2096199626","11943780","10.1074\u002Fjbc.m201907200",{"id":20,"text":1368,"url":1369,"identifiers":1370},"Deng Y, Wu X. Peg3\u002FPw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. Proc Natl Acad Sci U S A. 2000;97(22):12050–5. https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.97.22.12050.","https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.97.22.12050",{"mag":1371,"pmc":1372,"openalex":1373,"pm":1374,"doi":1375},"2139439596","17292","W2139439596","11050235","10.1073\u002Fpnas.97.22.12050",{"id":1377,"text":1378,"url":1379,"identifiers":1380},"71a8fbb8-fe8b-4d3d-9426-b732d3e2ceb9","Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PG, Kohler M, et al. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]. Gynecol Oncol. 2005;98(3):467–83. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ygyno.2005.05.003.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0090825805003537",{"doi":1381},"10.1016\u002Fj.ygyno.2005.05.003",{"id":20,"text":1383,"url":1384,"identifiers":1385},"Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol. 2009;113(1):18–25. https:\u002F\u002Fdoi.org\u002F10.1097\u002FAOG.0b013e31818f5008.","https:\u002F\u002Fdoi.org\u002F10.1097\u002Faog.0b013e31818f5008",{"mag":1386,"pmc":1387,"openalex":1388,"pm":1389,"doi":1390},"2041694981","2694845","W2041694981","19104355","10.1097\u002Faog.0b013e31818f5008",{"id":20,"text":1392,"url":1393,"identifiers":1394},"Skorstengaard M, Lynge E, Suhr J, Napolitano G. Conservative management of women with cervical intraepithelial neoplasia grade 2 in Denmark: a cohort study. BJOG. 2020;127(6):729-736. https:\u002F\u002Fdoi.org\u002F10.1111\u002F1471-0528.16081.","https:\u002F\u002Fdoi.org\u002F10.1111\u002F1471-0528.16081",{"mag":1395,"pmc":1396,"openalex":1397,"pm":1398,"doi":1399},"2998410045","7383715","W2998410045","31880054","10.1111\u002F1471-0528.16081",{"id":20,"text":1401,"url":1402,"identifiers":1403},"Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5 Suppl 1):S28–35. https:\u002F\u002Fdoi.org\u002F10.1097\u002FLGT.0b013e318285423c.","https:\u002F\u002Fdoi.org\u002F10.1097\u002Flgt.0b013e318285423c",{"mag":1404,"pmc":1405,"openalex":1406,"pm":1407,"doi":1408},"1972424675","3616419","W1972424675","23519302","10.1097\u002Flgt.0b013e318285423c",{"id":20,"text":1410,"url":1411,"identifiers":1412},"Dijkstra MG, Heideman DA, de Roy SC, Rozendaal L, Berkhof J, van Krimpen K, et al. p16(INK4a) immunostaining as an alternative to histology review for reliable grading of cervical intraepithelial lesions. J Clin Pathol. 2010;63(11):972–7. https:\u002F\u002Fdoi.org\u002F10.1136\u002Fjcp.2010.078634.","http:\u002F\u002Fdx.doi.org\u002F10.1136\u002Fjcp.2010.078634",{"doi":1413},"10.1136\u002Fjcp.2010.078634",{"id":1415,"createTime":1416,"updateTime":1417,"relativeEntities":1418,"slug":1419,"properties":1420,"entityType":131,"verifyStatus":132,"verifyTime":1431,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":105,"primaryUrl":1432,"fullTextUrl":20,"authors":1433,"publicationType":287,"publisherRelationship":1583,"citationCount":21,"citationInfo":1642,"publishDate":1645,"publishYear":1643,"citationAnalyzeStatus":1646,"lastCitationAnalyze":1647,"indexDatabases":1648,"openAccess":20,"references":20,"isForceReanalyzing":541},"213dadd6-8ddc-4fe8-8133-afaa685dce4b","2024-02-02T05:25:26.915+00:00","2026-07-11T02:00:38.149+00:00",[],"Human-papillomavirus-genotypes-associated-with-cervical-precancerous-lesions-and-cancer-in-the-highest-area-of-cervical-cancer-mortality-Longnan-China",{"abstract":1421,"title":1423,"gsPaper":1425,"references":1427,"doi":1429},{"EN":1422},"The mortality of cervical cancer in Longnan is as high as 39\u002F10 million, ranking first in China. Between 2012 to 2016, 329 samples with cervicitis, cervical intraepithelial neoplasia grade 1 to 3 (CINI to III), and invasive squamous cell carcinoma (SCC) were collected. HPV genotypes were examined with a validated kit for 23 different HPV subtypes. Compared to cervicitis, the HPV positivity is significantly higher in CINI, CIN II\u002FIII, and SCC (38.60%, 74.60%, 87.50% and 89.05%, P \u003C 0.001) and the positivity is also higher in SCC compared to CINI (P \u003C 0.01). The most frequently detected genotypes were HPV16 in cervicitis, HPV16, 58 and 52 in CINI and CIN II\u002FIII, and HPV16, 58 and 18 in SCC groups. HPV16 positivity in cervicitis, CINI, CIN II\u002FIII, and SCC patients were 45.46%, 46.81%, 60.32% and 78.69%, respectively. Compared to cervicitis and CINI, the odds ratios (OR) for SCC in HPV16 positive patients were 2.96 (95% confidence interval [CI]: 1.09–8.00, P \u003C 0.05) and 4.20 (95% confidence interval [CI]: 2.05–8.61, P \u003C 0.001), respectively. In addition, the multiple infections in cervicitis, CINI, CINII\u002FIII and SCC group are 9.09%, 27.66%, 26.98% and 25.41% and HPV16 + 58 was the most common combinations. These findings highlight the key role of HPV16, 58, 52 and 18 in the development of CIN and SCC in Longnan women and a fully aware of regional differences in HPV genotype distribution are tasks for cervical cancer control and prevention.",{"EN":1424},"Human papillomavirus genotypes associated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China",{"VOID":1426},"[\"12420541232629232967\"]",{"VOID":1428},"Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev Anti Infect Ther. 2010;8(5):1139–62.\nNobre RJ, Herráez-Hernández E, Fei JW, Langbein L, Kaden S, Gröne HJ, de Villiers EM. E7 oncoprotein of novel human papillomavirus type 108 lacking the E6 gene induces dysplasia in organotypic keratinocyte cultures. J Virol. 2009;83(7):2907–16.\nPillai MR, Lakshmi S, Sreekala S, Devi TG, Jayaprakash PG, Rajalakshmi TN, Devi CG, Nair MK, Nair MB. High-risk human papillomavirus infection and E6 protein expression in lesions of the uterine cervix. Pathobiology. 1998;66(5):240–6.\nTornesello ML, Duraturo ML, Botti G, Greggi S, Piccoli R, De Palo G, Montella M, Buonaguro L. Buonaguro FM; Italian HPV working group: prevalence of α-papillomavirus genotypes in cervical intraepithelial neoplasia and cervical cancer in the Italian population. J Med Virol. 2006;78(12):1663–72.\nArbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol. 2014;234(4):431–5.\nHalec G, Alemany L, Lloveras B, Schmitt M, Alejo M, Bosch FX, Tous S, Klaustermeier JE, Guimerà N, Grabe N, Lahrmann B, Gissmann L, Quint W, Bosch FX, de Sanjose S, Pawlita M. Retrospective international survey and HPV time trends study group; retrospective international survey and HPV time trends study group. Pathogenic role of the eight probably\u002Fpossibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol. 2014;234(4):441–51.\nTorre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.\nKim K, Zang R, Choi SC, Ryu SY, Kim JW. Current status of gynecological cancer in China. J Gynecol Oncol. 2009;20(2):72–6.\nBosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87(11):796–802.\nBosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26S:K1–16.\nde Sanjose S, Wim GVQ, Laia A, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.\nWright Jr TC, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206(1):46e1–11.\nDiaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008;99(2):230–8.\nKjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type- and age- specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer. 2008;123(8):1864–70.\nCastellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98(5):303–15.\nSchwartz SM, Daling JR, Shera KA, Madeleine MM, McKnight B, Galloway DA, Porter PL, McDougall JK. Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol. 2001;19(7):1906–15.\nBao YP, Li N, Smith JS, Qiao YL. ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer. 2008;18(1):71–9.\nShen Y, Gong JM, Li YQ, Gong YM, Lei DM, Cheng GM, Li XF. Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Henan Province. China Clinica Chimica Acta. 2013;415:297–301.\nLiu X, Zhang S, Ruan Q, Ji Y, Ma L, Zhang Y. Prevalence and type distribution of human papillomavirus in women with cervical lesions in Liaoning Province. China Int J Gynecol Cancer. 2010;20(1):147–53.\nJinke L, Dan Z, Yi Z, et al. Prevalence and genotype distribution of human papillomavirus in women with cervical cancer or highgrade precancerous lesions in Chengdu, western China. Int J Gynecol Obstet. 2011;112(2):131–4.\nYang L, Huangpu X-m, Zhang S-w, et al. Changes of mortality rate for cervical cancer during 1970’s and 1990’s periods in china. Acta Academiae Medicinae Sinicae. 2003;25(4):386–90.\nKurman RJ, Ellenson LH, Ronnett BM. Blaustein’s pathology of the female genital tract. 5th ed. New York: Springer; 2002.\nZhi YF, Cha XX, Li XF, Qiu C, Rong SH. Prevalence and genotype distribution of human papillomavirus in women in the Henan Province. Genet Mol Res. 2015;14(2):5452–61.\nMuñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ. International agency for research on cancer multicenter cervical cancer study group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27.\nClifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1157–64.\nWheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst. 2009;101(7):475–87.\nLiang H, Griffith CC, Ma L, Ling B, Feng D, Li Z, Zhao C. The sensitivity of Pap cytology and HPV testing to detect incident cervical cancer: Prior testing results in 178 patients with invasive cervical cancer at a large general hospital in China. J American Soc Cyto. 2015;4(6):S33–4.\nZheng B, Li Z, Griffith CC, Yan S, Chen C, Ding X, Liang X, Yang H, Zhao C. Prior high-risk HPV testing and Pap test results for 427 invasive cervical cancers in China’s largest CAP-certified laboratory. Cancer Cytopathol. 2015;123(7):428–34.\nBhatla N, Lal N, Bao YP, Ng T, Qiao YL. A meta-analysis of human papillomavirus type-distribution in women from South Asia: implications for vaccination. Vaccine. 2008;26(23):2811–7.\nLi N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–35.\nDillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, de Sanjose S, Naucler P, Lloveras B, Kjaer S, Cuzick J, van Ballegooijen M, Clavel C, Iftner T. JointEuropean Cohort Study. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ. 2008;337:a1754.\nWalboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.\nGu Y, Ma C, Zou J, Zhu Y, Yang R, Xu Y, Zhang Y. Prevalence characteristics of high-risk human papillomaviruses in women living in Shanghai with cervical precancerous lesions and cancer. Oncotarget. 2016;7(17):24656–63.\nChoi JW, Kim Y, Lee JH, Kim YS. The clinical performance of primary HPV screening, primary HPV screening plus cytology cotesting, and cytology alone at a tertiary care hospital. Cancer Cyto. 2016;124(2):144–52.\nBosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55(4):244–65.\nBruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789–99.\nWatari H, Michimata R, Yasuda M, Ishizu A, Tomaru U, Xiong Y, Hassan MK, Sakuragi N. High prevalence of multiple human papillomavirus infection in Japanese patients with invasive uterine cervical cancer. Pathobiology. 2011;78(4):220–6.\nXiao M, Xu Q, Li H, Gao H, Bie Y, Zhang Z. Prevalence of human papillomavirus genotypes among women with high-grade cervical lesions in Beijing. China Med (Baltimore). 2016;95(3), e2555.\nFrancois C, Samuel R, Agnihotram VR, et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol. 2011;83(6):1034–41.\nSang Ah L, Daehee K, Sang SS, et al. Multiple HPV infection in cervical cancer screened by HPV DNA Chip. Cancer Lett. 2003;198(2):187–92.\nLaskov I, Grisaru D, Efrat G, et al. Are the human papillomavirus genotypes different in cervical cancer and intraepithelial neoplasia in Jewish Israeli women, a low-risk population? Int J Gynecol Cancer. 2013;23(4):730–4.\nLucia R, Olaf R, Reinhard H, et al. Human papillomavirus in highgrade cervical lesions Austrian data of a European multicentre study. Wien Klin Wochenschr. 2013;125(19–20):591–9.\nRen H, Caiyan X, Songwen Z, et al. Distribution of human papillomavirus genotype and cervical neoplasia among women with abnormal cytology in Beijing. China Int J Gynaecol Obstet. 2012;119(3):257–61.",{"VOID":1430},"10.1186\u002Fs13027-017-0116-y","2024-06-23T21:28:51.938+00:00","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13027-017-0116-y",[1434,1449,1462,1477,1492,1505,1518,1531,1544,1557,1570],{"id":1435,"sortIndex":21,"researcher":20,"roles":1436,"affiliations":1437,"properties":1446,"displayName":1448,"givenName":20,"familyName":20},"3ac0b0f1-825b-4d2b-9f6c-bba876d5a924",[140],[1438],{"id":1439,"sortIndex":21,"affiliation":1440,"properties":20},"148f0730-925e-45d6-b012-7dd2555bdb9e",{"id":1439,"createTime":20,"updateTime":20,"relativeEntities":1441,"slug":20,"properties":1442,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1445,"statistic":20},[],{"title":1443},{"VI":1444},"Medical College of Northwest University for Nationalities, Lanzhou, People’s Republic of China",[],{"title":1447},{"VI":1448},"Jin Zhao",{"id":1450,"sortIndex":105,"researcher":20,"roles":1451,"affiliations":1452,"properties":1459,"displayName":1461,"givenName":20,"familyName":20},"d1d75174-5e9e-4830-ab26-b904fa8d4088",[140],[1453],{"id":1439,"sortIndex":21,"affiliation":1454,"properties":20},{"id":1439,"createTime":20,"updateTime":20,"relativeEntities":1455,"slug":20,"properties":1456,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1458,"statistic":20},[],{"title":1457},{"VI":1444},[],{"title":1460},{"VI":1461},"Zhong Guo",{"id":1463,"sortIndex":106,"researcher":20,"roles":1464,"affiliations":1465,"properties":1474,"displayName":1476,"givenName":20,"familyName":20},"e2b5df08-7765-4f4b-be15-792851869e51",[140],[1466],{"id":1467,"sortIndex":21,"affiliation":1468,"properties":20},"b51317ab-87b2-45e0-8801-e03bf3959217",{"id":1467,"createTime":20,"updateTime":20,"relativeEntities":1469,"slug":20,"properties":1470,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1473,"statistic":20},[],{"title":1471},{"VI":1472},"No.1 Hospital of Longnan City, Longnan, People’s Republic of China",[],{"title":1475},{"VI":1476},"Qiang Wang",{"id":1478,"sortIndex":107,"researcher":20,"roles":1479,"affiliations":1480,"properties":1489,"displayName":1491,"givenName":20,"familyName":20},"8fcefd0b-2ed4-4367-966d-e0826a0b3f73",[140],[1481],{"id":1482,"sortIndex":21,"affiliation":1483,"properties":20},"7a44a5fe-9694-4c0a-907c-9d6da1ec6ad4",{"id":1482,"createTime":20,"updateTime":20,"relativeEntities":1484,"slug":20,"properties":1485,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1488,"statistic":20},[],{"title":1486},{"VI":1487},"Gansu Provincial Cancer Hospital, Lanzhou, People’s Republic of China",[],{"title":1490},{"VI":1491},"Tianbin Si",{"id":1493,"sortIndex":202,"researcher":20,"roles":1494,"affiliations":1495,"properties":1502,"displayName":1504,"givenName":20,"familyName":20},"b8cf7584-ef78-4c0c-a38d-d19fbd6426c8",[140],[1496],{"id":1439,"sortIndex":21,"affiliation":1497,"properties":20},{"id":1439,"createTime":20,"updateTime":20,"relativeEntities":1498,"slug":20,"properties":1499,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1501,"statistic":20},[],{"title":1500},{"VI":1444},[],{"title":1503},{"VI":1504},"Shuyan Pei",{"id":1506,"sortIndex":216,"researcher":20,"roles":1507,"affiliations":1508,"properties":1515,"displayName":1517,"givenName":20,"familyName":20},"e5fb8f78-7ae3-4589-b034-3a71a5f64f18",[140],[1509],{"id":1439,"sortIndex":21,"affiliation":1510,"properties":20},{"id":1439,"createTime":20,"updateTime":20,"relativeEntities":1511,"slug":20,"properties":1512,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1514,"statistic":20},[],{"title":1513},{"VI":1444},[],{"title":1516},{"VI":1517},"Chenjing Wang",{"id":1519,"sortIndex":108,"researcher":20,"roles":1520,"affiliations":1521,"properties":1528,"displayName":1530,"givenName":20,"familyName":20},"b7628362-0a18-4e40-a2ff-c986bb8e8628",[140],[1522],{"id":1439,"sortIndex":21,"affiliation":1523,"properties":20},{"id":1439,"createTime":20,"updateTime":20,"relativeEntities":1524,"slug":20,"properties":1525,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1527,"statistic":20},[],{"title":1526},{"VI":1444},[],{"title":1529},{"VI":1530},"Hongmei Qu",{"id":1532,"sortIndex":245,"researcher":20,"roles":1533,"affiliations":1534,"properties":1541,"displayName":1543,"givenName":20,"familyName":20},"9a28d0b0-fea2-432f-b057-59ee5852e571",[140],[1535],{"id":1439,"sortIndex":21,"affiliation":1536,"properties":20},{"id":1439,"createTime":20,"updateTime":20,"relativeEntities":1537,"slug":20,"properties":1538,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1540,"statistic":20},[],{"title":1539},{"VI":1444},[],{"title":1542},{"VI":1543},"Jianbin Zhong",{"id":1545,"sortIndex":261,"researcher":20,"roles":1546,"affiliations":1547,"properties":1554,"displayName":1556,"givenName":20,"familyName":20},"83e67b4b-b8fb-4048-b9c5-50a5dd213929",[140],[1548],{"id":1439,"sortIndex":21,"affiliation":1549,"properties":20},{"id":1439,"createTime":20,"updateTime":20,"relativeEntities":1550,"slug":20,"properties":1551,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1553,"statistic":20},[],{"title":1552},{"VI":1444},[],{"title":1555},{"VI":1556},"Ying Ma",{"id":1558,"sortIndex":275,"researcher":20,"roles":1559,"affiliations":1560,"properties":1567,"displayName":1569,"givenName":20,"familyName":20},"d72e31d0-80bd-45d2-b8db-de8bdb3c5236",[140],[1561],{"id":1439,"sortIndex":21,"affiliation":1562,"properties":20},{"id":1439,"createTime":20,"updateTime":20,"relativeEntities":1563,"slug":20,"properties":1564,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1566,"statistic":20},[],{"title":1565},{"VI":1444},[],{"title":1568},{"VI":1569},"Cong Nie",{"id":1571,"sortIndex":1043,"researcher":20,"roles":1572,"affiliations":1573,"properties":1580,"displayName":1582,"givenName":20,"familyName":20},"8e517e6f-0b7b-42b0-a94b-52e07a7aa62c",[140],[1574],{"id":1439,"sortIndex":21,"affiliation":1575,"properties":20},{"id":1439,"createTime":20,"updateTime":20,"relativeEntities":1576,"slug":20,"properties":1577,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1579,"statistic":20},[],{"title":1578},{"VI":1444},[],{"title":1581},{"VI":1582},"Dan Zhang",{"url":1432,"publisher":1584,"properties":1637},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1585,"slug":10,"properties":1586,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1589,"manageAffiliations":1606,"indexDatabases":1617,"url":20,"thumbnailPath":20,"statistic":1632,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":1587,"title":1588},{"VOID":13},{"EN":15},[1590,1594,1598,1602],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1591,"label":1592,"description":1593,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1595,"label":1596,"description":1597,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1599,"label":1600,"description":1601,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":1603,"label":1604,"description":1605,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[1607,1612],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1608,"slug":20,"properties":1609,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1611,"statistic":20},[],{"title":1610},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":1613,"slug":20,"properties":1614,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1616,"statistic":20},[],{"title":1615},{"EN":60},[],[1618,1625],{"id":64,"indexDatabase":1619,"url":75,"indexYears":76,"academicFieldIds":1624,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1620,"label":1621,"description":1622,"key":72,"publicationTags":1623,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":1626,"url":97,"indexYears":20,"academicFieldIds":1631,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":1627,"label":1628,"description":1629,"key":93,"publicationTags":1630,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":1633,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":1634,"totalCitation":21,"totalCitationByYear":1635,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1636,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":1638,"volume":1640},{"VOID":1639},"1-7",{"VOID":1641},"12",{"total":21,"publishYear":1643,"statisticByYear":1644},2017,{},"2017-01-25","DONE_ANALYZE_CITATION","2026-07-11T02:00:38.148+00:00",[82,95],{"id":1650,"createTime":1651,"updateTime":1652,"relativeEntities":1653,"slug":1654,"properties":1655,"entityType":131,"verifyStatus":132,"verifyTime":1666,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1667,"fullTextUrl":20,"authors":1668,"publicationType":287,"publisherRelationship":1753,"citationCount":20,"citationInfo":20,"publishDate":1811,"publishYear":1157,"citationAnalyzeStatus":1812,"lastCitationAnalyze":1813,"indexDatabases":1814,"openAccess":20,"references":20,"isForceReanalyzing":541},"c9ba7b48-3d95-425e-8129-55aebdf01fd1","2024-02-05T22:32:00.354+00:00","2026-06-08T09:01:54.001+00:00",[],"Interplay-between-Epstein-Barr-virus-infection-and-environmental-xenobiotic-exposure-in-cancer",{"abstract":1656,"title":1658,"gsPaper":1660,"references":1662,"doi":1664},{"EN":1657},"Epstein-Barr virus (EBV) is a herpesvirus associated with lymphoid and epithelial malignancies. Both B cells and epithelial cells are susceptible and permissive to EBV infection. However, considering that 90% of the human population is persistently EBV-infected, with a minority of them developing cancer, additional factors are necessary for tumor development. Xenobiotics such as tobacco smoke (TS) components, pollutants, pesticides, and food chemicals have been suggested as cofactors involved in EBV-associated cancers. In this review, the suggested mechanisms by which xenobiotics cooperate with EBV for carcinogenesis are discussed. Additionally, a model is proposed in which xenobiotics, which promote oxidative stress (OS) and DNA damage, regulate EBV replication, promoting either the maintenance of viral genomes or lytic activation, ultimately leading to cancer. Interactions between EBV and xenobiotics represent an opportunity to identify mechanisms by which this virus is involved in carcinogenesis and may, in turn, suggest both prevention and control strategies for EBV-associated cancers.",{"EN":1659},"Interplay between Epstein-Barr virus infection and environmental xenobiotic exposure in cancer",{"VOID":1661},"[]",{"VOID":1663},"de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020;8:e180–90. https:\u002F\u002Fdoi.org\u002F10.1016\u002FS2214-109X(19)30488-7.\nParkin DM, Hämmerl L, Ferlay J, Kantelhardt EJ. Cancer in Africa 2018: The role of infections. Int J Cancer. 2020;146:2089–103. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.32538.\nAvanzi S, Alvisi G, Ripalti A. How virus persistence can initiate the tumorigenesis process. World J Virol. 2013;2:102–9. https:\u002F\u002Fdoi.org\u002F10.5501\u002Fwjv.v2.i2.102.\nWhite MK, Pagano JS, Khalili K. Viruses and human cancers: a long road of discovery of molecular paradigms. Clin Microbiol Rev. 2014;27:463–81. https:\u002F\u002Fdoi.org\u002F10.1128\u002FCMR.00124-13.\nEpstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964;1:702–3.\nYoung LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer. 2016;16:789–802. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc.2016.92.\nJayasooriya S, de Silva TI, Njie-jobe J, Sanyang C, Leese AM, Bell AI, et al. Early virological and immunological events in asymptomatic Epstein-Barr virus infection in African children. PLoS Pathog. 2015;11:e1004746. https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.ppat.1004746.\nBecker JA, Smith JA. Return to play after infectious mononucleosis. Sports Health. 2014;6:232–8. https:\u002F\u002Fdoi.org\u002F10.1177\u002F1941738114521984.\nTsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond B Biol Sci. 2017;372. https:\u002F\u002Fdoi.org\u002F10.1098\u002Frstb.2016.0270.\nCarrasco-Avino G, Riquelme I, Padilla O, Villaseca M, Aguayo FR, Corvalan AH. The conundrum of the Epstein-Barr virus-associated gastric carcinoma in the Americas. Oncotarget. 2017;8:75687–98. https:\u002F\u002Fdoi.org\u002F10.18632\u002Foncotarget.18497.\nde Lima MAP, Teodoro IPP, Galiza LE, Filho PHBM, Marques FM, Pinheiro Junior RFF, et al. Association between Epstein-Barr Virus and Oral Carcinoma: A Systematic Review with Meta-Analysis. Crit Rev Oncog. 2019;24:349–68. https:\u002F\u002Fdoi.org\u002F10.1615\u002FCritRevOncog.2019031897.\nHenderson EE, Franks C, Fronko G. Chemical carcinogen Epstein-Barr virus (EBV) synergism: EBV genome amplification and site-specific mutation during transformation. Int J Cancer. 1989;43:72–9. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.2910430116.\nWang WH, Chang LK, Liu ST. Molecular interactions of Epstein-Barr virus capsid proteins. J Virol. 2011;85:1615–24. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.01565-10.\nJohannsen E, Luftig M, Chase MR, Weicksel S, Cahir-McFarland E, Illanes D, et al. Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A. 2004;101:16286–91. https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.0407320101.\nMöhl BS, Chen J, Sathiyamoorthy K, Jardetzky TS, Longnecker R. Structural and Mechanistic Insights into the Tropism of Epstein-Barr Virus. Mol Cells. 2016;39:286–91. https:\u002F\u002Fdoi.org\u002F10.14348\u002Fmolcells.2016.0066.\nTemple RM, Zhu J, Budgeon L, Christensen ND, Meyers C, Sample CE. Efficient replication of Epstein-Barr virus in stratified epithelium in vitro. Proc Natl Acad Sci U S A. 2014;111:16544–9. https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.1400818111.\nTemple RM, Meyers C, Sample CE. Generation and Infection of Organotypic Cultures with Epstein-Barr Virus. Methods Mol Biol. 2017;1532:65–78. https:\u002F\u002Fdoi.org\u002F10.1007\u002F978-1-4939-6655-4_4.\nTsang CM, Deng W, Yip YL, Zeng MS, Lo KW, Tsao SW. Epstein-Barr virus infection and persistence in nasopharyngeal epithelial cells. Chin J Cancer. 2014;33:549–55. https:\u002F\u002Fdoi.org\u002F10.5732\u002Fcjc.014.10169.\nKikuchi K, Noguchi Y, de Rivera MW, Hoshino M, Sakashita H, Yamada T, et al. Detection of Epstein-Barr virus genome and latent infection gene expression in normal epithelia, epithelial dysplasia, and squamous cell carcinoma of the oral cavity. Tumour Biol. 2016;37:3389–404. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs13277-015-4167-7.\nSixbey JW, Vesterinen EH, Nedrud JG, Raab-Traub N, Walton LA, Pagano JS. Replication of Epstein-Barr virus in human epithelial cells infected in vitro. Nature. 1983;306:480–3. https:\u002F\u002Fdoi.org\u002F10.1038\u002F306480a0.\nPegtel DM, Middeldorp J, Thorley-Lawson DA. Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers. J Virol. 2004;78:12613–24. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.78.22.12613-12624.2004.\nMiller N, Hutt-Fletcher LM. Epstein-Barr virus enters B cells and epithelial cells by different routes. J Virol. 1992;66:3409–14. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.66.6.3409-3414.1992.\nFingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A. 1984;81:4510–4.\nWang X, Hutt-Fletcher LM. Epstein-Barr virus lacking glycoprotein gp42 can bind to B cells but is not able to infect. J Virol. 1998;72:158–63.\nWang X, Kenyon WJ, Li Q, Müllberg J, Hutt-Fletcher LM. Epstein-Barr virus uses different complexes of glycoproteins gH and gL to infect B lymphocytes and epithelial cells. J Virol. 1998;72:5552–8.\nChesnokova LS, Nishimura SL, Hutt-Fletcher LM. Fusion of epithelial cells by Epstein-Barr virus proteins is triggered by binding of viral glycoproteins gHgL to integrins alphavbeta6 or alphavbeta8. Proc Natl Acad Sci U S A. 2009;106:20464–9. https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.0907508106.\nChen J, Sathiyamoorthy K, Zhang X, Schaller S, Perez White BE, Jardetzky TS, et al. Ephrin receptor A2 is a functional entry receptor for Epstein-Barr virus. Nat Microbiol. 2018;3:172–80. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41564-017-0081-7.\nZhang H, Li Y, Wang HB, Zhang A, Chen ML, Fang ZX, et al. Ephrin receptor A2 is an epithelial cell receptor for Epstein-Barr virus entry. Nat Microbiol. 2018;3:1–8. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41564-017-0080-8.\nLieberman PM. Chromatin Structure of Epstein-Barr Virus Latent Episomes. Curr Top Microbiol Immunol. 2015;390:71–102. https:\u002F\u002Fdoi.org\u002F10.1007\u002F978-3-319-22822-8_5.\nSears J, Ujihara M, Wong S, Ott C, Middeldorp J, Aiyar A. The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes. J Virol. 2004;78:11487–505. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.78.21.11487-11505.2004.\nTsai K, Thikmyanova N, Wojcechowskyj JA, Delecluse HJ, Lieberman PM. EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription. PLoS Pathog. 2011;7:e1002376. https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.ppat.1002376.\nRooney CM, Rowe DT, Ragot T, Farrell PJ. The spliced BZLF1 gene of Epstein-Barr virus (EBV) transactivates an early EBV promoter and induces the virus productive cycle. J Virol. 1989;63:3109–16.\nDharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nat Rev Dis Primers. 2016;2:15088. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrdp.2015.88.\nShannon-Lowe C, Rickinson A. The Global Landscape of EBV-Associated Tumors. Front Oncol. 2019;9:713. https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffonc.2019.00713.\nThorley-Lawson DA. EBV Persistence--Introducing the Virus. Curr Top Microbiol Immunol. 2015;390:151–209. https:\u002F\u002Fdoi.org\u002F10.1007\u002F978-3-319-22822-8_8.\nYang J, Liu Z, Zeng B, Hu G, Gan R. Epstein-Barr virus-associated gastric cancer: A distinct subtype. Cancer Lett. 2020;495:191–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.canlet.2020.09.019.\nHau PM, Lung HL, Wu M, Tsang CM, Wong KL, Mak NK, et al. Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma. Front Oncol. 2020;10:600. https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffonc.2020.00600.\nHardwick JM, Lieberman PM, Hayward SD. A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol. 1988;62:2274–84.\nBuettner M, Lang A, Tudor CS, Meyer B, Cruchley A, Barros MH, et al. Lytic Epstein-Barr virus infection in epithelial cells but not in B-lymphocytes is dependent on Blimp1. J Gen Virol. 2012;93:1059–64. https:\u002F\u002Fdoi.org\u002F10.1099\u002Fvir.0.038661-0.\nJenkins PJ, Binné UK, Farrell PJ. Histone acetylation and reactivation of Epstein-Barr virus from latency. J Virol. 2000;74:710–20.\nLi H, Liu S, Hu J, Luo X, Li N. M Bode, A.; Cao, Y. Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. Int J Biol Sci. 2016;12:1309–18. https:\u002F\u002Fdoi.org\u002F10.7150\u002Fijbs.16564.\nChurch TM, Verma D, Thompson J, Swaminathan S. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV. J Virol. 2018;92. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.01794-17.\nNeuhierl B, Delecluse HJ. The Epstein-Barr virus BMRF1 gene is essential for lytic virus replication. J Virol. 2006;80:5078–81. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.80.10.5078-5081.2006.\nThierry E, Brennich M, Round A, Buisson M, Burmeister WP, Hutin S. Production and characterisation of Epstein-Barr virus helicase-primase complex and its accessory protein BBLF2\u002F3. Virus Genes. 2015;51:171–81. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs11262-015-1233-6.\nFujii K, Yokoyama N, Kiyono T, Kuzushima K, Homma M, Nishiyama Y, et al. The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2\u002F3 complex. J Virol. 2000;74:2550–7.\nHammerschmidt W, Sugden B. Identification and characterization of oriLyt, a lytic origin of DNA replication of Epstein-Barr virus. Cell. 1988;55:427–33.\nTsurumi T. Primer terminus recognition and highly processive replication by Epstein-Barr virus DNA polymerase. Biochem J. 1991;280(Pt 3):703–8.\nWu L, Li C, Pan L. Nasopharyngeal carcinoma: A review of current updates. Exp Ther Med. 2018;15:3687–92. https:\u002F\u002Fdoi.org\u002F10.3892\u002Fetm.2018.5878.\nCarioli G, Negri E, Kawakita D, Garavello W, La Vecchia C, Malvezzi M. Global trends in nasopharyngeal cancer mortality since 1970 and predictions for 2020: Focus on low-risk areas. Int J Cancer. 2017;(140):2256–64. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.30660.\nBrennan B. Nasopharyngeal carcinoma. Orphanet J Rare Dis. 2006;1:23. https:\u002F\u002Fdoi.org\u002F10.1186\u002F1750-1172-1-23.\nRichardo T, Prattapong P, Ngernsombat C, Wisetyaningsih N, Iizasa H, Yoshiyama H, et al. Epstein-Barr Virus Mediated Signaling in Nasopharyngeal Carcinoma Carcinogenesis. Cancers (Basel). 2020:12. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcancers12092441.\nShao JY, Ernberg I, Biberfeld P, Heiden T, Zeng YX, Hu LF. Epstein-Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma. Anticancer Res. 2004;24:2309–18.\nLiu MT, Chen YR, Chen SC, Hu CY, Lin CS, Chang YT, et al. Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene. 2004;23:2531–9. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsj.onc.1207375.\nChen Y, Zhou C, Li H, Li Y. Identifying Key Genes for Nasopharyngeal Carcinoma by Prioritized Consensus Differentially Expressed Genes Caused by Aberrant Methylation. J Cancer. 2021;12:874–84. https:\u002F\u002Fdoi.org\u002F10.7150\u002Fjca.49392.\nKaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res. 2012;72:3445–50. https:\u002F\u002Fdoi.org\u002F10.1158\u002F0008-5472.CAN-11-3919.\nGuo X, Li T, Li F, Xu Y, Wang H, Cheng W, et al. Intermittent abortive reactivation of Epstein-Barr virus during the progression of nasopharyngeal cancer as indicated by elevated antibody levels. Oral Oncol. 2019;93:85–90. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.oraloncology.2019.04.024.\nMartel-Renoir D, Grunewald V, Touitou R, Schwaab G, Joab I. Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. J Gen Virol. 1995;76(Pt 6):1401–8. https:\u002F\u002Fdoi.org\u002F10.1099\u002F0022-1317-76-6-1401.\nO'Neil JD, Owen TJ, Wood VHJ, Date KL, Valentine R, Chukwuma MB, et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol. 2008;89:2833–42. https:\u002F\u002Fdoi.org\u002F10.1099\u002Fvir.0.2008\u002F003392-0.\nWang L, Tian WD, Xu X, Nie B, Lu J, Liu X, et al. Epstein-Barr virus nuclear antigen 1 (EBNA1) protein induction of epithelial-mesenchymal transition in nasopharyngeal carcinoma cells. Cancer. 2014;120:363–72. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fcncr.28418.\nLi Z, Zhou Z, Wu X, Zhou Q, Liao C, Liu Y, et al. LMP1 promotes nasopharyngeal carcinoma metastasis through NTRK2-mediated anoikis resistance. Am J Cancer Res. 2020;10:2083–99.\nCai LM, Lyu XM, Luo WR, Cui XF, Ye YF, Yuan CC, et al. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene. 2015;34:2156–66. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fonc.2014.341.\nYang L, Liu L, Xu Z, Liao W, Feng D, Dong X, et al. EBV-LMP1 targeted DNAzyme enhances radiosensitivity by inhibiting tumor angiogenesis via the JNKs\u002FHIF-1 pathway in nasopharyngeal carcinoma. Oncotarget. 2015;6:5804–17. https:\u002F\u002Fdoi.org\u002F10.18632\u002Foncotarget.3331.\nDing L, Li LL, Yang J, Tao YG, Ye M, Shi Y, et al. Epstein-Barr virus encoded latent membrane protein 1 modulates nuclear translocation of telomerase reverse transcriptase protein by activating nuclear factor-kappaB p65 in human nasopharyngeal carcinoma cells. Int J Biochem Cell Biol, 2005. 37:1881–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.biocel.2005.04.012.\nKase K, Kondo S, Wakisaka N, Dochi H, Mizokami H, Kobayashi E, et al. Epstein-Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma. Microorganisms. 2021;9. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fmicroorganisms9030603.\nJiang R, Cabras G, Sheng W, Zeng Y, Ooka T. Synergism of BARF1 with Ras induces malignant transformation in primary primate epithelial cells and human nasopharyngeal epithelial cells. Neoplasia. 2009;11:964–73. https:\u002F\u002Fdoi.org\u002F10.1593\u002Fneo.09706.\nZhang Q, Luo D, Xie Z, He H, Duan Z. The Oncogenic Role of miR-BART19-3p in Epstein-Barr Virus-Associated Diseases. Biomed Res Int. 2020;2020:5217039. https:\u002F\u002Fdoi.org\u002F10.1155\u002F2020\u002F5217039.\nChoy EY, Siu KL, Kok KH, Lung RW, Tsang CM, To KF, et al. An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. J Exp Med. 2008;205:2551–60. https:\u002F\u002Fdoi.org\u002F10.1084\u002Fjem.20072581.\nLin C, Zong J, Lin W, Wang M, Xu Y, Zhou R, et al. EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1\u002F2 pathways. J Exp Clin Cancer Res. 2018;37:283. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs13046-018-0953-6.\nFerlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.29210.\nSandoval-Bórquez A, Saavedra K, Carrasco-Avino G, Garcia-Bloj B, Fry J, Wichmann I, et al. Noncoding Genomics in Gastric Cancer and the Gastric Precancerous Cascade: Pathogenesis and Biomarkers. Dis Markers. 2015;2015:503762. https:\u002F\u002Fdoi.org\u002F10.1155\u002F2015\u002F503762.\nYusefi AR, Bagheri Lankarani K, Bastani P, Radinmanesh M, Kavosi Z. Risk Factors for Gastric Cancer: A Systematic Review. Asian Pac J Cancer Prev. 2018;19:591–603. https:\u002F\u002Fdoi.org\u002F10.22034\u002FAPJCP.2018.19.3.591.\nBurke AP, Yen TS, Shekitka KM, Sobin LH. Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. Mod Pathol. 1990;3:377–80.\nShibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol. 1992;140:769–74.\nChen XZ, Chen H, Castro FA, Hu JK, Brenner H. Epstein-Barr virus infection and gastric cancer: a systematic review. Medicine (Baltimore). 2015;94:e792. https:\u002F\u002Fdoi.org\u002F10.1097\u002FMD.0000000000000792.\nRibeiro J, Oliveira C, Malta M, Sousa H. Epstein-Barr virus gene expression and latency pattern in gastric carcinomas: a systematic review. Future Oncol. 2017;13:567–79. https:\u002F\u002Fdoi.org\u002F10.2217\u002Ffon-2016-0475.\nWang A, Zhang W, Jin M, Zhang J, Li S, Tong F, et al. Differential expression of EBV proteins LMP1 and BHFR1 in EBV-associated gastric and nasopharyngeal cancer tissues. Mol Med Rep. 2016;13:4151–8. https:\u002F\u002Fdoi.org\u002F10.3892\u002Fmmr.2016.5087.\nChang KC, Huang GC, Jones D, Tsao CJ, Lee JY, Su IJ. Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors. Leuk Lymphoma. 2004;45:1375–84. https:\u002F\u002Fdoi.org\u002F10.1080\u002F10428194042000198849.\nMakita S, Maruyama D, Maeshima AM, Taniguchi H, Miyamoto K, Kitahara H, et al. Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol. 2016;104:236–44. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs12185-016-2007-1.\nMeng J, Chang C, Pan H, Zhu F, Xiao Y, Liu T, et al. Epidemiologic characteristics of malignant lymphoma in Hubei, China: A single-center 5-year retrospective study. Medicine (Baltimore). 2018;97:e12120. https:\u002F\u002Fdoi.org\u002F10.1097\u002FMD.0000000000012120.\nPiris MA, Medeiros LJ, Chang KC. Hodgkin lymphoma: a review of pathological features and recent advances in pathogenesis. Pathology. 2020;52:154–65. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.pathol.2019.09.005.\nKüppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9:15–27. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc2542.\nAmbinder RF, Browning PJ, Lorenzana I, Leventhal BG, Cosenza H, Mann RB, et al. Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood. 1993;81:462–7.\nChang KC, Khen NT, Jones D, Su IJ. Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. Hum Pathol. 2005;36:747–55. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.humpath.2005.05.003.\nSchrader A, Bentink S, Spang R, Lenze D, Hummel M, Kuo M, et al. High Myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas. Int J Cancer. 2012;131:E348–61. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.26423.\nGraham BS, Lynch DT. Burkitt Lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.\nChabay P, Lens D, Hassan R, Rodríguez Pinilla SM, Valvert Gamboa F, Rivera I, et al. Lymphotropic Viruses EBV, KSHV and HTLV in Latin America: Epidemiology and Associated Malignancies. A Literature-Based Study by the RIAL-CYTED. Cancers (Basel). 2020:12. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcancers12082166.\nMagrath IT. African Burkitt's lymphoma. History, biology, clinical features, and treatment. Am J Pediatr Hematol Oncol. 1991;13:222–46.\nGastwirt JP, Roschewski M. Management of adults with Burkitt lymphoma. Clin Adv Hematol Oncol. 2018;16:812–22.\nLinch DC. Burkitt lymphoma in adults. Br J Haematol. 2012;156:693–703. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1365-2141.2011.08877.x.\nMbulaiteye SM, Anderson WF, Ferlay J, Bhatia K, Chang C, Rosenberg PS, et al. Pediatric, elderly, and emerging adult-onset peaks in Burkitt's lymphoma incidence diagnosed in four continents, excluding Africa. Am J Hematol. 2012;87:573–8. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fajh.23187.\nDunleavy K, Little RF, Wilson WH. Update on Burkitt Lymphoma. Hematol Oncol Clin North Am. 2016;30:1333–43. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hoc.2016.07.009.\nMbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS. Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer. 2010;126:1732–9. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.24934.\nCasulo C, Friedberg JW. Burkitt lymphoma- a rare but challenging lymphoma. Best Pract Res Clin Haematol. 2018;31:279–84. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.beha.2018.07.013.\nMoormann AM, Bailey JA. Malaria - how this parasitic infection aids and abets EBV-associated Burkitt lymphomagenesis. Curr Opin Virol. 2016;20:78–84. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.coviro.2016.09.006.\nChoi SJ, Jung SW, Huh S, Cho H, Kang H. Phylogenetic comparison of Epstein-Barr virus genomes. J Microbiol. 2018;56:525–33. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs12275-018-8039-x.\nQuintana MDP, Smith-Togobo C, Moormann A, Hviid L. Endemic Burkitt lymphoma - an aggressive childhood cancer linked to Plasmodium falciparum exposure, but not to exposure to other malaria parasites. APMIS. 2020;128:129–35. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fapm.13018.\nFerla V, Rossi FG, Goldaniga MC, Baldini L. Biological Difference Between Epstein-Barr Virus Positive and Negative Post-transplant Lymphoproliferative Disorders and Their Clinical Impact. Front Oncol. 2020;10:506. https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffonc.2020.00506.\nHe Q, Zhou Y, Fu C, Zhu W, Zhou J, Liu S, et al. Lymphoepithelioma is a nonkeratinizing squamous cell carcinoma with Epstein-Barr virus infection in China. J Cancer Res Ther. 2017;13:807–12. https:\u002F\u002Fdoi.org\u002F10.4103\u002Fjcrt.JCRT_280_17.\nWenig BM. Lymphoepithelial-like carcinomas of the head and neck. Semin Diagn Pathol. 2015;32:74–86. https:\u002F\u002Fdoi.org\u002F10.1053\u002Fj.semdp.2014.12.004.\nRytkönen AE, Hirvikoski PP, Salo TA. Lymphoepithelial carcinoma: two case reports and a systematic review of oral and sinonasal cases. Head Neck Pathol. 2011;5:327–34. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs12105-011-0278-7.\nMozaffari HR, Ramezani M, Janbakhsh A, Sadeghi M. Malignant Salivary Gland Tumors and Epstein-Barr Virus (EBV) Infection: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev. 2017;18:1201–6. https:\u002F\u002Fdoi.org\u002F10.22034\u002FAPJCP.2017.18.5.1201.\nHan AJ, Xiong M, Zong YS. Association of Epstein-Barr virus with lymphoepithelioma-like carcinoma of the lung in southern China. Am J Clin Pathol. 2000;114:220–6. https:\u002F\u002Fdoi.org\u002F10.1309\u002F148K-ND54-6NJX-NA61.\nLee JH, Kim SH, Han SH, An JS, Lee ES, Kim YS. Clinicopathological and molecular characteristics of Epstein-Barr virus-associated gastric carcinoma: a meta-analysis. J Gastroenterol Hepatol. 2009;24:354–65. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1440-1746.2009.05775.x.\nYordanov A, Karamanliev M, Karcheva M, Konsoulova A, Vasileva-Slaveva M, Strashilov S. Single-Center Study of Lymphoepithelioma-Like Carcinoma of Uterine Cervix over a 10-Year Period. Medicina (Kaunas). 2019:55. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fmedicina55120780.\nSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https:\u002F\u002Fdoi.org\u002F10.3322\u002Fcaac.21660.\nWalboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9. https:\u002F\u002Fdoi.org\u002F10.1002\u002F(SICI)1096-9896(199909)189:1\u003C12::AID-PATH431>3.0.CO;2-F.\nSchlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst. 2003;95:1336–43. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fjnci\u002Fdjg037.\nde Lima MAP, Neto PJN, Lima LPM, Gonçalves Júnior J, Teixeira Junior AG, Teodoro IPP, et al. Association between Epstein-Barr virus (EBV) and cervical carcinoma: A meta-analysis. Gynecol Oncol. 2018;148:317–28. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ygyno.2017.10.005.\nSasagawa T, Shimakage M, Nakamura M, Sakaike J, Ishikawa H, Inoue M. Epstein-Barr virus (EBV) genes expression in cervical intraepithelial neoplasia and invasive cervical cancer: a comparative study with human papillomavirus (HPV) infection. Hum Pathol. 2000;31:318–26. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fs0046-8177(00)80245-2.\nKhenchouche A, Sadouki N, Boudriche A, Houali K, Graba A, Ooka T, et al. Human papillomavirus and Epstein-Barr virus co-infection in cervical carcinoma in Algerian women. Virol J. 2013;10:340. https:\u002F\u002Fdoi.org\u002F10.1186\u002F1743-422X-10-340.\nAguayo F, Muñoz JP, Perez-Dominguez F, Carrillo-Beltrán D, Oliva C, Calaf GM, Blanco R, Nuñez-Acurio D. High-Risk Human Papillomavirus and Tobacco Smoke Interactions in Epithelial Carcinogenesis. Cancers (Basel). 2020;12(8):2201. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcancers12082201.\nSun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, et al. Risk Factors and Preventions of Breast Cancer. Int J Biol Sci. 2017;13:1387–97. https:\u002F\u002Fdoi.org\u002F10.7150\u002Fijbs.21635.\nGannon OM, Antonsson A, Bennett IC, Saunders NA. Viral infections and breast cancer - A current perspective. Cancer Lett. 2018;420:182–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.canlet.2018.01.076.\nAl Hamad M, Matalka I, Al Zoubi MS, Armogida I, Khasawneh R, Al-Husaini M, et al. Human Mammary Tumor Virus, Human Papilloma Virus, and Epstein-Barr Virus Infection Are Associated With Sporadic Breast Cancer Metastasis. Breast Cancer (Auckl). 2020;14:1178223420976388. https:\u002F\u002Fdoi.org\u002F10.1177\u002F1178223420976388.\nGhaffari H, Tavakoli A, Nafissi N, Farahmand M, Ghorbani S, Moochani SS, et al. Human cytomegalovirus and Epstein-Barr virus infections in breast cancer: A molecular study on Iranian women. Breast Dis. 2021. https:\u002F\u002Fdoi.org\u002F10.3233\u002FBD-201019.\nKhatami A, Pormohammad A, Farzi R, Saadati H, Mehrabi M, Kiani SJ, et al. Bovine Leukemia virus (BLV) and risk of breast cancer: a systematic review and meta-analysis of case-control studies. Infect Agent Cancer. 2020;15:48. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs13027-020-00314-7.\nFarahmand M, Monavari SH, Shoja Z, Ghaffari H, Tavakoli M, Tavakoli A. Epstein-Barr virus and risk of breast cancer: a systematic review and meta-analysis. Future Oncol. 2019;15:2873–85. https:\u002F\u002Fdoi.org\u002F10.2217\u002Ffon-2019-0232.\nHu H, Luo ML, Desmedt C, Nabavi S, Yadegarynia S, Hong A, et al. Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation. EBioMedicine. 2016;9:148–60. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ebiom.2016.05.025.\nArbach H, Viglasky V, Lefeu F, Guinebretière JM, Ramirez V, Bride N, et al. Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol. 2006;80:845–53. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.80.2.845-853.2006.\nSinclair AJ, Moalwi MH, Amoaten T. Is EBV Associated with Breast Cancer in Specific Geographic Locations? Cancers (Basel). 2021;13. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcancers13040819.\nJohnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of colorectal cancer risk factors. Cancer Causes Control. 2013;24:1207–22. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10552-013-0201-5.\nCarr PR, Walter V, Brenner H, Hoffmeister M. Meat subtypes and their association with colorectal cancer: Systematic review and meta-analysis. Int J Cancer. 2016;138:293–302. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.29423.\nChen H, Chen XZ, Waterboer T, Castro FA, Brenner H. Viral infections and colorectal cancer: a systematic review of epidemiological studies. Int J Cancer. 2015;137:12–24. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.29180.\nBedri S, Sultan AA, Alkhalaf M, Al Moustafa AE, Vranic S. Epstein-Barr virus (EBV) status in colorectal cancer: a mini review. Hum Vaccin Immunother. 2019;15:603–10. https:\u002F\u002Fdoi.org\u002F10.1080\u002F21645515.2018.1543525.\nGupta I, Al Farsi H, Jabeen A, Skenderi F, Al-Thawadi H, AlAhmad YM, et al. High-Risk Human Papillomaviruses and Epstein-Barr Virus in Colorectal Cancer and Their Association with Clinicopathological Status. Pathogens. 2020;9. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fpathogens9060452.\nKarpinski P, Myszka A, Ramsey D, Kielan W, Sasiadek MM. Detection of viral DNA sequences in sporadic colorectal cancers in relation to CpG island methylation and methylator phenotype. Tumour Biol. 2011;32:653–9. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs13277-011-0165-6.\nMorales-Sánchez A, Fuentes-Panana EM. The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis. Cancers (Basel). 2018:10. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fcancers10040098.\nCochet C, Martel-Renoir D, Grunewald V, Bosq J, Cochet G, Schwaab G, et al. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology. 1993;197:358–65. https:\u002F\u002Fdoi.org\u002F10.1006\u002Fviro.1993.1597.\nRamayanti O, Juwana H, Verkuijlen SA, Adham M, Pegtel MD, Greijer AE, et al. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin. Int J Cancer. 2017;140:149–62. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.30418.\nRosemarie Q, Sugden B. Epstein-Barr Virus: How Its Lytic Phase Contributes to Oncogenesis. Microorganisms. 2020;8. https:\u002F\u002Fdoi.org\u002F10.3390\u002Fmicroorganisms8111824.\nMünz C. Tumor Microenvironment Conditioning by Abortive Lytic Replication of Oncogenic γ-Herpesviruses. Adv Exp Med Biol. 2020;1225:127–35. https:\u002F\u002Fdoi.org\u002F10.1007\u002F978-3-030-35727-6_9.\nHong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, Kenney SC. Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol. 2005;79:13993–4003. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.79.22.13993-14003.2005.\nMa SD, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y, et al. An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol. 2012;86:7976–87. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.00770-12.\nChang Y, Tung CH, Huang YT, Lu J, Chen JY, Tsai CH. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J Virol. 1999;73:8857–66.\nWu CC, Liu MT, Chang YT, Fang CY, Chou SP, Liao HW, et al. Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Res. 2010:38, 1932–1949. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fnar\u002Fgkp1169.\nChiu SH, Wu CC, Fang CY, Yu SL, Hsu HY, Chow YH, et al. Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma. Oncotarget. 2014;5:8583–601. https:\u002F\u002Fdoi.org\u002F10.18632\u002Foncotarget.2323.\nHumans, I.W.G.o.t.E.o.C.R.t. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum 2004, 83, 1-1438.\nJethwa AR, Khariwala SS. Tobacco-related carcinogenesis in head and neck cancer. Cancer Metastasis Rev. 2017;36:411–23. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10555-017-9689-6.\nPhillips DH, Venitt S. DNA and protein adducts in human tissues resulting from exposure to tobacco smoke. Int J Cancer. 2012;131:2733–53. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.27827.\nHuang RY, Chen GG. Cigarette smoking, cyclooxygenase-2 pathway and cancer. Biochim Biophys Acta. 1815;2011:158–69. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.bbcan.2010.11.005.\nChen RJ, Chang LW, Lin P, Wang YJ. Epigenetic effects and molecular mechanisms of tumorigenesis induced by cigarette smoke: an overview. J Oncol. 2011;2011:654931. https:\u002F\u002Fdoi.org\u002F10.1155\u002F2011\u002F654931.\nLiu X, Baecker A, Wu M, Zhou JY, Yang J, Han RQ, et al. Interaction between tobacco smoking and hepatitis B virus infection on the risk of liver cancer in a Chinese population. Int J Cancer. 2018;142:1560–7. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.31181.\nHassan MM, Spitz MR, Thomas MB, El-Deeb AS, Glover KY, Nguyen NT, et al. Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. Int J Cancer. 2008:123, 1883–1891. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.23730.\nCamargo MC, Koriyama C, Matsuo K, Kim WH, Herrera-Goepfert R, Liao LM, et al. Case-case comparison of smoking and alcohol risk associations with Epstein-Barr virus-positive gastric cancer. Int J Cancer. 2014;134:948–53. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.28402.\nChang ET, Liu Z, Hildesheim A, Liu Q, Cai Y, Zhang Z, et al. Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. Am J Epidemiol. 2017;185:1272–80. https:\u002F\u002Fdoi.org\u002F10.1093\u002Faje\u002Fkwx018.\nLin JH, Jiang CQ, Ho SY, Zhang WS, Mai ZM, Xu L, et al. Smoking and nasopharyngeal carcinoma mortality: a cohort study of 101,823 adults in Guangzhou. China. BMC Cancer. 2015;15:906. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12885-015-1902-9.\nXu FH, Xiong D, Xu YF, Cao SM, Xue WQ, Qin HD, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. J Natl Cancer Inst. 2012;104:1396–410. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fjnci\u002Fdjs320.\nGlaser SL, Keegan TH, Clarke CA, Darrow LA, Gomez SL, Dorfman RF, et al. Smoking and Hodgkin lymphoma risk in women United States. Cancer Causes Control. 2004;15:387–97. https:\u002F\u002Fdoi.org\u002F10.1023\u002FB:CACO.0000027497.00558.e2.\nBakkalci D, Jia Y, Winter JR, Lewis JE, Taylor GS, Stagg HR. Risk factors for Epstein Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. J Glob Health. 2020;10:010405. https:\u002F\u002Fdoi.org\u002F10.7189\u002Fjogh.10.010405.\nHsu WL, Chien YC, Huang YT, Yu KJ, Ko JY, Lin CY, et al. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis. Cancer Med. 2020:9, 1867–1876. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fcam4.2832.\nOkekpa SI, S M N Mydin RB, Mangantig E, Azmi NSA, Zahari SNS, Kaur G, et al. Nasopharyngeal Carcinoma (NPC) Risk Factors: A Systematic Review and Meta-Analysis of the Association with Lifestyle, Diets, Socioeconomic and Sociodemographic in Asian Region. Asian Pac J Cancer Prev. 2019;20:3505–14. https:\u002F\u002Fdoi.org\u002F10.31557\u002FAPJCP.2019.20.11.3505.\nLong M, Fu Z, Li P, Nie Z. Cigarette smoking and the risk of nasopharyngeal carcinoma: a meta-analysis of epidemiological studies. BMJ Open. 2017;7:e016582. https:\u002F\u002Fdoi.org\u002F10.1136\u002Fbmjopen-2017-016582.\nZhou T, Yang DW, He YQ, Xue WQ, Liao Y, Zheng MQ, et al. Associations between environmental factors and serological Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma in South China. Cancer Med. 2019;8:4852–66. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fcam4.2348.\nHu T, Lin CY, Xie SH, Chen GH, Lu YQ, Ling W, et al. Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein-Barr Virus: An analysis of a prospective study in southern China. Cancer Med. 2019;8:2561–71. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fcam4.2083.\nHe YQ, Xue WQ, Xu FH, Xu YF, Zhang JB, Yu HL, et al. The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China. EBioMedicine. 2018;30:184–91. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ebiom.2018.02.019.\nYang QY, He YQ, Xue WQ, Zhou T, Liao Y, Zheng MQ, et al. Association Between Serum Cotinine Level and Serological Markers of Epstein-Barr Virus in Healthy Subjects in South China Where Nasopharyngeal Carcinoma Is Endemic. Front Oncol. 2019;9:865. https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffonc.2019.00865.\nChen Y, Xu Y, Zhao W, Xiao X, Zhou X, Lin L, et al. Lack of association between cigarette smoking and Epstein Barr virus reactivation in the nasopharynx in people with elevated EBV IgA antibody titres. BMC Cancer. 2018;18:190. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12885-018-4110-6.\nPathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995;333:693–8. https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJM199509143331103.\nYoung LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer. 2004;4:757–68. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrc1452.\nWei L, Griego AM, Chu M, Ozbun MA. Tobacco exposure results in increased E6 and E7 oncogene expression, DNA damage and mutation rates in cells maintaining episomal human papillomavirus 16 genomes. Carcinogenesis. 2014;35:2373–81. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fcarcin\u002Fbgu156.\nPena N, Carrillo D, Munoz JP, Chnaiderman J, Urzua U, Leon O, et al. Tobacco Smoke Activates Human Papillomavirus 16 p97 Promoter and Cooperates with High-Risk E6\u002FE7 for Oxidative DNA Damage in Lung Cells. Plos One. 2015;10. https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0123029.\nTsang CM, Yip YL, Lo KW, Deng W, To KF, Hau PM, et al. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells. Proc Natl Acad Sci U S A. 2012;109:E3473–82. https:\u002F\u002Fdoi.org\u002F10.1073\u002Fpnas.1202637109.\nLo KW, Chung GT, To KF. Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol. 2012;22:79–86. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.semcancer.2011.12.011.\nLo KW, Huang DP, Lau KM. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res. 1995;55:2039–43.\nPrueitt RL, Goodman JE, Valberg PA. Radionuclides in cigarettes may lead to carcinogenesis via p16(INK4a) inactivation. J Environ Radioact. 2009;100:157–61. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jenvrad.2008.11.008.\nGuzman LM, Koriyama C, Akiba S, Eizuru Y, Castillo D, Corvalan A, et al. High frequency of p16 promoter methylation in non-small cell lung carcinomas from Chile. Biol Res. 2007;40:365–72. S0716-97602007000400011.\nvon Zeidler SV, Miracca EC, Nagai MA, Birman EG. Hypermethylation of the p16 gene in normal oral mucosa of smokers. Int J Mol Med. 2004;14:807–11. https:\u002F\u002Fdoi.org\u002F10.3892\u002Fijmm.14.5.807.\nXu J, Gimenez-Conti IB, Cunningham JE, Collet AM, Luna MA, Lanfranchi HE, et al. Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer. 1998;83:204–12. https:\u002F\u002Fdoi.org\u002F10.1002\u002F(sici)1097-0142(19980715)83:2\u003C204::aid-cncr2>3.0.co;2-q.\nSuzuki S, Cohen SM, Arnold LL, Pennington KL, Kato H, Naiki T, et al. Cotinine, a major nicotine metabolite, induces cell proliferation on urothelium in vitro and in vivo. Toxicology. 2020;429:152325. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.tox.2019.152325.\nCalaf GM, Echiburú-Chau C. Synergistic effect of malathion and estrogen on mammary gland carcinogenesis. Oncol Rep. 2012;28:640–6. https:\u002F\u002Fdoi.org\u002F10.3892\u002For.2012.1817.\nCalaf GM, Bleak TC, Muñoz JP, Aguayo F. Markers of epithelial-mesenchymal transition in an experimental breast cancer model induced by organophosphorous pesticides and estrogen. Oncol Lett. 2020;20:84. https:\u002F\u002Fdoi.org\u002F10.3892\u002Fol.2020.11945.\nNavaranjan G, Hohenadel K, Blair A, Demers PA, Spinelli JJ, Pahwa P, et al. Exposures to multiple pesticides and the risk of Hodgkin lymphoma in Canadian men. Cancer Causes Control. 1661-1673;2013:24. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10552-013-0240-y.\nLuo D, Zhou T, Tao Y, Feng Y, Shen X, Mei S. Exposure to organochlorine pesticides and non-Hodgkin lymphoma: a meta-analysis of observational studies. Sci Rep. 2016;6:25768. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fsrep25768.\nIARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Some Organophosphate Insecticides and Herbicides. Lyon (FR): International Agency for Research on Cancer; 2017.\nCalaf GM, Garrido F. Catechol estrogens as biomarkers for mammary gland cancer. Int J Oncol. 2011;39:177–83. https:\u002F\u002Fdoi.org\u002F10.3892\u002Fijo.2011.1008.\nMuñoz JP, Bleak TC, Calaf GM. Glyphosate and the key characteristics of an endocrine disruptor: A review. Chemosphere. 2020;128619. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.chemosphere.2020.128619.\nZhao L, Xie F, Wang TT, Liu MY, Li JL, Shang L, et al. Chlorpyrifos Induces the Expression of the Epstein-Barr Virus Lytic Cycle Activator BZLF-1 via Reactive Oxygen Species. Oxid Med Cell Longev. 2015;2015:309125. https:\u002F\u002Fdoi.org\u002F10.1155\u002F2015\u002F309125.\nHardell E, Eriksson M, Lindström G, Van Bavel B, Linde A, Carlberg M, et al. Case-control study on concentrations of organohalogen compounds and titers of antibodies to Epstein-Barr virus antigens in the etiology of non-Hodgkin lymphoma. Leuk Lymphoma. 2001;42:619–29. https:\u002F\u002Fdoi.org\u002F10.3109\u002F10428190109099322.\nHardell L, Eriksson M. A case-control study of non-Hodgkin lymphoma and exposure to pesticides. Cancer. 1999;85:1353–60. https:\u002F\u002Fdoi.org\u002F10.1002\u002F(sici)1097-0142(19990315)85:6\u003C1353::aid-cncr19>3.0.co;2-1.\nHardell L, Lindström G, van Bavel B, Hardell K, Linde A, Carlberg M, et al. Adipose tissue concentrations of dioxins and dibenzofurans, titers of antibodies to Epstein-Barr virus early antigen and the risk for non-Hodgkin lymphoma. Environ Res. 2001;87:99–107. https:\u002F\u002Fdoi.org\u002F10.1006\u002Fenrs.2001.4295.\nNordström M, Hardell L, Lindström G, Wingfors H, Hardell K, Linde A. Concentrations of organochlorines related to titers to Epstein-Barr virus early antigen IgG as risk factors for hairy cell leukemia. Environ Health Perspect. 2000;108:441–5. https:\u002F\u002Fdoi.org\u002F10.1289\u002Fehp.108-1638040.\nHarabuchi Y, Yamanaka N, Kataura A, Imai S, Kinoshita T, Mizuno F, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet. 1990;335:128–30. https:\u002F\u002Fdoi.org\u002F10.1016\u002F0140-6736(90)90002-m.\nKanavaros P, Lescs MC, Brière J, Divine M, Galateau F, Joab I, et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood. 1993;81:2688–95.\nMedeiros LJ, Jaffe ES, Chen YY, Weiss LM. Localization of Epstein-Barr viral genomes in angiocentric immunoproliferative lesions. Am J Surg Pathol. 1992;16:439–47. https:\u002F\u002Fdoi.org\u002F10.1097\u002F00000478-199205000-00002.\nWeiss LM, Gaffey MJ, Chen YY, Frierson HF. Frequency of Epstein-Barr viral DNA in \"Western\" sinonasal and Waldeyer's ring non-Hodgkin's lymphomas. Am J Surg Pathol. 1992;16:156–62. https:\u002F\u002Fdoi.org\u002F10.1097\u002F00000478-199202000-00008.\nXu JX, Hoshida Y, Yang WI, Inohara H, Kubo T, Kim GE, et al. Life-style and environmental factors in the development of nasal NK\u002FT-cell lymphoma: a case-control study in East Asia. Int J Cancer. 2007;120:406–10. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.22313.\nAyee R, Ofori MEO, Wright E, Quaye O. Epstein Barr Virus Associated Lymphomas and Epithelia Cancers in Humans. J Cancer. 2020;11:1737–50. https:\u002F\u002Fdoi.org\u002F10.7150\u002Fjca.37282.\nRudant J, Menegaux F, Leverger G, Baruchel A, Nelken B, Bertrand Y, et al. Household exposure to pesticides and risk of childhood hematopoietic malignancies: The ESCALE study (SFCE). Environ Health Perspect. 2007;115:1787–93. https:\u002F\u002Fdoi.org\u002F10.1289\u002Fehp.10596.\nLatifovic L, Freeman LEB, Spinelli JJ, Pahwa M, Kachuri L, Blair A, et al. Pesticide use and risk of Hodgkin lymphoma: results from the North American Pooled Project (NAPP). Cancer Causes Control. 2020;31:583–99. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10552-020-01301-4.\nMavoungou S, Rios P, Pacquement H, Nolla M, Rigaud C, Simonin M, et al. Maternal exposure to pesticides and risk of childhood lymphoma in France: A pooled analysis of the ESCALE and ESTELLE studies (SFCE). Cancer Epidemiol. 2020;68:101797. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.canep.2020.101797.\nBunch KJ, Kendall GM, Stiller CA, Vincent TJ, Murphy MFG. Case-control study of paternal occupational exposures and childhood lymphoma in Great Britain, 1962-2010. Br J Cancer. 2019;120:1153–61. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41416-019-0469-7.\nCarozza SE, Li B, Wang Q, Horel S, Cooper S. Agricultural pesticides and risk of childhood cancers. Int J Hyg Environ Health. 2009;212:186–95. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijheh.2008.06.002.\nHardell K, Carlberg M, Hardell L, Björnfoth H, Ericson Jogsten I, Eriksson M, et al. Concentrations of organohalogen compounds and titres of antibodies to Epstein-Barr virus antigens and the risk for non-Hodgkin lymphoma. Oncol Rep. 2009;21:1567–76. https:\u002F\u002Fdoi.org\u002F10.3892\u002For_00000389.\nStancek D, Kosecká G, Oltman M, Keleová A, Jahnová E. Links between prolonged exposure to xenobiotics, increased incidence of hepatopathies, immunological disturbances and exacerbation of latent Epstein-Barr virus infections. Int J Immunopharmacol. 1995;17:321–8. https:\u002F\u002Fdoi.org\u002F10.1016\u002F0192-0561(95)00006-n.\nRifkin E, LaKind J. Dioxin bioaccumulation: key to a sound risk assessment methodology. J Toxicol Environ Health. 1991;33:103–12. https:\u002F\u002Fdoi.org\u002F10.1080\u002F15287399109531509.\nUSEPA. Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodiobenzo-p-dioxin (TCDD) and Related Compounds (September 2000 Draft). Part I: Estimating Exposure to dioxin-like compounds. 2000b, Volume 3: Properties, environmental levels and background exposures.\nFernandes AR, Falandysz J. Polybrominated dibenzo-p-dioxins and furans (PBDD\u002FFs): Contamination in food, humans and dietary exposure. Sci Total Environ. 2020;143191. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.scitotenv.2020.143191.\nBertazzi PA, Bernucci I, Brambilla G, Consonni D, Pesatori AC. The Seveso studies on early and long-term effects of dioxin exposure: a review. Environ Health Perspect. 1998;106(Suppl 2):625–33. https:\u002F\u002Fdoi.org\u002F10.1289\u002Fehp.98106625.\nInoue H, Mishima K, Yamamoto-Yoshida S, Ushikoshi-Nakayama R, Nakagawa Y, Yamamoto K, et al. Aryl hydrocarbon receptor-mediated induction of EBV reactivation as a risk factor for Sjögren's syndrome. J Immunol. 2012;188:4654–62. https:\u002F\u002Fdoi.org\u002F10.4049\u002Fjimmunol.1101575.\nSorg O. AhR signalling and dioxin toxicity. Toxicol Lett. 2014;230:225–33. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.toxlet.2013.10.039.\nBeischlag TV, Luis Morales J, Hollingshead BD, Perdew GH. The aryl hydrocarbon receptor complex and the control of gene expression. Crit Rev Eukaryot Gene Expr. 2008;18:207–50. https:\u002F\u002Fdoi.org\u002F10.1615\u002Fcritreveukargeneexpr.v18.i3.20.\nGutiérrez-Vázquez C, Quintana FJ. Regulation of the Immune Response by the Aryl Hydrocarbon Receptor. Immunity. 2018;48:19–33. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.immuni.2017.12.012.\nQuintana FJ, Sherr DH. Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev. 2013;65:1148–61. https:\u002F\u002Fdoi.org\u002F10.1124\u002Fpr.113.007823.\nStockinger B, Di Meglio P, Gialitakis M, Duarte JH. The aryl hydrocarbon receptor: multitasking in the immune system. Annu Rev Immunol. 2014;32:403–32. https:\u002F\u002Fdoi.org\u002F10.1146\u002Fannurev-immunol-032713-120245.\nKashuba EV, Gradin K, Isaguliants M, Szekely L, Poellinger L, Klein G, et al. Regulation of transactivation function of the aryl hydrocarbon receptor by the Epstein-Barr virus-encoded EBNA-3 protein. J Biol Chem. 2006;281:1215–23. https:\u002F\u002Fdoi.org\u002F10.1074\u002Fjbc.M509036200.\nHildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev. 1993;15:466–85. https:\u002F\u002Fdoi.org\u002F10.1093\u002Foxfordjournals.epirev.a036130.\nPoirier S, Ohshima H. de-Thé, G.; Hubert, A.; Bourgade, M.C.; Bartsch, H. Volatile nitrosamine levels in common foods from Tunisia, south China and Greenland, high-risk areas for nasopharyngeal carcinoma (NPC). Int J Cancer. 1987;39:293–6. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.2910390305.\nZou XN, Lu SH, Liu B. Volatile N-nitrosamines and their precursors in Chinese salted fish--a possible etological factor for NPC in china. Int J Cancer. 1994;59:155–8. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.2910590202.\nBouvier G, Poirier S, Shao YM, Malaveille C, Ohshima H, Polack A, et al. Epstein-Barr virus activators, mutagens and volatile nitrosamines in preserved food samples from high-risk areas for nasopharyngeal carcinoma. IARC Sci Publ. 1991:204–9.\nFang CY, Huang SY, Wu CC, Hsu HY, Chou SP, Tsai CH, et al. The synergistic effect of chemical carcinogens enhances Epstein-Barr virus reactivation and tumor progression of nasopharyngeal carcinoma cells. PLoS One. 2012;7:e44810. https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0044810.\nFeng BJ, Jalbout M, Ayoub WB, Khyatti M, Dahmoul S, Ayad M, et al. Dietary risk factors for nasopharyngeal carcinoma in Maghrebian countries. Int J Cancer. 2007;121:1550–5. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fijc.22813.\nAccardi R, Gruffat H, Sirand C, Fusil F, Gheit T, Hernandez-Vargas H, et al. The mycotoxin aflatoxin B1 stimulates Epstein-Barr virus-induced B-cell transformation in in vitro and in vivo experimental models. Carcinogenesis. 2015;36:1440–51. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fcarcin\u002Fbgv142.\nLiu L, Yang J, Ji W, Wang C. Curcumin Inhibits Proliferation of Epstein-Barr Virus-Associated Human Nasopharyngeal Carcinoma Cells by Inhibiting EBV Nuclear Antigen 1 Expression. Biomed Res Int. 2019;2019:8592921. https:\u002F\u002Fdoi.org\u002F10.1155\u002F2019\u002F8592921.\nAedo-Aguilera V, Carrillo-Beltrán D, Calaf GM, Muñoz JP, Guerrero N, Osorio JC, et al. Curcumin decreases epithelial-mesenchymal transition by a Pirin-dependent mechanism in cervical cancer cells. Oncol Rep. 2019;42:2139–48. https:\u002F\u002Fdoi.org\u002F10.3892\u002For.2019.7288.\nGallardo M, Kemmerling U, Aguayo F, Bleak TC, Muñoz JP, Calaf GM. Curcumin rescues breast cells from epithelial-mesenchymal transition and invasion induced by anti-miR-34a. Int J Oncol. 2020;56:480–93. https:\u002F\u002Fdoi.org\u002F10.3892\u002Fijo.2019.4939.\nWu CC, Fang CY, Cheng YJ, Hsu HY, Chou SP, Huang SY, et al. Inhibition of Epstein-Barr virus reactivation by the flavonoid apigenin. J Biomed Sci. 2017;24:2. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12929-016-0313-9.",{"VOID":1665},"10.1186\u002Fs13027-021-00391-2","2024-05-17T07:37:01.228+00:00","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13027-021-00391-2",[1669,1684,1699,1714,1738],{"id":1670,"sortIndex":21,"researcher":20,"roles":1671,"affiliations":1672,"properties":1681,"displayName":1683,"givenName":20,"familyName":20},"99e9f30e-2e3e-4fed-ba87-35882dda68a9",[140],[1673],{"id":1674,"sortIndex":21,"affiliation":1675,"properties":20},"e3fa72aa-180c-4718-8ef2-b91f8815904c",{"id":1674,"createTime":20,"updateTime":20,"relativeEntities":1676,"slug":20,"properties":1677,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1680,"statistic":20},[],{"title":1678},{"VI":1679},"Universidad de Tarapacá, Arica, Chile",[],{"title":1682},{"VI":1683},"Francisco Aguayo",{"id":1685,"sortIndex":105,"researcher":20,"roles":1686,"affiliations":1687,"properties":1696,"displayName":1698,"givenName":20,"familyName":20},"5277f1e9-8299-421f-979f-6015b2e84f61",[140],[1688],{"id":1689,"sortIndex":21,"affiliation":1690,"properties":20},"45d63cf5-62bc-4a2f-be43-9c87c9c5cd51",{"id":1689,"createTime":20,"updateTime":20,"relativeEntities":1691,"slug":20,"properties":1692,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1695,"statistic":20},[],{"title":1693},{"VI":1694},"Laboratory of Oncovirology, Department of Microbiology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil",[],{"title":1697},{"VI":1698},"Enrique Boccardo",{"id":1700,"sortIndex":106,"researcher":20,"roles":1701,"affiliations":1702,"properties":1711,"displayName":1713,"givenName":20,"familyName":20},"9f97c4dc-0b07-41d8-bfc6-74dae6b6cb15",[140],[1703],{"id":1704,"sortIndex":21,"affiliation":1705,"properties":20},"59e317c5-0dcc-4ebf-aec8-64adbe3f7fef",{"id":1704,"createTime":20,"updateTime":20,"relativeEntities":1706,"slug":20,"properties":1707,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1710,"statistic":20},[],{"title":1708},{"VI":1709},"Advanced Center for Chronic Diseases (ACCDiS), Pontificia Universidad Católica de Chile, Santiago, Chile",[],{"title":1712},{"VI":1713},"Alejandro Corvalán",{"id":1715,"sortIndex":107,"researcher":20,"roles":1716,"affiliations":1717,"properties":1735,"displayName":1737,"givenName":20,"familyName":20},"2d10334c-4d93-4d59-a2b2-cef8830e890d",[140],[1718,1726],{"id":1719,"sortIndex":21,"affiliation":1720,"properties":20},"b0e0b121-0ed0-4a95-973e-adce29718c28",{"id":1719,"createTime":20,"updateTime":20,"relativeEntities":1721,"slug":20,"properties":1722,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1725,"statistic":20},[],{"title":1723},{"VI":1724},"Instituto de Alta Investigación, Universidad de Tarapacá, Arica, Chile",[],{"id":1727,"sortIndex":105,"affiliation":1728,"properties":1734},"5aac1f2d-d642-4016-8541-49aa8663d394",{"id":1727,"createTime":20,"updateTime":20,"relativeEntities":1729,"slug":20,"properties":1730,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1733,"statistic":20},[],{"title":1731},{"VI":1732},"Center for Radiological Research, Columbia University Medical Center, New York, USA",[],{},{"title":1736},{"VI":1737},"Gloria M. Calaf",{"id":1739,"sortIndex":202,"researcher":20,"roles":1740,"affiliations":1741,"properties":1750,"displayName":1752,"givenName":20,"familyName":20},"3f8aa764-e8ba-4e24-b7d8-608140d38229",[140],[1742],{"id":1743,"sortIndex":21,"affiliation":1744,"properties":20},"29924a9a-af3f-48f2-93da-9452817febde",{"id":1743,"createTime":20,"updateTime":20,"relativeEntities":1745,"slug":20,"properties":1746,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1749,"statistic":20},[],{"title":1747},{"VI":1748},"Laboratorio de Oncovirología, Programa de Virología, Instituto de Ciencias Biomédicas (ICBM), Facultad de Medicina, Universidad de Chile, Santiago, Chile",[],{"title":1751},{"VI":1752},"Rancés Blanco",{"url":1667,"publisher":1754,"properties":1807},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1755,"slug":10,"properties":1756,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1759,"manageAffiliations":1776,"indexDatabases":1787,"url":20,"thumbnailPath":20,"statistic":1802,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":1757,"title":1758},{"VOID":13},{"EN":15},[1760,1764,1768,1772],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1761,"label":1762,"description":1763,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1765,"label":1766,"description":1767,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1769,"label":1770,"description":1771,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":1773,"label":1774,"description":1775,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[1777,1782],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1778,"slug":20,"properties":1779,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1781,"statistic":20},[],{"title":1780},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":1783,"slug":20,"properties":1784,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1786,"statistic":20},[],{"title":1785},{"EN":60},[],[1788,1795],{"id":64,"indexDatabase":1789,"url":75,"indexYears":76,"academicFieldIds":1794,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1790,"label":1791,"description":1792,"key":72,"publicationTags":1793,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":1796,"url":97,"indexYears":20,"academicFieldIds":1801,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":1797,"label":1798,"description":1799,"key":93,"publicationTags":1800,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":1803,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":1804,"totalCitation":21,"totalCitationByYear":1805,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1806,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":1808,"volume":1810},{"VOID":1809},"1-15",{"VOID":1155},"2021-06-30","ERROR_IN_GET_PLATFORM_ID","2026-06-08T09:01:54.000+00:00",[82,95],{"id":1816,"createTime":1817,"updateTime":1818,"relativeEntities":1819,"slug":1820,"properties":1821,"entityType":131,"verifyStatus":132,"verifyTime":1828,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1829,"fullTextUrl":20,"authors":1830,"publicationType":287,"publisherRelationship":1879,"citationCount":20,"citationInfo":20,"publishDate":1938,"publishYear":1939,"citationAnalyzeStatus":19,"lastCitationAnalyze":1940,"indexDatabases":1941,"openAccess":20,"references":20,"isForceReanalyzing":541},"84bab3a6-ee36-4e42-811c-c57ee0f9d720","2023-12-08T02:48:21.642+00:00","2026-05-09T12:48:41.631+00:00",[],"Evaluation-of-Epstein-Barr-virus-EBV-and-human-herpes-virus-8-HHV-8-in-HIV-associated-persistent-generalized-lymphadenopathy-PGL-",{"title":1822,"gsPaper":1824,"doi":1826},{"EN":1823},"Evaluation of Epstein-Barr virus (EBV) and human herpes virus-8 (HHV-8) in HIV-associated persistent generalized lymphadenopathy (PGL)",{"VOID":1825},"[\"14239506244277697514\"]",{"VOID":1827},"10.1186\u002F1750-9378-4-S2-P7","2024-06-23T09:35:56.718+00:00","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002F1750-9378-4-S2-P7",[1831,1846,1864],{"id":1832,"sortIndex":21,"researcher":20,"roles":1833,"affiliations":1834,"properties":1843,"displayName":1845,"givenName":20,"familyName":20},"50e9e4fb-a863-420a-b8c4-19f0f0726f33",[140],[1835],{"id":1836,"sortIndex":21,"affiliation":1837,"properties":20},"196aa8dd-dad7-4585-874d-88d6467c90ad",{"id":1836,"createTime":20,"updateTime":20,"relativeEntities":1838,"slug":20,"properties":1839,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1842,"statistic":20},[],{"title":1840},{"VI":1841},"The Ohio State University, Columbus, Ohio. USA",[],{"title":1844},{"VI":1845},"LW Ayers",{"id":1847,"sortIndex":105,"researcher":20,"roles":1848,"affiliations":1849,"properties":1861,"displayName":1863,"givenName":20,"familyName":20},"c5a42087-215b-42a0-886f-7910fe23c1b8",[140],[1850],{"id":1851,"sortIndex":21,"affiliation":1852,"properties":1858},"ae1f206f-fbfc-477e-81e2-a203ce81b374",{"id":1851,"createTime":20,"updateTime":20,"relativeEntities":1853,"slug":20,"properties":1854,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1857,"statistic":20},[],{"title":1855},{"EN":1856},"National Cancer Institute, Bethesda, Maryland ;, United States",[],{"title":1859},{"VI":1860},"National Cancer Institute, Bethesda, Maryland, USA",{"title":1862},{"VI":1863},"G Dominguez",{"id":1865,"sortIndex":106,"researcher":20,"roles":1866,"affiliations":1867,"properties":1876,"displayName":1878,"givenName":20,"familyName":20},"f31e744d-0447-4f00-a343-a7e295a52c55",[140],[1868],{"id":1851,"sortIndex":21,"affiliation":1869,"properties":1874},{"id":1851,"createTime":20,"updateTime":20,"relativeEntities":1870,"slug":20,"properties":1871,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1873,"statistic":20},[],{"title":1872},{"EN":1856},[],{"title":1875},{"VI":1860},{"title":1877},{"VI":1878},"K Bhatia",{"url":1829,"publisher":1880,"properties":1933},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1881,"slug":10,"properties":1882,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1885,"manageAffiliations":1902,"indexDatabases":1913,"url":20,"thumbnailPath":20,"statistic":1928,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":1883,"title":1884},{"VOID":13},{"EN":15},[1886,1890,1894,1898],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1887,"label":1888,"description":1889,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":1891,"label":1892,"description":1893,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":1895,"label":1896,"description":1897,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":1899,"label":1900,"description":1901,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[1903,1908],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1904,"slug":20,"properties":1905,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1907,"statistic":20},[],{"title":1906},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":1909,"slug":20,"properties":1910,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1912,"statistic":20},[],{"title":1911},{"EN":60},[],[1914,1921],{"id":64,"indexDatabase":1915,"url":75,"indexYears":76,"academicFieldIds":1920,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1916,"label":1917,"description":1918,"key":72,"publicationTags":1919,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":1922,"url":97,"indexYears":20,"academicFieldIds":1927,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":1923,"label":1924,"description":1925,"key":93,"publicationTags":1926,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":1929,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":1930,"totalCitation":21,"totalCitationByYear":1931,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":1932,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":1934,"volume":1936},{"VOID":1935},"1-2",{"VOID":1937},"4","2009-06-17",2009,"2026-05-09T12:48:41.630+00:00",[82,95],{"id":1943,"createTime":1944,"updateTime":1945,"relativeEntities":1946,"slug":1947,"properties":1948,"entityType":131,"verifyStatus":132,"verifyTime":1957,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1958,"fullTextUrl":20,"authors":1959,"publicationType":287,"publisherRelationship":2071,"citationCount":21,"citationInfo":2129,"publishDate":2131,"publishYear":1157,"citationAnalyzeStatus":19,"lastCitationAnalyze":2132,"indexDatabases":2133,"openAccess":20,"references":2134,"isForceReanalyzing":541},"5cc0668e-2031-4b60-8057-0e04b75fe87c","2023-12-22T17:39:58.019+00:00","2026-04-29T08:31:53.110+00:00",[],"The-degradation-of-Rap1GAP-via-E6AP-mediated-ubiquitin-proteasome-pathway-is-associated-with-HPV16-18-infection-in-cervical-cancer-cells",{"abstract":1949,"title":1951,"gsPaper":1953,"doi":1955},{"EN":1950},"Cervical cancers are closely associated with persistent high-risk human papillomaviruses (HR HPV) infection. The main mechanism involves the targeting of tumor suppressors, such as p53 and pRB, for degradation by HR HPV-encoded oncoproteins, thereby leading to tumorigenesis. Rap1GAP, a tumor suppressor gene, is down-regulated in many cancers. Previous studies have revealed that down-regulation of Rap1GAP is correlated with HPV16\u002F18 infection in cervical cancer. However, the molecular mechanism remains unclear. In this study, we aimed to address the degradation pathway of Rap1GAP in HPV-positive cervical cancer cells. HPV-positive (HeLa and SiHa) and negative (C33A) cervical cancer cells were used to analyze the pathways of Rap1GAP degradation. MG132 (carbobenzoxy-leucyl-leucyl-leucine) was used to inhibit protein degradation by proteasome. Co-immunoprecipitation (co-IP) was used to detect the interaction between Rap1GAP and E6AP. siRNA for E6AP was used to silence the expression of E6AP. Rapamycin was used to induce cell autophagy. Western blotting was used to check the levels of proteins. Following treatment with MG132, the levels of Rap1GAP were increased in the HR HPV-positive HeLa and SiHa cells, but not in the HPV-negative C33A cells. Co-immunoprecipitation assay revealed ubiquitinated Rap1GAP protein in HeLa and SiHa cells, but not in C33A cells. E6-associated protein (E6AP) mediated the ubiquitination of Rap1GAP by binding to it in HeLa and SiHa cells, but not in C33A cells. However, the levels of Rap1GAP were decreased in HeLa and SiHa cells after knocking down E6AP by siRNA. Silencing of E6AP did not affect the levels of Rap1GAP in C33A cells. Autophagy marker p62 was decreased and LC3 II\u002FLC3 I was increased after knocking down E6AP in HeLa cells, but not in C33A cells. The levels of Rap1GAP were decreased after treating the cells with rapamycin to induce cell autophagy in HeLa and C33A cells. Rap1GAP may be degraded by autophagy in cervical cancer cells, but HPV infection can switch the degradation pathway from autophagy to E6AP-mediated ubiquitin-proteasome degradation. E6AP may be a key component of the switch.",{"EN":1952},"The degradation of Rap1GAP via E6AP-mediated ubiquitin-proteasome pathway is associated with HPV16\u002F18-infection in cervical cancer cells",{"VOID":1954},"[\"16040886258314522383\"]",{"VOID":1956},"10.1186\u002Fs13027-021-00409-9","2024-05-02T09:40:32.706+00:00","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13027-021-00409-9",[1960,1984,1997,2010,2023,2045,2058],{"id":1961,"sortIndex":21,"researcher":20,"roles":1962,"affiliations":1963,"properties":1981,"displayName":1983,"givenName":20,"familyName":20},"a858131d-fdf7-47c0-97f0-5542844d66c0",[140],[1964,1972],{"id":1965,"sortIndex":21,"affiliation":1966,"properties":20},"d91243e1-a603-4eb3-a001-66ec8be2b925",{"id":1965,"createTime":20,"updateTime":20,"relativeEntities":1967,"slug":20,"properties":1968,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1971,"statistic":20},[],{"title":1969},{"VI":1970},"College of Laboratory Medicine, Dalian Medical University, Dalian, Liaoning, China",[],{"id":1973,"sortIndex":105,"affiliation":1974,"properties":1980},"40327e08-cf3e-4da0-af4a-56e239b8306c",{"id":1973,"createTime":20,"updateTime":20,"relativeEntities":1975,"slug":20,"properties":1976,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1979,"statistic":20},[],{"title":1977},{"VI":1978},"Liaoning Provincial Center for Disease Control and Prevention, Shenyang, China",[],{},{"title":1982},{"VI":1983},"Yinghui Wang",{"id":1985,"sortIndex":105,"researcher":20,"roles":1986,"affiliations":1987,"properties":1994,"displayName":1996,"givenName":20,"familyName":20},"c849da0c-4622-4e25-b9a9-a148695b4037",[140],[1988],{"id":1965,"sortIndex":21,"affiliation":1989,"properties":20},{"id":1965,"createTime":20,"updateTime":20,"relativeEntities":1990,"slug":20,"properties":1991,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1993,"statistic":20},[],{"title":1992},{"VI":1970},[],{"title":1995},{"VI":1996},"Yihang Xie",{"id":1998,"sortIndex":106,"researcher":20,"roles":1999,"affiliations":2000,"properties":2007,"displayName":2009,"givenName":20,"familyName":20},"3538fc58-b0e8-4a22-b895-d5b8b3802628",[140],[2001],{"id":1965,"sortIndex":21,"affiliation":2002,"properties":20},{"id":1965,"createTime":20,"updateTime":20,"relativeEntities":2003,"slug":20,"properties":2004,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2006,"statistic":20},[],{"title":2005},{"VI":1970},[],{"title":2008},{"VI":2009},"Boxuan Sun",{"id":2011,"sortIndex":107,"researcher":20,"roles":2012,"affiliations":2013,"properties":2020,"displayName":2022,"givenName":20,"familyName":20},"0d0df37d-d01a-41e3-86c0-9ea0a94a763f",[140],[2014],{"id":1965,"sortIndex":21,"affiliation":2015,"properties":20},{"id":1965,"createTime":20,"updateTime":20,"relativeEntities":2016,"slug":20,"properties":2017,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2019,"statistic":20},[],{"title":2018},{"VI":1970},[],{"title":2021},{"VI":2022},"Yuwei Guo",{"id":2024,"sortIndex":202,"researcher":20,"roles":2025,"affiliations":2026,"properties":2042,"displayName":2044,"givenName":20,"familyName":20},"dc551939-4722-4a9f-824a-97224df2a3c1",[140],[2027,2033],{"id":1965,"sortIndex":21,"affiliation":2028,"properties":20},{"id":1965,"createTime":20,"updateTime":20,"relativeEntities":2029,"slug":20,"properties":2030,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2032,"statistic":20},[],{"title":2031},{"VI":1970},[],{"id":2034,"sortIndex":105,"affiliation":2035,"properties":2041},"65f2d332-b778-4be0-a421-23e91cdd1179",{"id":2034,"createTime":20,"updateTime":20,"relativeEntities":2036,"slug":20,"properties":2037,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2040,"statistic":20},[],{"title":2038},{"VI":2039},"Foruth Teaching Hospital, Tianjin University of Traditional Chinese Medicine, Tianjin, China",[],{},{"title":2043},{"VI":2044},"Ling Song",{"id":2046,"sortIndex":216,"researcher":20,"roles":2047,"affiliations":2048,"properties":2055,"displayName":2057,"givenName":20,"familyName":20},"e0784e69-a276-4bb7-aa59-039a68d42b42",[140],[2049],{"id":1965,"sortIndex":21,"affiliation":2050,"properties":20},{"id":1965,"createTime":20,"updateTime":20,"relativeEntities":2051,"slug":20,"properties":2052,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2054,"statistic":20},[],{"title":2053},{"VI":1970},[],{"title":2056},{"VI":2057},"Dawit Eman Mohammednur",{"id":2059,"sortIndex":108,"researcher":20,"roles":2060,"affiliations":2061,"properties":2068,"displayName":2070,"givenName":20,"familyName":20},"d5284e57-5634-4852-8377-7acdc652dd3f",[140],[2062],{"id":1965,"sortIndex":21,"affiliation":2063,"properties":20},{"id":1965,"createTime":20,"updateTime":20,"relativeEntities":2064,"slug":20,"properties":2065,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2067,"statistic":20},[],{"title":2066},{"VI":1970},[],{"title":2069},{"VI":2070},"Chunyan Zhao",{"url":1958,"publisher":2072,"properties":2125},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2073,"slug":10,"properties":2074,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":2077,"manageAffiliations":2094,"indexDatabases":2105,"url":20,"thumbnailPath":20,"statistic":2120,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":2075,"title":2076},{"VOID":13},{"EN":15},[2078,2082,2086,2090],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":2079,"label":2080,"description":2081,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":2083,"label":2084,"description":2085,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":2087,"label":2088,"description":2089,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":2091,"label":2092,"description":2093,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[2095,2100],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":2096,"slug":20,"properties":2097,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2099,"statistic":20},[],{"title":2098},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":2101,"slug":20,"properties":2102,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2104,"statistic":20},[],{"title":2103},{"EN":60},[],[2106,2113],{"id":64,"indexDatabase":2107,"url":75,"indexYears":76,"academicFieldIds":2112,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":2108,"label":2109,"description":2110,"key":72,"publicationTags":2111,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":2114,"url":97,"indexYears":20,"academicFieldIds":2119,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":2115,"label":2116,"description":2117,"key":93,"publicationTags":2118,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":2121,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":2122,"totalCitation":21,"totalCitationByYear":2123,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":2124,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":2126,"volume":2128},{"VOID":2127},"1-11",{"VOID":1155},{"total":21,"publishYear":1157,"statisticByYear":2130},{},"2021-12-24","2026-04-29T08:31:53.109+00:00",[82,95],[2135,2141,2144,2147,2150,2153,2156,2159,2162,2165,2168,2171,2174,2177,2180,2183,2186,2189,2192,2195,2198,2201,2204,2207,2210,2218,2227,2230,2233,2239,2242,2245,2248,2251,2254,2257,2260,2263,2266,2269,2272,2275,2278,2281,2284,2287,2290,2293,2296,2299],{"id":2136,"text":2137,"url":2138,"identifiers":2139},"5f42e3df-5d30-4f1a-bb20-4f0691e21ded","Mabelele M, Materu J, Ng’ida FD, Mahande MJ. Knowledge towards cervical cancer prevention and screening practices among women who attended reproductive and child health clinic at Magu district hospital, Lake Zone Tanzania: a cross-sectional study. BMC Cancer. 2018;18:565.","https:\u002F\u002Fbmccancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs12885-018-4490-7",{"doi":2140},"10.1186\u002Fs12885-018-4490-7",{"id":360,"text":2142,"url":362,"identifiers":2143},"Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10:550.",{"doi":364},{"id":360,"text":2145,"url":362,"identifiers":2146},"Chow LT, Broker TR. Human Papillomavirus infections: warts or cancer? Cold Spring Harbor Perspect Biol. 2013;5:a012997.",{"doi":364},{"id":360,"text":2148,"url":362,"identifiers":2149},"Soto D, Song C, McLaughlin-Drubin ME. Epigenetic alterations in human Papillomavirus-associated cancers. Viruses. 2017;9:248.",{"doi":364},{"id":360,"text":2151,"url":362,"identifiers":2152},"Juline P, Elise B, Marie-Laure S, Patricia C, Yves N, Louis J, et al. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system. FEBS J. 2017;284:3171.",{"doi":364},{"id":360,"text":2154,"url":362,"identifiers":2155},"Bandilovska I, Keam SP, Gamell C, Machicado C, Haupt S, Haupt Y. E6AP goes viral: the role of E6AP in viral- and non-viral-related cancers. Carcinogenesis. 2019;40:707.",{"doi":364},{"id":360,"text":2157,"url":362,"identifiers":2158},"Nellore A, Paziana K, Ma CQ, Tsygankova OM, Wang Y, Puttaswamy K, et al. Loss of Rap1GAP in papillary thyroid cancer. J Clin Endocrinol Metab. 2009;94:1026.",{"doi":364},{"id":360,"text":2160,"url":362,"identifiers":2161},"Kim WJ, Gersey Z, Daaka Y. Rap1GAP regulates renal cell carcinoma invasion. Cancer Lett. 2012;320:65.",{"doi":364},{"id":360,"text":2163,"url":362,"identifiers":2164},"Zheng H, Gao L, Feng Y, Yuan L, Zhao H, Cornelius LA. Down-regulation of Rap1GAP via promoter hypermethylation promotes melanoma cell proliferation, survival, and migration. Cancer Res. 2009;69:449.",{"doi":364},{"id":360,"text":2166,"url":362,"identifiers":2167},"Zhang Z, Mitra RS, Henson BS, Datta NS, McCauley LK, Kumar P, et al. Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol. 2006;168:585.",{"doi":364},{"id":360,"text":2169,"url":362,"identifiers":2170},"Zhang L, Chenwei L, Mahmood R, Datta NS, McCauley LK, Kumar P, et al. Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. Cancer Res. 2006;66:898.",{"doi":364},{"id":360,"text":2172,"url":362,"identifiers":2173},"Tsygankova OM, Ma C, Tang W, Korch C, Feldman MD, Lv Y, et al. Downregulation of Rap1GAP in human tumor cells alters cell\u002Fmatrix and cell\u002Fcell adhesion. Mol Cell Biol. 2010;30:3262.",{"doi":364},{"id":360,"text":2175,"url":362,"identifiers":2176},"Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268.",{"doi":364},{"id":360,"text":2178,"url":362,"identifiers":2179},"Banerjee R, Mani RS, Russo N, Tsodikov A, Jing X, Cao Q, et al. The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene. 2011;30:4339.",{"doi":364},{"id":360,"text":2181,"url":362,"identifiers":2182},"Mitra RS, Goto M, Lee JS, Maldonado D, Taylor JMG, Pan Q, et al. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res. 2008;68:3959.",{"doi":364},{"id":360,"text":2184,"url":362,"identifiers":2185},"Zuo H, Gandhi M, Edreira MM, Hochbaum D, Nimgaonkar VL, Zhang P, et al. Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res. 2010;70:1389.",{"doi":364},{"id":360,"text":2187,"url":362,"identifiers":2188},"Dong X, Tang W, Stopenski S, Brose MS, Korch C, Meinkoth JL. RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells. Endocr Relat Cancer. 2012;19:575.",{"doi":364},{"id":360,"text":2190,"url":362,"identifiers":2191},"Dong X, Korch C, Meinkoth JL. Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells. Endocr Relat Cancer. 2011;18:301.",{"doi":364},{"id":360,"text":2193,"url":362,"identifiers":2194},"Zhao J, Mai C, Weng D, Chen C, Zhou Z, Liu Y, et al. Reduced expression of Rap1GAP as a prognostic biomarker for primary gastric cancer patients. Cancer Biomark. 2018;22:375.",{"doi":364},{"id":360,"text":2196,"url":362,"identifiers":2197},"Yang Y, Zhang J, Yan Y, Cai H, Li M, Sun K, et al. Low expression of Rap1GAP is associated with epithelial-mesenchymal transition (EMT) and poor prognosis in gastric cancer. Oncotarget. 2017;8:8057.",{"doi":364},{"id":360,"text":2199,"url":362,"identifiers":2200},"Gao WL, Ye GC, Liu LW, Wei L. The downregulation of Rap1 GTPase-activating protein is associated with a poor prognosis in colorectal cancer and may impact on tumor progression. Oncol Lett. 2018;15:7661.",{"doi":364},{"id":360,"text":2202,"url":362,"identifiers":2203},"Qi X, Chen Z, Qian J, Cen J, Gu M. Expression of Rap1GAP in human myeloid disease following microarray selection. Genet Mol Res. 2008;7:379.",{"doi":364},{"id":360,"text":2205,"url":362,"identifiers":2206},"Tamate M, Tanaka R, Osogami H, Matsuura M, Satohisa S, Iwasaki M, et al. Rap1GAP inhibits tumor progression in endometrial cancer. Biochem Biophys Res Commun. 2017;485:476.",{"doi":364},{"id":20,"text":2208,"url":20,"identifiers":2209},"Kong FD, Li CH, Zhao CY. The expression of Rap1GAP in cervical cancer and its relationship with HPV16\u002F18 infection. Journal of Dalian Medical University. 2010;32:142 (in Chinese).",{},{"id":20,"text":2211,"url":2212,"identifiers":2213},"Zheng L, Ding H, Lu Z, Li Y, Pan Y, Ning T, Ke Y. E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6. Genes Cells. 2008;13(3):285–94. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1365-2443.2008.01162.x.","https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1365-2443.2008.01162.x",{"mag":2214,"openalex":2215,"pm":2216,"doi":2217},"1965816740","W1965816740","18298802","10.1111\u002Fj.1365-2443.2008.01162.x",{"id":20,"text":2219,"url":2220,"identifiers":2221},"Kelley ML, Keiger KE, Lee CJ, Huibregtse JM. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase. J Virol. 2005;79(6):3737–47. https:\u002F\u002Fdoi.org\u002F10.1128\u002FJVI.79.6.3737-3747.2005.","https:\u002F\u002Fdoi.org\u002F10.1128\u002Fjvi.79.6.3737-3747.2005",{"mag":2222,"pmc":2223,"openalex":2224,"pm":2225,"doi":2226},"2164554492","1075713","W2164554492","15731267","10.1128\u002Fjvi.79.6.3737-3747.2005",{"id":360,"text":2228,"url":362,"identifiers":2229},"Drews CM, Brimer N, Vande Pol SB. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity. PLoS Pathog. 2020;16:e1008295.",{"doi":364},{"id":360,"text":2231,"url":362,"identifiers":2232},"Lin YW, Kong FD, Li Y, Wang YH, Song L, Zhao CY. The tumor suppressor OVCA1 is a short half-life protein degraded by the ubiquitin-proteasome pathway. Oncol Lett. 2019;17:2328.",{"doi":364},{"id":2234,"text":2235,"url":2236,"identifiers":2237},"f1fc887d-70f8-4a4e-b815-b0155d33f339","Kwon SK, Saindane M, Baek KH. p53 stability is regulated by diverse deubiquitinating enzymes. Biochem Biophys Acta. 2017;1868:404.","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS0304419X1730077X",{"doi":2238},"10.1016\u002Fj.bbcan.2017.08.001",{"id":360,"text":2240,"url":362,"identifiers":2241},"Mantovani F, Banks L. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene. 1999;18:3309.",{"doi":364},{"id":360,"text":2243,"url":362,"identifiers":2244},"Anwar A, Norris DA, Fujita M. Ubiquitin proteasomal pathway mediated degradation of p53 in melanoma. Arch Biochem Biophys. 2011;508:198.",{"doi":364},{"id":360,"text":2246,"url":362,"identifiers":2247},"Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996;56:2649.",{"doi":364},{"id":360,"text":2249,"url":362,"identifiers":2250},"Chowdary DR, Dermody JJ, Jha KK, Ozer HL. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol. 1994;14:1997.",{"doi":364},{"id":360,"text":2252,"url":362,"identifiers":2253},"Scheffner M, Münger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA. 1991;88:5523.",{"doi":364},{"id":360,"text":2255,"url":362,"identifiers":2256},"Hougardy BMT, Maduro JH, van der Zee AGJ, de Groot DJA, van den Heuvel FAJ, de Vries EGE, et al. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer. 2006;118:1892.",{"doi":364},{"id":360,"text":2258,"url":362,"identifiers":2259},"Ristriani T, Fournane S, Orfanoudakis G, Travé G, Masson M. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells. Oncogene. 2008;28:10.",{"doi":364},{"id":360,"text":2261,"url":362,"identifiers":2262},"Sun L, Shen X, Liu Y, Zhang G, Wei J, Zhang H, et al. The location of endogenous wild-type p53 protein in 293T and HEK293 cells expressing low-risk HPV-6E6 fusion protein with GFP. Acta Biochim Biophys Sin (Shanghai). 2010;42:230.",{"doi":364},{"id":360,"text":2264,"url":362,"identifiers":2265},"Sailer C, Offensperger F, Julier A, Kammer K-M, Walker-Gray R, Gold MG, et al. Structural dynamics of the E6AP\u002FUBE3A-E6-p53 enzyme-substrate complex. Nat Commun. 2018;9:4441.",{"doi":364},{"id":360,"text":2267,"url":362,"identifiers":2268},"Wang Y, Liu X, Zhou L, Duong D, Bhuripanyo K, Zhao B, et al. Identifying the ubiquitination targets of E6AP by orthogonal ubiquitin transfer. Nat Commun. 2017;8:2232.",{"doi":364},{"id":360,"text":2270,"url":362,"identifiers":2271},"Talis AL, Huibregtse JM, Howley PM. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells. J Biol Chem. 1998;273:6439.",{"doi":364},{"id":360,"text":2273,"url":362,"identifiers":2274},"Kao WH, Beaudenon SL, Talis AL, Huibregtse JM, Howley PM. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J Virol. 2000;74:6408.",{"doi":364},{"id":360,"text":2276,"url":362,"identifiers":2277},"Michnov O, Solomayer E, Fehm T, Stubenrauch F, Iftner T. Knock down of p53 or its ubiquitin ligase E6AP does not affect the sensitivity of human papillomavirus-positive cervical cancer cells to cisplatin. Am J Cancer Res. 2012;2:309.",{"doi":364},{"id":360,"text":2279,"url":362,"identifiers":2280},"Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ, Scheffner M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci. 2001;98:1218.",{"doi":364},{"id":360,"text":2282,"url":362,"identifiers":2283},"Hengstermann A, D’Silva MA, Kuballa P, Butz K, Hoppe-Seyler F, Scheffner M. Growth suppression induced by downregulation of E6-AP expression in human papillomavirus-positive cancer cell lines depends on p53. J Virol. 2005;79:9296.",{"doi":364},{"id":360,"text":2285,"url":362,"identifiers":2286},"Choi S, Chen M, Cryns VL, Anderson RA. A nuclear phosphoinositide kinase complex regulates p53. Nat Cell Biol. 2019;21:462.",{"doi":364},{"id":360,"text":2288,"url":362,"identifiers":2289},"Ingallina E, Sorrentino G, Bertolio R, Lisek K, Zannini A, Azzolin L, et al. Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis. Nat Cell Biol. 2018;20:28.",{"doi":364},{"id":360,"text":2291,"url":362,"identifiers":2292},"Wiech M, Olszewski MB, Tracz-Gaszewska Z, Wawrzynow B, Zylicz M, Zylicz A. Molecular mechanism of mutant p53 stabilization: the role of HSP70 and MDM2. PLoS ONE. 2012;7:e51426.",{"doi":364},{"id":360,"text":2294,"url":362,"identifiers":2295},"Dikic I. Proteasomal and autophagic degradation systems. Annu Rev Biochem. 2017;86:193.",{"doi":364},{"id":360,"text":2297,"url":362,"identifiers":2298},"Kocaturk NM, Gozuacik D. Crosstalk between mammalian autophagy and the ubiquitin-proteasome system. Front Cell Dev Biol. 2018;6:128.",{"doi":364},{"id":360,"text":2300,"url":362,"identifiers":2301},"Mattoscio D, Medda A, Chiocca S. Human papilloma virus and autophagy. Int J Mol Sci. 2018;19:1775.",{"doi":364},{"id":2303,"createTime":2304,"updateTime":2305,"relativeEntities":2306,"slug":2307,"properties":2308,"entityType":131,"verifyStatus":132,"verifyTime":2318,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":2319,"fullTextUrl":20,"authors":2320,"publicationType":287,"publisherRelationship":2388,"citationCount":20,"citationInfo":20,"publishDate":2446,"publishYear":2447,"citationAnalyzeStatus":1812,"lastCitationAnalyze":2448,"indexDatabases":2449,"openAccess":20,"references":20,"isForceReanalyzing":541},"97d0fd4a-fce1-4a6e-80cb-db0a6bf1a753","2024-02-10T16:40:54.921+00:00","2026-03-10T04:58:53.749+00:00",[],"Association-of-schistosomiasis-and-risk-of-prostate-cancer-development-in-residents-of-Murehwa-rural-community-Zimbabwe",{"abstract":2309,"title":2311,"gsPaper":2313,"references":2314,"doi":2316},{"EN":2310},"Prostatic male genital schistosomiasis and prostate cancer co-existence cases are uncommon however, some studies have indicated that schistosomiasis may trigger development of prostate cancer regardless of age. Schistosomiasis is a public health problem in sub-Saharan Africa and may account for some undocumented cases of schistosomiasis prostatic cancer in schistosome endemic rural communities. It is against this background that we investigated the association between schistosomiasis and risk of prostate cancer development in residents of Murehwa Community, a schistosomiasis endemic area. We conducted a cross sectional study involving 366 men residing in Murehwa District, Zimbabwe. Schistosoma haematobium and S. mansoni infection was diagnosed using urine filtration and Kato Katz techniques, respectively. Haematuria was detected using urinalysis reagent strip test. A structured questionnaire was used to obtain history of schistosomiasis infection among study participants. Risk of prostate cancer development was assessed by measuring prostate-specific antigen levels in serum using the ELISA. Prevalence of S. haematobium and S. mansoni infection was 12.3% and 1.4%, respectively. Individuals with schistosomiasis had higher prostate-specific antigen levels (mean 1.208 ± SD 1.557 ng\u002FmL) compared to those without schistosomiasis (mean 0.7721 ± SD 1.173 ng\u002FmL; p \u003C 0.05). Older individuals > 50 years had higher prostate specific antigen levels (mean 0.7212 ± SD 1.313 ng\u002FmL) compared to individuals \u003C 50 years old (mean 0.4159 ± SD 0.8622 ng\u002FmL; p \u003C 0.05). Prostate-specific antigen levels log10 (mean 0.2584 ± SD 0.2128 ng\u002FmL) and were associated to S. haematobium infection intensity log10 (mean 1.121 ± SD 0.5371 eggs\u002F10 mL), r(s) = − 0.3225, p \u003C 0.05. There was a correlation between prostate-specific antigen levels log10 (mean 0.2246 ± SD 0.1858 ng\u002FmL) and S. haematobium infection intensity log10 (mean 1.169 ± SD 0.5568 eggs\u002F10 mL) among participants with a history of schistosomiasis infection (r(s) = − 0.3520; p \u003C 0.05). There was no correlation between prostate-specific antigen levels of > 4 ng\u002FmL (mean 5.324 ± SD1.568 ng\u002FmL) and schistosome eggs log10 (mean 1.057 ± SD 0.6730 eggs\u002F10 mL; p > 0.05). Urogenital schistosome infections and history of schistosome infections were associated with prostate specific antigen levels, an indicator for risk of prostate cancer. Therefore, S. haematobium schistosome egg burden was associated with the risk of prostate cancer development in adult males residing in Murehwa District, Zimbabwe.",{"EN":2312},"Association of schistosomiasis and risk of prostate cancer development in residents of Murehwa rural community, Zimbabwe",{"VOID":1661},{"VOID":2315},"Al Adnani MS. Schistosomiasis, metaplasia and squamous cell carcinoma of the prostate: Histogenesis of the squamous cancer cells determined by localization of specific markers. Neoplasma. 1985;32(5):613–22.\nLodhia J, Mremi A, Pyuz JJ, Bartholomeo N, Herman AM. Schistosomiasis and cancer: experience from a zonal hospital in Tanzania and opportunities for prevention. J Surgical Case Reports. 2020;5(44):1–5.\nGodec CJ, Grunberger I, Carr GA. Simultaneous presence of schistosomiasis and advanced cancer in prostate. J Urol. 1992;39(6):547–9.\nMa TK, Srigley JR. Adenocarcinoma of prostate and schistosomiasis: a rare association. Histopathol. 1995;27(2):187–9.\nPeiffer LB, Poynton SL, Ernst SE, Hicks JL, Marzo AM, Sfanos KS. Inflammation-associated pathologies in a case of prostate schistosomiasis: implications for a causal role in prostate carcinogenesis. Prostate. 2019;79(11):1316–25.\nInternational Agency for Research on Cancer. GLOBOCAN 2012: Cancer incidence and mortality worldwide in 2012. http:\u002F\u002Fglobocan.iarc.fr\u002FPages\u002Ffact_sheets_cancer.aspx# (2012). Accessed 12 May 2020.\nBray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.\nZimbabwe National Cancer Registry (ZNCR). Profile of Cancer in Zimbabwe 2014. http:\u002F\u002Fwww.zimcancerregistry.co.zw\u002Fcancer-profile-in-zimbabwe.html (2015). Accessed 19 May 2020.\nChokunonga E, Borok M, Chirenje Z, Nyakabau A, Parkin D. Trends in the incidence of cancer in the black population of Harare, Zimbabwe 1991-2010. Int J Cancer. 2013;133(3):721–9.\nThe Cancer Association of Zimbabwe. Prostate cancer. https:\u002F\u002Fcancerzimbabwe.org (2017). Accessed 18 November 2018.\nMottet N, Bastian PJ, Bastian J, Bellmunt Van def-Berg RCN, Bolla M, Van-Casteren NJ, et al. European Association of Urology. Guidelines on Prostate Cancer. (2015)https:\u002F\u002Furoweb.org\u002Fwp-content\u002Fuploads\u002F1607-Prostate-Cancer_LRV3.pd . Accessed 20 November 2018.\nWilt TJ. Prostate cancer: epidemiology and screening. Rev Urol. 2003;5(6):S3–9.\nOesterling JE. Prostate-specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145(5):907–92.\nNadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2):407–13.\nIlic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720.\nWolf AM, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60(2):70–98.\nU.S. Preventive Services Task Force. Screening for Prostate Cancer: Recommendations and Rationale. Ann Intern Med. 2002;137:915–6.\nThompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level \u003C or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.\nFang J, Metter EJ, Landis P, Chan DW, Morrell CH, Carter HB. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore longitudinal study of aging. Urology. 2001;58(3):411–6.\nGann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;273(4):289–94.\nElfaki TEM, Kebayer MHA, Elsayid M. Association between urinary schistosomiasis and prostate cancer in Al-Shajara area Khartoum, Sudan. IJNRHN. 2015;2(3):91–7.\nColley DC, Secor WE. Immunology of human Schistosomiasis. Parasite Immunol. 2014;36:347–57.\nWorld Health Organisation. Epidemiology table of schistosomiasis current estimated total number of individuals with morbidity and mortality due to Schistosomiasis haematobium and S. mansoni infection in Sub-Saharan Africa. 2019http:\u002F\u002Fwww.who.int\u002Fschistosomiasis\u002Fepidemiology\u002Ftable\u002Fen\u002F . Accessed 13 May 2019.\nAdenowo AF, Oyinloye BE, Ogunyinka BI, Kappo AP. Impact of human schistosomiasis in sub-Saharan Africa. Braz J Infect Dis. 2015;19(2):196–205.\nUmar MA, Umar AU, Usman ID, Yahaya A, Dambazau SA. Schistosoma haematobium infections: prevalence and morbidity indicators in communities around Wasai dam, Minjibir, Kano state, and northern Nigeria. Inter J of Trop Disease & Health. 2016;17(2):1–8.\nKjetland EF, Hegertun IE, Baay MF, Onsrud M, Ndhlovu PD, Taylor M. Genital schistosomiasis and its unacknowledged role on HIV transmission in the STD intervention studies. Int J STD AIDS. 2014;25(10):705–15.\nWorld Health Organisation. Cancer country profiles2014. https:\u002F\u002Fwww.who.int\u002Fcancer\u002Fcountry-profiles\u002Fen\u002F . Accessed 17 September 2019.\nMbabazi PS, Andan O, Fitzgerald DW, Chitsulo L, Engels D, Downs JA. Examining the relationship between urogenital schistosomiasis and HIV infection. PLOS Neg Trop Dis. 2011;5:e1396.\nFeldmeier H, Leutscher P, Poggensee G, Harms G. Male genital schistosomiasis and haemospermia. Trop Med and Inter Healt. 1999;4(12):791–3.\nCohen RJ, Edgar SG, Cooper K. Schistosomiasis and prostate cancer. Path. 1995;27(2):115–6.\nGelfand M, Ross CMD, Blair DM. Schistosomiasis of the male pelvic organs. Severity of infection as determined by digestion of tissue and histologic methods in 300 cadavers. Am J Trop Med Hyg. 1970;19(5):779–84.\nStecher CW, Kallestrup P, Kjetland EF, Vennervald B, Petersen E. Considering treatment of male genital Schistosomiasis as a tool for future HIV prevention: a systematic review. Int J Public Health. 2015;60(7):839–48.\nFigueiredo JC, Richter J, Borja N, Balaca A, Costa S, Belo S, et al. Prostate adenocarcinoma associated with prostatic infection due to Schistosoma haematobium: case report and systematic review. Parasitol Res. 2015;114(2):351–8.\nBasilio-de-Oliveira CA, Aquino A, Simon EF, Eyer-Silva WA. Concomitant prostatic schistosomiasis and adenocarcinoma: case report and review. Braz J Infect Dis. 2002;6(1):45–9.\nEl-Hawary AK, Foda AAM. Incidentally detected schistosomiasis in male genital organs: case reports and review of literature. Am J Cas Rep. 2016;4(1):25–30.\nMetrogos V, Ramos N, Marialva C, Bastos J. Rare association between prostate adenocarcinoma and schistosomiasis: a case report. ACTA Urológica Portuguesa. 2017;34(3–4):41–3.\nMidzi N, Mduluza T, Chimbari MJ, Tshuma C, Charimari L, Mhlanga G, et al. Distribution of schistosomiasis and soil transmitted helminthiasis in Zimbabwe: towards a national plan of action for control and elimination. PLoS Negl Trop Dis. 2014;8:e3014.\nCity population Murehwa District. https:\u002F\u002Fwww.citypopulation.de\u002Fphp\u002Fzimbabwe-admin.php?adm2id=306. Accessed August 2020.\nMott KE, Baltes R, Bambagha J, Baldassini B. Field studies of a reusable polyamide filter for detection of Schistosoma haematobium eggs by urine filtration. Tropenmed Parasitol. 1982;3(4):227–8.\nBarbosa CS, Gomes ECS, Marcelino JMR, Cavalcante KRLJ, Nascimento WRC. Quality control of the slides by Kato-Katz method for the parasitological diagnosis of schistosomiasis infection by Schistosoma mansoni. J Bras Patol Med Lab. 2017;53(2):110–4.\nMontresor A, Crompton DWT, Bundy DAP, Hall A, Savioli L. Guidelines for the evaluation of soil-transmitted helminthiasisand schistosomiasis at community level: World Health Organisation; 1998. https:\u002F\u002Fapps.who.int\u002Firis\u002Fhandle\u002F10665\u002F63821 . Accessed 10 October 2019.\nCatalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324(17):1156–61.\nAmerican Cancer Society. Screening tests for prostate cancer. 2020https:\u002F\u002Fwww.cancer.org\u002Fcancer\u002Fprostate-cancer\u002Fdetection-diagnosis-staging\u002Ftests.html . Accessed 9 January 2020.\nEhsani L, Adeboye OO. Schistosomiasis of the prostate: a case report. Anal Quant Cytol Histol. 2013;35(3):178–80.\nLambertucci RJ, Voieta I, Barbosa A. Schistosomiasis mansoni of the prostate. Rev Soc Bras Med Trop. 2006;39(2):233–4.\nDe Marzo AM, Nelson WG, Meeker AK, et al. Stem cell features of benign and malignant prostate epithelial cells. J Urol. 1998;160(6II):2381–92.\nGomez EC, Domingues ALC, Júnior FCA, Santos K, Rehn V, Lira M, et al. First record of prostatic schistosomiasis in Pernambuco, Brazil: signs of chronicity in an endemic disease. Rev Patol Trop. 2016;45(10):132–8.\nSharma R, Mahore SD, Kolhe H, Patil R, Bathale K, Wilkinson A. Schistosoma in the prostate: a case report. Int J of Allied Med Sci and Clin Research. 2015;3(3):293–7.\nPerdana NR, Mochtar CA, Umbas R, Hamid AR. The risk factors of prostate cancer and its prevention: a literature review. Acta Med Indones. 2016;48(3):228–38.\nVickers AJ. Prostate cancer screening: time to question how to optimize the ratio of benefits and harms. Ann Intern Med. 2017;167(7):509–10.\nAnosike JC, Nwoke BEB, Njoku AJ. The validity of haematuria in the community diagnosis of urinary schistosomiasis infections. J Helminthol. 2001;75(3):223–5.",{"VOID":2317},"10.1186\u002Fs13027-020-00327-2","2024-05-11T13:52:47.930+00:00","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13027-020-00327-2",[2321,2336,2360,2375],{"id":2322,"sortIndex":21,"researcher":20,"roles":2323,"affiliations":2324,"properties":2333,"displayName":2335,"givenName":20,"familyName":20},"4edf7642-1244-46ba-a990-302652a6d326",[140],[2325],{"id":2326,"sortIndex":21,"affiliation":2327,"properties":20},"a80ca6db-bfbe-4372-ba9c-db6018d26ae4",{"id":2326,"createTime":20,"updateTime":20,"relativeEntities":2328,"slug":20,"properties":2329,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2332,"statistic":20},[],{"title":2330},{"VI":2331},"University of KwaZulu Natal, School of Nursing and Public Health, Durban, South Africa",[],{"title":2334},{"VI":2335},"Emilia T. Choto",{"id":2337,"sortIndex":105,"researcher":20,"roles":2338,"affiliations":2339,"properties":2357,"displayName":2359,"givenName":20,"familyName":20},"1a028d75-85a5-498f-b40d-1c55330c9a1f",[140],[2340,2348],{"id":2341,"sortIndex":21,"affiliation":2342,"properties":20},"6a73e275-abeb-4902-956c-38cfaed8f142",{"id":2341,"createTime":20,"updateTime":20,"relativeEntities":2343,"slug":20,"properties":2344,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2347,"statistic":20},[],{"title":2345},{"VI":2346},"University of Zimbabwe, Biochemistry Department, Harare, Zimbabwe",[],{"id":2349,"sortIndex":105,"affiliation":2350,"properties":2356},"f0291b9e-1d26-4ce4-84da-be1cd8246898",{"id":2349,"createTime":20,"updateTime":20,"relativeEntities":2351,"slug":20,"properties":2352,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2355,"statistic":20},[],{"title":2353},{"VI":2354},"University of KwaZulu Natal, School of Laboratory Medicine and Medical Sciences, Howard College, Durban, South Africa",[],{},{"title":2358},{"VI":2359},"Takafira Mduluza",{"id":2361,"sortIndex":106,"researcher":20,"roles":2362,"affiliations":2363,"properties":2372,"displayName":2374,"givenName":20,"familyName":20},"1f17a9f1-96ae-4f96-86f9-11db7278e6f5",[140],[2364],{"id":2365,"sortIndex":21,"affiliation":2366,"properties":20},"69de37f3-0a21-4c87-8db9-ba388074013a",{"id":2365,"createTime":20,"updateTime":20,"relativeEntities":2367,"slug":20,"properties":2368,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2371,"statistic":20},[],{"title":2369},{"VI":2370},"Centre for Infection, Immunity and Evolution, Institute of Immunology and Infection Research, University of Edinburgh, Ashworth Laboratories, King’s Buildings, Edinburgh, UK",[],{"title":2373},{"VI":2374},"Francisca Mutapi",{"id":2376,"sortIndex":107,"researcher":20,"roles":2377,"affiliations":2378,"properties":2385,"displayName":2387,"givenName":20,"familyName":20},"4ceb7ec3-2dfa-437e-9304-1f8167ac947c",[140],[2379],{"id":2326,"sortIndex":21,"affiliation":2380,"properties":20},{"id":2326,"createTime":20,"updateTime":20,"relativeEntities":2381,"slug":20,"properties":2382,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2384,"statistic":20},[],{"title":2383},{"VI":2331},[],{"title":2386},{"VI":2387},"Moses J. Chimbari",{"url":2319,"publisher":2389,"properties":2442},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2390,"slug":10,"properties":2391,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":2394,"manageAffiliations":2411,"indexDatabases":2422,"url":20,"thumbnailPath":20,"statistic":2437,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":2392,"title":2393},{"VOID":13},{"EN":15},[2395,2399,2403,2407],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":2396,"label":2397,"description":2398,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":2400,"label":2401,"description":2402,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":2404,"label":2405,"description":2406,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":2408,"label":2409,"description":2410,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[2412,2417],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":2413,"slug":20,"properties":2414,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2416,"statistic":20},[],{"title":2415},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":2418,"slug":20,"properties":2419,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2421,"statistic":20},[],{"title":2420},{"EN":60},[],[2423,2430],{"id":64,"indexDatabase":2424,"url":75,"indexYears":76,"academicFieldIds":2429,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":2425,"label":2426,"description":2427,"key":72,"publicationTags":2428,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":2431,"url":97,"indexYears":20,"academicFieldIds":2436,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":2432,"label":2433,"description":2434,"key":93,"publicationTags":2435,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":2438,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":2439,"totalCitation":21,"totalCitationByYear":2440,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":2441,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":2443,"volume":2444},{"VOID":2127},{"VOID":2445},"15","2020-10-06",2020,"2026-03-10T04:58:53.748+00:00",[82,95],{"id":2451,"createTime":2452,"updateTime":2453,"relativeEntities":2454,"slug":2455,"properties":2456,"entityType":131,"verifyStatus":132,"verifyTime":2467,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":2468,"fullTextUrl":20,"authors":2469,"publicationType":287,"publisherRelationship":2567,"citationCount":20,"citationInfo":20,"publishDate":2625,"publishYear":2447,"citationAnalyzeStatus":19,"lastCitationAnalyze":2453,"indexDatabases":2626,"openAccess":20,"references":20,"isForceReanalyzing":541},"8dff8615-121a-45a0-80c7-0ebde628c6a3","2024-01-18T23:00:02.325+00:00","2026-01-31T14:13:39.078+00:00",[],"Human-papillomavirus-HPV-16-infection-is-not-detected-in-rectal-carcinoma",{"abstract":2457,"title":2459,"gsPaper":2461,"references":2463,"doi":2465},{"EN":2458},"Persistence of human papillomavirus (HPV) infections is associated with squamous cell carcinomas of different human anatomic sites. Several studies have suggested a potential role for HPV infection, particularly HPV16 genotype, in rectal cancer carcinogenesis.. The aim of this study was to assess the frequency of oncogenic HPV 16 viral DNA sequences in rectal carcinomas cases retrieved from the pathology archive of Braga Hospital, North Portuga. TaqMan-based type-specific real-time PCR for HPV 16 was performed using primers and probe targeting HPV16 E7 region. Most of the rectal cancer patients (88.5%, n = 206 patients), were symptomatic at diagnosis. The majority of the lesions (55.3%, n = 129) presented malignancies of polypoid\u002Fvegetant phenotype. 26.8% (n = 63) had synchronic metastasis at diagnosis. 26.2% (n = 61) patients had clinical indication for neoadjuvant therapy. Most patients with rectal cancer were stage IV (19.7% patients), followed by stage IIA (19.3%) and stage I (18.5%). All cases of the present series tested negative for HPV16. The total of negative tests for HPV 16 infection is a robust argument to support the assumption that HPV 16 infection, despite of previous evidences, is not involved in rectal cancer carcinogenesis and progression.",{"EN":2460},"Human papillomavirus (HPV) 16 infection is not detected in rectal carcinoma",{"VOID":2462},"[\"4424616903411509338\"]",{"VOID":2464},"Zur HH. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50.\nRusan M, Li YY, Hammerman PS. Genomic landscape of human papillomavirus-associated cancers. Clin Cancer Res. 2015;21(9):2009–19.\nSchiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, Stanley MA, Franceschi S. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.\nVan Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in human papillomavirus-associated cancers - United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2018;67(33):918–24.\nde Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15. https:\u002F\u002Fdoi.org\u002F10.1016\u002FS1470-2045(12)70137-7.\nIARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1–636.\nda Costa AM, Fregnani JHTG, Pastrez PRA, Mariano VS, Neto CS, Guimarães DP, de Oliveira KMG, Neto SAZ, Nunes EM, Ferreira S, Sichero L, Villa LL, Syrjanen KJ, Longatto-Filho A. Prevalence of high risk HPV DNA in esophagus is high in Brazil but not related to esophageal squamous cell carcinoma. Histol Histopathol. 2018;33(4):357–63.\nPastrez PRA, Mariano VS, da Costa AM, Silva EM, Scapulatempo Neto C, Guimarães DP, Fava G, Neto SAZ, Nunes EM, Sichero L, Villa LL, Syrjanen KJ, Longatto-Filho A. The relation of HPV infection and expression of p53 and p16 proteins in esophageal squamous cells carcinoma. J Cancer. 2017;8(6):1062–70.\nSyrjänen S. Oral manifestations of human papillomavirus infections. Eur J Oral Sci. 2018;126(Suppl 1):49–66.\nGhaffari H, Nafissi N, Hashemi-Bahremani M, Alebouyeh MR, Tavakoli A, Javanmard D, Bokharaei-Salim F, Mortazavi HS, Monavari SH. Molecular prevalence of human papillomavirus infection among Iranian women with breast cancer. Breast Dis. 2018. https:\u002F\u002Fdoi.org\u002F10.3233\u002FBD-180333.\nKouloura A, Nicolaidou E, Misitzis I, Panotopoulou E, Kassiani T, Smyrniotis V, Corso G, Veronesi P, Arkadopoulos N. HPV infection and breast cancer. Results of a microarray approach. Breast. 2018;40:165–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.breast.2018.05.010 Epub 2018 Jun 4. Erratum in: Breast. 2018 Oct;41:136. PubMed PMID: 29890463.\nMalhone C, Longatto-Filho A, Filassi JR. Is human papilloma virus associated with breast Cancer? A review of the molecular evidence. Acta Cytol. 2018;62(3):166–77.\nKim Y, Pierce CM, Robinson LA. Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer. 2018 Aug 22;18(1):843. https:\u002F\u002Fdoi.org\u002F10.1186\u002Fs12885-018-4748-0.\nLiang H, Pan Z, Cai X, Wang W, Guo C, He J, Chen Y, Liu Z, Wang B, He J. LiangW; AME lung Cancer cooperative group. The association between human papillomavirus presence and epidermal growth factor receptor mutations in Asian patients with non-small cell lung cancer. Transl Lung Cancer Res. 2018;7(3):397–403.\nDooley KE, Warburton A, McBride AA. Tandemly Integrated HPV16 Can Form a Brd4-Dependent Super-Enhancer-Like Element That Drives Transcription of Viral Oncogenes. mBio. 2016;7(5):e01446–16. https:\u002F\u002Fdoi.org\u002F10.1128\u002FmBio.01446-16.\nVande Pol SB, Klingelhutz AJ. Papillomavirus E6 oncoproteins. Virology. 2013;445(1–2):115–37.\nFeng D, Yan K, Zhou Y, Liang H, Liang J, Zhao W, Dong Z, Ling B. Piwil2 is reactivated by HPV oncoproteins and initiates cell reprogramming via epigenetic regulation during cervical cancer tumorigenesis. Oncotarget. 2016;7(40):64575–88.\nGillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky D, Gillison ML, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709–20.\nFakhry C, Zhang Q, Nguyen-Tan PF, Rosenthal D, El-Naggar A, Garden AS, Soulieres D, Trotti A, Avizonis V, Ridge JA, Harris J, Le QT, Gillison M. Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. J Clin Oncol. 2014;32(30):3365–73.\nGuo T, Qualliotine JR, Ha PK, Califano JA, Kim Y, Saunders JR, Blanco RG, D'Souza G, Zhang Z, Chung CH, Kiess A, Gourin CG, Koch W, Richmon JD, Agrawal N, Eisele DW, Fakhry C. Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer. 2015;121(12):1977–84.\nIyer NG, Dogan S, Palmer F, Rahmati R, Nixon IJ, Lee N, Patel SG, Shah JP, Ganly I. Detailed analysis of Clinicopathologic factors demonstrate distinct difference in outcome and prognostic factors between surgically treated HPV-positive and negative Oropharyngeal Cancer. Ann Surg Oncol. 2015;13:4411–21.\nLarsen CG, Jensen DH, Carlander AF, Kiss K, Andersen L, Olsen CH, Andersen E, Garnæs E, Cilius F, Specht L, von Buchwald C. Novel nomograms for survival and progression in HPV+ and HPV- oropharyngeal cancer: a population-based study of 1,542 consecutive patients. Oncotarget. 2016;7(44):71761–72.\nAlemany L, Saunier M, Alvarado-Cabrero I, et al. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136:98–107.\nDe Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626–36.\nLorenzon L, Ferri M, Pilozzi E, Torrisi MR, Ziparo V, French D. Human papillomavirus and colorectal cancer: evidences and pitfalls of published literature. Int J Color Dis. 2011;26:135–42.\nBaandrup L, Thomsen LT, Olesen TB, Andersen KK, Norrild B, Kjaer SK. The prevalence of human papillomavirus in colorectal adenomas and adenocarcinomas: a systematic review and metaanalysis. Eur J Cancer. 2014;50:1446–61.\nDamin DC, Ziegelmann PK, Damin AP. Human papillomavirus infection and colorectal cancer risk: a meta-analysis. Color Dis. 2013;15:e420–8.\nTanaka A, Sadahiro S, Suzuki T, Okada K, Saito G. A comparison of the localization of rectal carcinomas according to the general rules of the Japanese classification of colorectal carcinoma (JCCRC) and Western guidelines. Surg Today. 2017;47(9):1086–93.\nGreene FL, Page DL, Fleming ID, et al. E. AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002.\nWalboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.\nMartins SF, Amorim R, Reis RM, Pinheiro C, Rodrigues M, et al. A hospital based cohort study of colorectal Cancer cases treated at Braga hospital, northern Portugal. J Gastroint Dig Syst. 2013;3:146. https:\u002F\u002Fdoi.org\u002F10.4172\u002F2161-069X.1000146.\nGiuliani L, Ronci C, Bonifacio D, Di Bonito L, Favalli C, Perno CF, Syrjanen K, Ciotti M. Detection of oncogenic DNA viruses in colorectal Cancer. Anticancer Res. 2008;28:1405–10.\nPicanço-Junior OM, Oliveira AL, Freire LT, Brito RB, Villa LL, Matos DMD. Differentiation., association between human papillomavirus and colorectal adenocarcinoma and its influence on tumor staging and degree of cell. Arq Bras Cir Dig. 2014;27(3):172–6.\nSvagzdys S, Lesauskaite V, Pavalkis D, Nedzelskienė I, Pranys D, Tamelis A. Microvessel density as new prognostic marker after radiotherapy in rectal cancer. BMC Cancer. 2009;9(1):95.\nDes Guetz G, Uzzan B, Nicolas P, Cucherat M, Morere JF. Benamouzig R BJ andPerretG-Y. microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer. 2006;94:1823–32.\nBrenner H, Hoffmeister M, Haug U. Should colorectal cancer screening start at the same age in European countries? Contributions from descriptive epidemiology. Br J Cancer. 2008;99:532–5.\nMartins SF, Reis RM, Rodrigues AM, Baltazar F, Longatto-Filho A. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies. World J Clin Oncol. 2011;10(2):272–80.\nParkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153–6.\nGLOBOCAN Factsheet Colorectal cancer estimated incidence, mortality and prevalence worldwide in 2012. 2012;Available at: http:\u002F\u002Fglobocan.iarc.fr\u002FPages\u002Ffact.\nRoreno – Registo Oncológico Regional do Norte [homepage na internet]. Taxas de incidência de cancro na região Norte de Portugal; 2014. 2014;Available at: http:\u002F\u002Fwww.roreno.com.pt\u002Fpt\u002Festatis.\nLambert DW, Wood IS, Ellis A, Shirazi-Beechey SP. Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer. 2002;86(8):1262–9.\nAmerican Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.\nNeagoe A, Molnar A-M, Acalovschi M, Seicean A, Serban A. Risk factors for colorectal cancer: an epidemiologic descriptive study of a series of 333 patients. Rom J Gastroenterol. 2004;13(3):187–93.\nCenter MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal Cancer. CA Cancer J Clin. 2009;59(6):366–78.\nJemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.\nDe Paoli P, Carbone A. Carcinogenic viruses and solid cancers without sufficient evidence of causal association. Int J Cancer. 2013;133(7):1517–29.\nBodaghi S, Yamanegi K, Xiao SY, et al. Colorectal papillomavirus infection in patients with colorectal cancer. Clin Cancer Res. 2005;11:2862–7.\nBurnett-Hartman AN, Newcomb P, Potter JD. Infectious agents and colorectal cancer: a review of helicobacter pylori, Streptococcus bovis, JC virus, and human papillomavirus. Cancer Epidemiol Biomark Prev. 2008;17:2970–9.\nCollins D, Hogan AM, Winter DC. Microbial and viral pathogens in colorectal cancer. Lancet Oncol. 2011;12:504–12.\nGornick MC, Castellsague X, Sanchez G, et al. Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes Control. 2010;21:737–43.\nBaltzell K, Buehring GC, Krishamarty S, et al. Limited evidence of human papillomavirus in breast tissue using molecular in situ methods. Cancer. 2011;118:1212–20.\nKirgan D, Manalo P, Hall M, et al. Association of Human Papillomavirus and Colon neoplasms. Arch Surg. 1990;125:862–5.\nBiesaga B, Janecka-Widła A, Kołodziej-Rzepa M, Słonina D, Darasz Z, Gasińska A. The prevalence of HPV infection in rectal cancer - report from south – Central Poland Cracow region. Pathol Res Pract. 2019 Sep;215(9):152513. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.prp.2019.152513.",{"VOID":2466},"10.1186\u002Fs13027-020-00281-z","2024-05-12T01:04:28.981+00:00","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13027-020-00281-z",[2470,2503,2518,2531],{"id":2471,"sortIndex":21,"researcher":20,"roles":2472,"affiliations":2473,"properties":2500,"displayName":2502,"givenName":20,"familyName":20},"f6db37a8-1d45-43d6-8c82-e669ca3d363f",[140],[2474,2482,2491],{"id":2475,"sortIndex":21,"affiliation":2476,"properties":20},"176ed01a-2f6d-49ec-8c46-00563665b675",{"id":2475,"createTime":20,"updateTime":20,"relativeEntities":2477,"slug":20,"properties":2478,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2481,"statistic":20},[],{"title":2479},{"VI":2480},"Life and Health Science Research Institute (ICVS), School of Health Sciences, School of Medicine, University of Minho, Braga, Portugal",[],{"id":2483,"sortIndex":105,"affiliation":2484,"properties":2490},"22c36037-d55a-40e1-ab55-78baae25be52",{"id":2483,"createTime":20,"updateTime":20,"relativeEntities":2485,"slug":20,"properties":2486,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2489,"statistic":20},[],{"title":2487},{"VI":2488},"ICVS\u002F3B’s-PT Government Associate Laboratory, Braga\u002FGuimarães, Braga, Portugal",[],{},{"id":2492,"sortIndex":106,"affiliation":2493,"properties":2499},"1a50f8c9-edd4-468b-8ef7-5f4b263ec6fa",{"id":2492,"createTime":20,"updateTime":20,"relativeEntities":2494,"slug":20,"properties":2495,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2498,"statistic":20},[],{"title":2496},{"VI":2497},"Coloproctology Unit, Braga Hospital, Braga, Portugal",[],{},{"title":2501},{"VI":2502},"Sandra F. Martins",{"id":2504,"sortIndex":105,"researcher":20,"roles":2505,"affiliations":2506,"properties":2515,"displayName":2517,"givenName":20,"familyName":20},"b8feec4e-20b6-450f-8400-8e69cfb6d8e1",[140],[2507],{"id":2508,"sortIndex":21,"affiliation":2509,"properties":20},"afbb54d0-d848-461b-bda0-0c4cf91c2094",{"id":2508,"createTime":20,"updateTime":20,"relativeEntities":2510,"slug":20,"properties":2511,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2514,"statistic":20},[],{"title":2512},{"VI":2513},"Molecular Oncology Research Center, São Paulo, Brazil",[],{"title":2516},{"VI":2517},"Vânia Mariano",{"id":2519,"sortIndex":106,"researcher":20,"roles":2520,"affiliations":2521,"properties":2528,"displayName":2530,"givenName":20,"familyName":20},"9b4a327b-1b65-4665-90c6-3ecba347ff47",[140],[2522],{"id":2492,"sortIndex":21,"affiliation":2523,"properties":20},{"id":2492,"createTime":20,"updateTime":20,"relativeEntities":2524,"slug":20,"properties":2525,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2527,"statistic":20},[],{"title":2526},{"VI":2497},[],{"title":2529},{"VI":2530},"Mesquita Rodrigues",{"id":2532,"sortIndex":107,"researcher":20,"roles":2533,"affiliations":2534,"properties":2564,"displayName":2566,"givenName":20,"familyName":20},"d729f728-4062-486d-819e-7bcf956c5178",[140],[2535,2541,2548,2555],{"id":2475,"sortIndex":21,"affiliation":2536,"properties":20},{"id":2475,"createTime":20,"updateTime":20,"relativeEntities":2537,"slug":20,"properties":2538,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2540,"statistic":20},[],{"title":2539},{"VI":2480},[],{"id":2483,"sortIndex":105,"affiliation":2542,"properties":2547},{"id":2483,"createTime":20,"updateTime":20,"relativeEntities":2543,"slug":20,"properties":2544,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2546,"statistic":20},[],{"title":2545},{"VI":2488},[],{},{"id":2508,"sortIndex":106,"affiliation":2549,"properties":2554},{"id":2508,"createTime":20,"updateTime":20,"relativeEntities":2550,"slug":20,"properties":2551,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2553,"statistic":20},[],{"title":2552},{"VI":2513},[],{},{"id":2556,"sortIndex":107,"affiliation":2557,"properties":2563},"37a7e45e-6691-4ed1-b022-5289677108c2",{"id":2556,"createTime":20,"updateTime":20,"relativeEntities":2558,"slug":20,"properties":2559,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2562,"statistic":20},[],{"title":2560},{"VI":2561},"Laboratory of Medical Investigation (LIM) 14, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil",[],{},{"title":2565},{"VI":2566},"Adhemar Longatto-Filho",{"url":2468,"publisher":2568,"properties":2621},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2569,"slug":10,"properties":2570,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":2573,"manageAffiliations":2590,"indexDatabases":2601,"url":20,"thumbnailPath":20,"statistic":2616,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":2571,"title":2572},{"VOID":13},{"EN":15},[2574,2578,2582,2586],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":2575,"label":2576,"description":2577,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":2579,"label":2580,"description":2581,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":2583,"label":2584,"description":2585,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":2587,"label":2588,"description":2589,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[2591,2596],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":2592,"slug":20,"properties":2593,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2595,"statistic":20},[],{"title":2594},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":2597,"slug":20,"properties":2598,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2600,"statistic":20},[],{"title":2599},{"EN":60},[],[2602,2609],{"id":64,"indexDatabase":2603,"url":75,"indexYears":76,"academicFieldIds":2608,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":2604,"label":2605,"description":2606,"key":72,"publicationTags":2607,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":2610,"url":97,"indexYears":20,"academicFieldIds":2615,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":2611,"label":2612,"description":2613,"key":93,"publicationTags":2614,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":2617,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":2618,"totalCitation":21,"totalCitationByYear":2619,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":2620,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":2622,"volume":2624},{"VOID":2623},"1-5",{"VOID":2445},"2020-03-05",[82,95],{"id":2628,"createTime":2629,"updateTime":2630,"relativeEntities":2631,"slug":2632,"properties":2633,"entityType":131,"verifyStatus":132,"verifyTime":2644,"verifyNote":134,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":2645,"fullTextUrl":20,"authors":2646,"publicationType":287,"publisherRelationship":2786,"citationCount":20,"citationInfo":20,"publishDate":2843,"publishYear":349,"citationAnalyzeStatus":19,"lastCitationAnalyze":2844,"indexDatabases":2845,"openAccess":20,"references":20,"isForceReanalyzing":541},"8b289f55-5c24-46a1-80b8-a34b4a095809","2024-02-06T21:38:29.017+00:00","2026-01-24T13:46:13.131+00:00",[],"Combination-of-the-gamma-glutamyltransferase-to-prealbumin-ratio-and-other-indicators-may-be-a-novel-marker-for-predicting-the-prognosis-of-patients-with-hepatocellular-carcinoma-undergoing-locoregional-ablative-therapies",{"abstract":2634,"title":2636,"gsPaper":2638,"references":2640,"doi":2642},{"EN":2635},"The aim of this study was to investigate the prognostic significance of the serum γ-glutamyltransferase (γ-GT)-to-prealbumin ratio (GPR) and whether combining this ratio with other parameters can lead to an improved prognostic value for patients with hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) combined with local ablation therapy. A total of 235 HCC patients who were treated with combined therapies were retrospectively analyzed. The demographic data and clinicopathological data were collected. A fibrinogen (Fib)-GPR score of 2 was assigned to patients with elevated Fib and GPR values, and a score of 1 or 0 was assigned to patients with one or neither of these two markers, respectively. In addition, an N-score of 2 was assigned to patients with low neutrophil and high GPR values, and a score of 1 or 0 was assigned to patients with one or neither of these two markers, respectively. The optimal cutoff values and prognostic roles of GPR and other markers were identified according to the time-dependent receiver operating characteristic (ROC) curves and Youden’s index. Multiple tumors, high levels of α-fetoprotein (AFP) and Fib, as well as a high GPR, were found to be independent risk factors in recurrent patients, while multiple tumors, a low neutrophil count, and a high GPR were associated with reduced overall survival (OS) in patients with HCC who received combined therapies. Patients with a Fib-GPR score of 2 and N-GPR score of 2 had poor recurrence-free survival (RFS) and OS, respectively. Fib-GPR and N-GPR scores may be helpful in predicting both recurrence and the prognosis of HCC patients, thereby assisting in the process to make a true clinical decision and optimize therapeutic options.",{"EN":2637},"Combination of the gamma-glutamyltransferase-to-prealbumin ratio and other indicators may be a novel marker for predicting the prognosis of patients with hepatocellular carcinoma undergoing locoregional ablative therapies",{"VOID":2639},"[\"15492977085510493891\"]",{"VOID":2641},"Bertuccio P, Turati F, Carioli G, Rodriguez T, la Vecchia C, Malvezzi M, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302–9.\nWu M, Shen F. Liver cancer. 3rd ed. Beijing: Peking University Medical Press; 2010.\nWang M, Wang Y, Feng X, Wang R, Wang Y, Zeng H, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese national cancer center. Int J Infect Dis. 2017;65:15–21.\nWang WD, Zhang LH, Ni JY, Jiang XY, Chen D, Chen YT, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for hepatocellular carcinoma within the Milan criteria: a meta-analysis. Korean J Radiol. 2018;19:613–22.\nZhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23:787–93.\nSun L, Wang R, Gao FY, Li YX, Geng MF, Chen JL, et al. Predictive value of serum gamma-glutamyltransferase levels in patients with hepatocellular carcinoma. Neoplasma. 2017;64:444–52.\nSun P, Li Y, Chang L, Tian X. Prognostic and clinicopathological significance of gamma-glutamyltransferase in patients with hepatocellular carcinoma. Medicine. 2019;98:e15603.\nWen X, Yao M, Lu Y, Chen J, Zhou J, Chen X, et al. Integration of prealbumin into child-pugh classification improves prognosis predicting accuracy in HCC patients considering curative surgery. J Clin Transl Hepatol. 2018;6:377–84.\nLi JD, Xu XF, Han J, Wu H, Xing H, Li C, et al. Preoperative prealbumin level as an independent predictor of long-term prognosis after liver resection for hepatocellular carcinoma: a multi-institutional study. HPB (Oxford). 2019;21:157–66.\nHeimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.\nChen K, Zhan MX, Hu BS, Li Y, He X, Fu SR, et al. Combination of the neutrophil to lymphocyte ratio and the platelet to lymphocyte ratio as a useful predictor for recurrence following radiofrequency ablation of hepatocellular carcinoma. Oncol Lett. 2018;15:315–23.\nLiu CJ, Ma XW, Zhang XJ, Shen SQ. pri-miR-34b\u002Fc rs4938723 polymorphism is associated with hepatocellular carcinoma risk: a case-control study in a Chinese population. Int J Mol Epidemiol Genet. 2017;8:1–7.\nLiu FT, Gao H, Wu CW, Zhu ZM. The association of plasma fibrinogen with clinicopathological features and prognosis in esophageal cancer patients. Oncotarget. 2017;8:93029–38.\nLv GY, Yu Y, An L, Sun XD, Sun DW. Preoperative plasma fibrinogen is associated with poor prognosis in esophageal carcinoma: a meta-analysis. Clin Transl Oncol. 2018;20:853–61.\nMatsuda S, Takeuchi H, Kawakubo H, Fukuda K, Nakamura R, Suda K, et al. Prognostic impact of change in the fibrinogen and albumin score during preoperative treatment in esophageal cancer patients. World J Surg. 2017;41:2788–95.\nFan S, Guan Y, Zhao G, An G. Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma. Thorac Cancer. 2018;9:146–51.\nChen P, Wang C, Cheng B, Nesa EU, Liu Y, Jia Y, et al. Plasma fibrinogen and serum albumin levels (FA score) act as a promising prognostic indicator in non-small cell lung cancer. Onco Targets Ther. 2017;10:3107–18.\nHuang G, Jiang H, Lin Y, Wu Y, Cai W, Shi B, et al. Prognostic value of plasma fibrinogen in hepatocellular carcinoma: a meta-analysis. Cancer Manag Res. 2018;10:5027–41.\nZhang L, Chen QG, Li SQ, Zhang J, Min QH, Gao QF, et al. Preoperative fibrinogen to prealbumin ratio as a novel predictor for clinical outcome of hepatocellular carcinoma. Future Oncol. 2019;15:13–22.\nYang SL, Liu LP, Yang S, Liu L, Ren JW, Fang X, et al. Preoperative serum alpha-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma. Br J Surg. 2016;103:716–24.\nGomaa AI, Al-Khatib A, Abdel-Razek W, Hashim MS, Waked I. Ascites and alpha-fetoprotein improve prognostic performance of Barcelona clinic liver cancer staging. World J Gastroenterol. 2015;21:5654–62.\nKabir T, Ye M, Mohd Noor NA, Woon W, Junnarkar SP, Shelat VG. Preoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes after curative resection for hepatocellular carcinoma. Int J Hepatol. 2019;2019:4239463.\nHanigan MH. Gamma-glutamyl transpeptidase: redox regulation and drug resistance. Adv Cancer Res. 2014;122:103–41.\nCarr BI, Guerra V. Hepatocellular carcinoma size: platelets, γ-glutamyl transpeptidase, and alkaline phosphatase. Oncology. 2013;85:153–9.\nBelcastro E, Franzini M, Cianchetti S, Lorenzini E, Masotti S, Fierabracci V, et al. Monocytes\u002Fmacrophages activation contributes to b-gamma-glutamyltransferase accumulation inside atherosclerotic plaques. J Transl Med. 2015;13:325.\nCorti A, Franzini M, Cianchetti S, Bergamini G, Lorenzini E, Melotti P, et al. Contribution by polymorphonucleate granulocytes to elevated gamma-glutamyltransferase in cystic fibrosis sputum. PLoS One. 2012;7:e34772.\nShirai Y, Okugawa Y, Hishida A, Ogawa A, Okamoto K, Shintani M, et al. Fish oil-enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. Sci Rep. 2017;7:4826.\nIngenbleek Y, Young V. Transthyretin (Prealbumin) in health and disease: nutritional implications. Annu Rev Nutr. 1994;14:495–533.\nHuang J, Wang Y, Yuan Y, Chen Y, Kong W, Chen H, et al. Preoperative serum pre-albumin as an independent prognostic indicator in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy. Oncotarget. 2017;8:36772–9.\nKuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011;54:948–55.\nBambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237–49.\nBağırsakçı E, Şahin E, Atabey N, Erdal E, Guerra V, Carr BI. Role of albumin in growth inhibition in hepatocellular carcinoma. Oncology. 2017;93:136–43.\nD’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–31.\nHe C, Zhang Y, Cai Z, Lin X. The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy. Cancer Manag Res. 2019;11:1391–400.\nLee SK, Song MJ, Kim SH, Park M. Comparing various scoring system for predicting overall survival according to treatment modalities in hepatocellular carcinoma focused on platelet-albumin-bilirubin (PALBI) and albumin-bilirubin (ALBI) grade: a nationwide cohort study. PLoS One. 2019;14:e0216173.",{"VOID":2643},"10.1186\u002Fs13027-019-0266-1","2024-05-14T04:58:31.960+00:00","https:\u002F\u002Finfectagentscancer.biomedcentral.com\u002Farticles\u002F10.1186\u002Fs13027-019-0266-1",[2647,2662,2677,2690,2703,2716,2729,2742,2757],{"id":2648,"sortIndex":21,"researcher":20,"roles":2649,"affiliations":2650,"properties":2659,"displayName":2661,"givenName":20,"familyName":20},"01ffb6c3-1d2a-4931-aeef-26c8d3907837",[140],[2651],{"id":2652,"sortIndex":21,"affiliation":2653,"properties":20},"6670d085-af5c-456d-9b40-337882d4da42",{"id":2652,"createTime":20,"updateTime":20,"relativeEntities":2654,"slug":20,"properties":2655,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2658,"statistic":20},[],{"title":2656},{"VI":2657},"Research Center for Biomedical Resources, Beijing You’an Hospital, Capital Medical University, Beijing, China",[],{"title":2660},{"VI":2661},"Q. Wang",{"id":2663,"sortIndex":105,"researcher":20,"roles":2664,"affiliations":2665,"properties":2674,"displayName":2676,"givenName":20,"familyName":20},"0730ce57-1037-4450-906d-7a7581beace1",[140],[2666],{"id":2667,"sortIndex":21,"affiliation":2668,"properties":20},"993d4858-d3e3-44d3-b5cb-5da4da41aec4",{"id":2667,"createTime":20,"updateTime":20,"relativeEntities":2669,"slug":20,"properties":2670,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2673,"statistic":20},[],{"title":2671},{"VI":2672},"Interventional Therapy Center for Oncology, Beijing You’an Hospital, Capital Medical University, Beijing, China",[],{"title":2675},{"VI":2676},"P. Zhao",{"id":2678,"sortIndex":106,"researcher":20,"roles":2679,"affiliations":2680,"properties":2687,"displayName":2689,"givenName":20,"familyName":20},"5b78fd62-6c51-493c-8a3a-f8d00058166c",[140],[2681],{"id":2667,"sortIndex":21,"affiliation":2682,"properties":20},{"id":2667,"createTime":20,"updateTime":20,"relativeEntities":2683,"slug":20,"properties":2684,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2686,"statistic":20},[],{"title":2685},{"VI":2672},[],{"title":2688},{"VI":2689},"N. He",{"id":2691,"sortIndex":107,"researcher":20,"roles":2692,"affiliations":2693,"properties":2700,"displayName":2702,"givenName":20,"familyName":20},"6b628d05-d01c-4470-89e6-26930dbea5a4",[140],[2694],{"id":2652,"sortIndex":21,"affiliation":2695,"properties":20},{"id":2652,"createTime":20,"updateTime":20,"relativeEntities":2696,"slug":20,"properties":2697,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2699,"statistic":20},[],{"title":2698},{"VI":2657},[],{"title":2701},{"VI":2702},"J. P. Sun",{"id":2704,"sortIndex":202,"researcher":20,"roles":2705,"affiliations":2706,"properties":2713,"displayName":2715,"givenName":20,"familyName":20},"36d8143d-cb09-4bca-b342-dbe061ba38f5",[140],[2707],{"id":2652,"sortIndex":21,"affiliation":2708,"properties":20},{"id":2652,"createTime":20,"updateTime":20,"relativeEntities":2709,"slug":20,"properties":2710,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2712,"statistic":20},[],{"title":2711},{"VI":2657},[],{"title":2714},{"VI":2715},"K. Li",{"id":2717,"sortIndex":216,"researcher":20,"roles":2718,"affiliations":2719,"properties":2726,"displayName":2728,"givenName":20,"familyName":20},"ba90414a-9513-4c5f-b9b5-3a305f887541",[140],[2720],{"id":2652,"sortIndex":21,"affiliation":2721,"properties":20},{"id":2652,"createTime":20,"updateTime":20,"relativeEntities":2722,"slug":20,"properties":2723,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2725,"statistic":20},[],{"title":2724},{"VI":2657},[],{"title":2727},{"VI":2728},"C. R. Zang",{"id":2730,"sortIndex":108,"researcher":20,"roles":2731,"affiliations":2732,"properties":2739,"displayName":2741,"givenName":20,"familyName":20},"54ee6768-61db-4dd0-b577-0c3aa12cb9e7",[140],[2733],{"id":2652,"sortIndex":21,"affiliation":2734,"properties":20},{"id":2652,"createTime":20,"updateTime":20,"relativeEntities":2735,"slug":20,"properties":2736,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2738,"statistic":20},[],{"title":2737},{"VI":2657},[],{"title":2740},{"VI":2741},"Y. N. Zhao",{"id":2743,"sortIndex":245,"researcher":20,"roles":2744,"affiliations":2745,"properties":2754,"displayName":2756,"givenName":20,"familyName":20},"89c595b6-e696-482c-8353-31f9aeee5841",[140],[2746],{"id":2747,"sortIndex":21,"affiliation":2748,"properties":20},"a51dba30-99d1-4176-aebb-3ac8c0d689ff",{"id":2747,"createTime":20,"updateTime":20,"relativeEntities":2749,"slug":20,"properties":2750,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2753,"statistic":20},[],{"title":2751},{"VI":2752},"Clinical detection center, Beijing You’an Hospital, Capital Medical University, Beijing, China",[],{"title":2755},{"VI":2756},"Y. Zhao",{"id":2758,"sortIndex":261,"researcher":20,"roles":2759,"affiliations":2760,"properties":2783,"displayName":2785,"givenName":20,"familyName":20},"dac2e6a0-3621-4d64-bbfc-e32b3335bd95",[140],[2761,2767,2774],{"id":2652,"sortIndex":21,"affiliation":2762,"properties":20},{"id":2652,"createTime":20,"updateTime":20,"relativeEntities":2763,"slug":20,"properties":2764,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2766,"statistic":20},[],{"title":2765},{"VI":2657},[],{"id":2667,"sortIndex":105,"affiliation":2768,"properties":2773},{"id":2667,"createTime":20,"updateTime":20,"relativeEntities":2769,"slug":20,"properties":2770,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2772,"statistic":20},[],{"title":2771},{"VI":2672},[],{},{"id":2775,"sortIndex":106,"affiliation":2776,"properties":2782},"a7fc0cc3-b5e8-4429-af04-093daddd42b4",{"id":2775,"createTime":20,"updateTime":20,"relativeEntities":2777,"slug":20,"properties":2778,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2781,"statistic":20},[],{"title":2779},{"VI":2780},"Research center for biomedical resources; Interventional therapy center for oncology; Beijing You’an Hospital, Capital Medical University, Beijing, China",[],{},{"title":2784},{"VI":2785},"Y. H. Zhang",{"url":2645,"publisher":2787,"properties":2840},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":2788,"slug":10,"properties":2789,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":2792,"manageAffiliations":2809,"indexDatabases":2820,"url":20,"thumbnailPath":20,"statistic":2835,"gsStatistic":20,"type":111,"analyzePriority":20},[],{"issn":2790,"title":2791},{"VOID":13},{"EN":15},[2793,2797,2801,2805],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":2794,"label":2795,"description":2796,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},{"id":30,"createTime":20,"updateTime":20,"relativeEntities":2798,"label":2799,"description":2800,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":33},{},{"id":36,"createTime":20,"updateTime":20,"relativeEntities":2802,"label":2803,"description":2804,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":39},{},{"id":42,"createTime":20,"updateTime":20,"relativeEntities":2806,"label":2807,"description":2808,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":45},{},[2810,2815],{"id":49,"createTime":20,"updateTime":20,"relativeEntities":2811,"slug":20,"properties":2812,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2814,"statistic":20},[],{"title":2813},{"EN":53},[],{"id":56,"createTime":20,"updateTime":20,"relativeEntities":2816,"slug":20,"properties":2817,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":2819,"statistic":20},[],{"title":2818},{"EN":60},[],[2821,2828],{"id":64,"indexDatabase":2822,"url":75,"indexYears":76,"academicFieldIds":2827,"indexDatabaseRanking":82},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":2823,"label":2824,"description":2825,"key":72,"publicationTags":2826,"standard":20},[],{"EN":69,"VI":69},{"EN":69,"VI":71},[74],[78,79,80,81],{"id":84,"indexDatabase":2829,"url":97,"indexYears":20,"academicFieldIds":2834,"indexDatabaseRanking":20},{"id":86,"createTime":20,"updateTime":20,"relativeEntities":2830,"label":2831,"description":2832,"key":93,"publicationTags":2833,"standard":20},[],{"EN":89,"VI":89},{"EN":91,"VI":92},[95,96],[99,100],{"impactFactor":21,"impactFactorByYear":2836,"i10Index":21,"i10IndexLast5Year":21,"totalPublication":103,"totalPublicationByYear":2837,"totalCitation":21,"totalCitationByYear":2838,"totalCitationPerPublication":21,"totalCitationPerPublicationByYear":2839,"hindexLast5Year":21,"hindex":21},{},{"2006":105,"2007":106,"2009":105,"2010":106,"2012":105,"2013":106,"2015":106,"2016":107,"2018":106,"2019":105,"2020":105,"2021":106,"2022":105,"2023":105,"2024":108},{},{},{"pages":2841,"volume":2842},{"VOID":2127},{"VOID":346},"2019-12-19","2026-01-24T13:46:13.130+00:00",[82,95]]